TerraVia™
SOLAZYME INC (Form: 10-K, Received: 03/14/2014 06:02:06)
Table of Contents
Index to Financial Statements

 

 

 

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

 

 

FORM 10-K

 

 

(Mark One)

 

x ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

For the fiscal year ended December 31, 2013

OR

 

¨ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

For the Transition Period from            to            

Commission File Number: 001-35189

 

 

Solazyme, Inc.

(Exact name of Registrant as specified in its charter)

 

 

 

Delaware   33-1077078

(State or Other Jurisdiction of

Incorporation or Organization)

 

(I.R.S. Employer

Identification Number)

Solazyme, Inc.

225 Gateway Boulevard

South San Francisco, CA 94080

(650) 780-4777

(Address and telephone number principal executive offices)

Securities Registered Pursuant to Section 12(b) of the Exchange Act:

 

Title of Each Class:

 

Name of Each Exchange on which Registered:

Common Stock, par value $0.001 per share

  The NASDAQ Global Select Market

Securities Registered Pursuant to Section 12(g) of the Exchange Act: None.

 

 

Indicate by check mark if the registrant is a well-known seasoned issuer, as defined in Rule 405 of the Securities Act.    Yes   x     No   ¨

Indicate by check mark if the registrant is not required to file reports pursuant to Section 13 or Section 15(d) of the Exchange Act.    Yes   ¨     No   x

Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Exchange Act during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days.    Yes   x     No   ¨

Indicate by check mark whether the registrant has submitted electronically and posted on its corporate Web site, if any, every Interactive Data File required to be submitted and posted pursuant to Rule 405 of Regulation S-T (§232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit and post such files).    Yes   x     No   ¨

Indicate by check mark if disclosure of delinquent filers pursuant to Item 405 of Regulation S-K is not contained herein, and will not be contained, to the best of registrant’s knowledge, in definitive proxy or information statements incorporated by reference in Part III of this Form 10-K or any amendment to this Form 10-K.     x

Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer or a smaller reporting company. See definitions of “large accelerated filer,” “accelerated filer” and “smaller reporting company” in Rule 12b-2 of the Exchange Act. (Check one.)

 

Large accelerated filer   ¨    Accelerated filer   x
Non-accelerated filer   ¨ (Do not check if a smaller reporting company)    Smaller reporting company   ¨

Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act.):    Yes   ¨     No   x

The aggregate market value of the registrant’s common stock, $0.001 par value, held by non-affiliates of the registrant as of June 28, 2013, the last business day of our second fiscal quarter, was approximately $481.5 million based on the closing sale price as reported on the Nasdaq Global Select Market.

As of February 28, 2014, there were 69,195,980 shares of the registrant’s common stock, par value $0.001 per share, outstanding.

Documents Incorporated by Reference

Portions of the registrant’s definitive proxy statement for its 2014 Annual Meeting of Stockholders are incorporated by reference into Part III hereof.

 

 

 


Table of Contents
Index to Financial Statements

Solazyme, Inc.

Annual Report on Form 10-K

For The Year Ended December 31, 2013

INDEX

 

PART I

  
Item 1       Business      3   
Item 1A       Risk Factors      18   
Item 1B       Unresolved Staff Comments      46   
Item 2       Properties      46   
Item 3       Legal Proceedings      46   
Item 4       Mine Safety Disclosures      46   
PART II   
Item 5       Market for Registrant’s Common Equity, Related Stockholder Matters and Issuer Purchases of Equity Securities      47   
Item 6       Selected Financial Data      49   
Item 7       Management’s Discussion and Analysis of Financial Condition and Results of Operation      50   
Item 7A       Quantitative and Qualitative Disclosures About Market Risk      72   
Item 8       Financial Statements and Supplementary Data      73   
Item 9       Changes in and Disagreements with Accountants on Accounting and Financial Disclosures      118   
Item 9A       Controls and Procedures      118   
Item 9B       Other Information      119   
PART III   
Item 10       Directors, Executive Officers and Corporate Governance      120   
Item 11       Executive Compensation      120   
Item 12       Security Ownership of Certain Beneficial Owners and Management and Related Stockholder Matters      120   
Item 13       Certain Relationships and Related Transactions, and Director Independence      120   
Item 14       Principal Accounting Fees and Services      120   
PART IV   
Item 15       Exhibits and Financial Statement Schedules      121   
Signatures      122   

Our registered trademarks include Solazyme ® , Soladiesel ® , Algenist ® , Alguronic Acid ® and Golden Chlorella ® . This Annual Report on Form 10-K also contains trademarks, service marks and trade names owned by us as well as others.

 

2


Table of Contents
Index to Financial Statements

The following discussion and analysis should be read together with our audited consolidated financial statements and the related notes and other financial information appearing elsewhere in this Annual Report on Form 10-K. This Annual Report on Form 10-K contains forward-looking statements reflecting our current expectations and involves risks and uncertainties. In some cases, you can identify forward-looking statements by terminology such as “may,” “will,” “should,” “expect,” “plan,” “anticipate,” “believe,” “estimate,” “predict,” “intend,” “potential” or “continue” or the negative of these terms or other comparable terminology. For example, statements regarding our expectations as to future financial performance, expense levels, future manufacturing capacity, addressable market size, target average selling prices and liquidity sources are forward-looking statements. Our actual results and the timing of events may differ materially from those discussed in our forward-looking statements as a result of various factors, including those discussed below and those discussed in the section entitled “Risk Factors” included in this Annual Report on Form 10-K and in our other filings with the Securities and Exchange Commission (SEC).

PART I

Item 1. Business

Our Company

We make renewable oils and other bioproducts. Our proprietary technology uses highly optimized microalgae in an industrial fermentation process to transform a growing range of abundant plant-based sugars into high-value triglyceride oils and other bioproducts. Globally, triglyceride oils touch our lives in numerous ways; from food and industrial oils, to fuels and personal care products.

Our main commercial focus is on selling oil-based products, including tailored oils and powdered oils, to companies that use them as intermediates and ingredients. We have also invested in a consumer-focused business (Solazyme Consumer Products) that commercializes branded products manufactured through our various proprietary processes.

Our renewable products can replace or enhance products derived from the world’s three existing sources of oils: petroleum, plants, and animal fats. We tailor the composition of our oils and other bioproducts to address specific customer requirements, offering superior performance characteristics and value. Our renewable products can replace or improve intermediates and ingredients in major markets served by conventional oils as well as myriad specialty markets where characteristics such as lubricity and thermal and oxidative stress are key performance factors. In addition, our first powdered products can replace oil/fat and protein based ingredients such as butter, eggs and whey for many foods where customers are seeking improved nutrition, hypoallergenic and organoleptic properties.

Our tailored oils offer additional value as compared to conventional oils. For example, our tailored, renewable oils can enable our customers to improve product performance, reduce processing costs and/or improve their products’ sustainability profile. Many of our products are drop-in replacements and can be used in the existing production, refining, finishing and distribution infrastructure in our target markets. We anticipate that the average selling prices (ASPs) of our products will capture the enhanced value that results from tailoring compositions of oils that enable heightened performance. As such, we expect our products to generate attractive margins in our target markets.

Market Need

Rapidly growing global demand for both triglyceride and petroleum oils coupled with a number of substantive issues are driving the need to find alternative oil sources. Specifically, petroleum is a finite, non-renewable resource that is becoming increasingly difficult to extract, raising local and geopolitical energy security concerns and causing environmental damage. Meanwhile, plant-based oils present their own set of challenges, including wide annual production and cost variances related to unpredictable weather, and continuing

 

3


Table of Contents
Index to Financial Statements

forest and habitat destruction resulting from expanded planting. Additionally, conventional petroleum, plant and animal sources of oils are extremely limited in the variety of oil profiles available.

With global population growth of over 80 million people per year and developing economies such as India and China expanding rapidly, the demand for oil and specifically triglyceride oil, is higher than ever. Higher industrial output, rapid urbanization, higher living standards, and changing diets are driving increasing demand for food, transportation, personal care items, plastics and other oil-based products. While demand for petroleum oil is rapidly growing, global reserves are finite, and new sources of petroleum oil are often heavier, lower quality oil. Similarly, due to climate constraints, the supply of plant oils is limited as the vast majority of global arable land is better suited to cultivation of high-density, carbohydrate-based plants such as corn and sugarcane. The ability to grow and convert such carbohydrate-rich plants into unique high-value oils offers a potential solution to the insatiable global demand for oil and oil-based products.

Companies are aggressively seeking new sources of oils that have greater price stability than petroleum and other conventional oils. Companies are also looking for new sources of oils with improved characteristics versus conventional oils. Finally, initiatives focused on fulfillment of corporate sustainability objectives and government mandates support an increased use of renewable oils.

Our Strategy

We intend to be the global market leader in the design and production of renewable oils and related bioproducts. Our products supplement, replace or enhance conventional products derived from petroleum, plant or animal sources. The principal elements of our strategy are:

 

   

Execute on our customer-driven approach to technology and product development. We focus our innovation efforts on creating a broad suite of tailored products that meet defined market needs. We intend to continue to work closely with our partners and customers to understand their requirements and design products to specifically address their needs.

 

   

Execute on our capital-efficient strategy to access feedstock and manufacturing capacity . We expect to further scale up production in a capital-efficient manner by signing agreements under which our partners will invest capital and operational resources in building manufacturing capacity, while providing us access to feedstock. By working with us, we expect that partners can improve the return they realize on their feedstock and diversify their business beyond their current product portfolios, enabling potentially higher margins and reducing price volatility. In addition to our work with existing partners, we are actively evaluating a range of possible new partners and feedstock sources.

 

   

Prioritize market entry based on unit economics and capital requirements. We have been working for years to bring large-scale manufacturing of our products online. In advance of this, we initiated our commercialization efforts several years ago by launching low-volume, high-margin branded skin and personal care products and nutritional supplement ingredients that could be produced on an economically attractive basis via tolled manufacturing. Our large-scale Clinton/Galva Facilities are now online, and the commissioning of the facility at Moema is underway. As such, we are now expanding into large-scale, high-volume commercial production and sales of intermediate and ingredient products across food, industrial, fuel and personal care markets. While the margins on these products are somewhat lower than those launched initially, the volumes are dramatically larger and present excellent market opportunities.

 

   

Enter into sales agreements and additional partnership agreements to advance commercialization efforts. We are currently engaged in development activities with multiple partners. In addition to funding development work and performing application testing, we expect that our partners will enter into long-term purchase agreements with us.

 

4


Table of Contents
Index to Financial Statements

Our Technology

We create renewable oils that mirror or enhance the chemical composition of conventional oils used today. Until now, the physical and chemical characteristics of conventional oils have been dictated by oil compositions found in nature. Our platform technology enables us to design and produce a variety of novel tailored oils that cannot be achieved through blending of existing oils alone.

Our ability to tailor the composition and properties of oil is based on our unique and proprietary technology and instructed by a deep understanding of triglyceride chemistry. The functionality of oils that are formulated into everyday products is derived from differences in the chemistry of triglycerides.

Triglyceride molecules are comprised of three fatty acids attached to a glycerol backbone.

 

LOGO

We have pioneered an industrial biotechnology platform that allows us to optimize oil profiles by tailoring the structures of the oil molecules; our proprietary tool kit allows us to manipulate important functional characteristics such as melting points, oxidative stability and viscosity. First, we can specify the carbon chain lengths of the fatty acid chains. Second, we can alter the saturation level of a fatty acid chain, which refers to the existence, or lack thereof, and number of double bonds between carbon molecules within the chain. Third, we can determine the position of specific fatty acid chains on the glycerol backbone. In addition, we can add specific functional groups, such as hydroxyl groups, to the fatty acid chains, which further alters the performance characteristics of the triglyceride oils.

 

LOGO

In this diagram, the three fatty acid chains are shown extending from the glycerol backbone of a triglyceride molecule. Our proprietary technology allows us to alter the number of carbons in each fatty acid chain.

 

LOGO

This diagram demonstrates the use of our technology to alter the saturation levels within the fatty acid chains. Saturation is a critical determinant of many of the physical properties of oils.

 

5


Table of Contents
Index to Financial Statements

 

LOGO

This diagram demonstrates the use of our technology to change the position of the fatty acids on the glycerol backbone, which also affects the physical characteristics of the oil.

Our technology platform combines a highly efficient and productive oil-producing organism, microalgae, for the creation of oils with scalable and cost-effective standard industrial fermentation processes in order to deliver high value, cost effective, tailored oils.

Microalgae have long been recognized as organisms capable of rapid and efficient oil production under certain conditions. Oleaginous microalgae evolved over billions of years, synthesizing large amounts of oil rapidly when exposed to the right environment. Our proprietary microalgae are heterotrophic. They grow in the dark by consuming sugars derived from plants that have already harnessed the sun’s energy. Our process is therefore a form of “indirect photosynthesis.” When grown in the absence of light, our microalgae are highly efficient at converting the sun’s energy embedded within the plant sugars (feedstocks) into valuable end products.

Our proprietary, highly productive microalgae produce and accumulate oil that routinely constitutes over 80% of the dry cell weight. Typical wild microalgae, in contrast, usually have only 5-20% oil content. Beyond these primary products, our technology platform also yields residual materials when oil is separated from the microalgae. We call these residual materials Algal Meal Products (AMPs). We are in the process of commercializing specialty AMPs for a range of product applications that utilize the protein, fiber and other compounds found in the cell wall and algal body of the microalgae.

We rely on multiple microalgae strains including natural, classically improved, and/or targeted recombinant strains. The key components of our industrial biotechnology platform are strain screening, classical strain improvement, strain optimization through targeted gene recombination, fermentation process development, and downstream process development. Our selection process is iterative; as strains progress through classical strain improvement and targeted recombinant strain optimization they feed back into the strain screening program, re-emerging for additional rounds of strain improvement, strain optimization, and process development.

We use standard industrial fermentation equipment to efficiently scale and accelerate microalgae’s natural oil production time to a few days. Our platform is feedstock flexible and can utilize a wide variety of renewable plant-based sugars, including sugarcane-based sucrose, corn-based dextrose, and sugar from other sustainable biomass sources including cellulosics, which we believe will represent an important alternative feedstock in the future.

The controlled environment of the standard industrial fermentation tanks minimizes contamination and allows us to tightly regulate acidity, temperature and other key parameters. Our core competencies include (1) identifying, isolating and further optimizing strains of microalgae to achieve high cell densities, high yields converting sugar to product and high time-based productivity rates compared to other alternatives, and (2) tailoring the oil outputs to meet specific market needs.

 

6


Table of Contents
Index to Financial Statements

We believe that the following advantages of our platform allow us to offer a new source of renewable oils to address the major markets served by conventional oils:

 

   

Large and diverse market opportunities. Because we make oils, we can access the vast markets currently served by petroleum, plant oils and animal fats. In addition, we leverage our proprietary biotechnology platform to tailor oils that address specific customer requirements by offering superior performance, improved supply chain logistics and sustainability compared to conventional oils.

 

   

Cost-competitive at commercial scale. We harness the innate oil-producing characteristics of microalgae through a proven industrial fermentation process in a controlled environment to produce large volumes of oils in a cost-effective, scalable and predictable manner.

 

   

Compatible with existing equipment and infrastructure. We use standard industrial fermentation and downstream processing equipment that needs little or no modification. Our oils are compatible with existing production, refining, finishing and distribution infrastructure, logistics channels, and technical specifications, which enables them to be a drop-in replacement for conventional oils.

 

   

Rapid time to market. Our tailored-to-specification oils can improve upon triglyceride oils currently used in commerce and can be integrated quickly into our customers’ platforms because they are chemically similar to existing conventional oils. Additionally, if a customer desires a novel oil profile, our development timelines for new profiles can be on a scale of several months to two years as opposed to timelines demonstrated with plant-based oils, which are on the scale of 10-15 years.

In summary, our cost-effective industrial biotechnology platform exploits the prolific oil production capabilities of microalgae as a biocatalyst while leveraging standard fermentation processes and existing industrial equipment to transform plant-based sugars and other types of renewable biomass into tailored oils.

Our Products

Our primary products are the targeted outputs from our processes and include tailored oils, powdered oils, and other bioproducts.

We are commercializing our primary products as either intermediates/ingredients, or, in some cases as branded consumer products, within a division called Solazyme Consumer Products.

Our main intermediates/ingredients business includes tailored oils, powdered oils, and closely related products like powdered protein formulations targeted at customers in the chemicals, fuels and food markets. Our technology allows us to devise tailored solutions for our customers ranging from drop-in equivalents for replacement of conventionally-sourced products to novel offerings providing a broad array of value-add benefits.

Within Solazyme Consumer Products, we are currently selling our Algenist ® and EverDeep ® lines into the skin and personal care market and we are developing additional products.

 

7


Table of Contents
Index to Financial Statements

Intermediates/Ingredients

We are commercializing two main classes of products: renewable tailored oils and powdered oils. The inherent flexibility of our technology platform and the broad usage of triglyceride oils across multiple industries, allows us to approach a wide range of customers across myriad end markets. Some of our industrial solution products are listed in the table below.

 

 
Intermediates/Ingredients Representative Products
   
Product Platform   Target End Markets
Caprylic/Capric  

•      Lubricants, Performance Nutrition, Oleochemicals

Oleic  

•      Lubricants, Functional Fluids, Oleochemicals, Food Service, Frying Oils, Food Spray Oils, Baking Oils, Processed Foods

Lauric  

•      Surfactants, Oleochemicals, Personal Care, Foods

Myristic  

•      Surfactants, Oleochemicals, Personal Care

Cocoa Butter Equivalent  

•      Packaged Foods, Personal Care

Erucic Acid  

•      Emulsifiers, Surfactants, Plastic Additives

Whole Algal Flours and Proteins  

•      Bakery, Ice Cream, Sauces/Dressings, Snack Bars, Beverages

Tailored Oils

Triglyceride oils feature prominently in multiple industrial markets. We have many oils in various stages of development that can address one or more end markets. For example, our oleic oils (including high oleic and high stability high oleic) provide sustainable solutions within the food, lubricant, functional fluid and oleochemical markets, offering advantages such as better nutrition, higher lubricity, longer life, and lower levels of volatile organic compounds. Similarly, we are commercializing our renewable, sustainable lauric oils within the home and personal care markets for surfactant and oleochemical use.

We tailor our products to meet industry specifications and unique customer demands, and we believe we will be able to charge premium pricing as a result of the higher performance, higher value products we can deliver. Products derived from our oils also offer drop-in replacements and higher value blendstocks for marine, motor vehicle and jet fuels, as well as replacements for petrochemicals, oleochemicals and functional fluids.

Industrial Fluids

We believe our renewable oils will become the basis for a next generation of high performance bio-based industrial functional fluids. Our tailored oils platform enables replacement and enhancement of petroleum-, plant-, or animal-derived oils that are used as raw materials for the chemicals industry. In many cases, we expect to create novel oils and high-performing end products that do not exist in nature or are prohibitively expensive to synthesize. In the industrial fluids markets, we have already developed first-of-a-kind oils and have begun to sell those oils to industrial chemical companies that can either use the oils directly as functional fluids (often including an additive package) or as intermediates to convert into replacements and enhancements for their existing petrochemical and oleochemical products.

For example, within functional fluids, our high stability high oleic oils can replace synthetic petroleum-based lubricants used in machinery and hydraulics without compromising performance. In oleochemical applications, our ability to modify oil profiles allows us to make oil that is high in myristic acid, a common ingredient used as an emollient within the home and personal care markets. We are focusing our initial tailored oils for the industrial markets in two distinct target areas:

 

   

Oleochemicals are chemicals that are derived from plant or animal fats. Oleochemicals appear in the industrial, home and personal care industries in applications such as surfactants, detergents, soaps,

 

8


Table of Contents
Index to Financial Statements
 

cosmetics, lubricants and many others. Triglyceride oils derived from plants and animals are processed through a variety of oleochemical manufacturing steps including fatty acid splitting, fatty alcohol production, and esterification. We plan to sell our oils to industry partners that will either incorporate our oils directly, or use them as intermediates/ingredients to replace and/or enhance existing products.

 

   

Functional Fluids span a wide range of non-fuel industrial applications such as lubricants, heat transfer fluids, antifreeze, dielectric fluids, defoamers, solvents, and drying agents. Physical properties (e.g., viscosity and pour point), chemical properties (e.g., oxidation and reactivity) and environmental impact (e.g., biodegradability) of the oils tend to be the principal drivers of value in the functional fluid segment.

We have identified many novel applications for our tailored products that have been validated with our customer and partner relationships. As manufacturing capacity becomes available in 2014 and beyond, we expect to sell our oils into the sample applications listed in the table below, as well as a wide array of other opportunities. We have produced oils suitable for all of these applications, and expect to build on our initial library of oils in the future.

 

Market Segment    Sample Application    Value Proposition
Oleochemicals    Surfactants   

•      Novel surfactants from natural sources

•      Improved margins to fatty alcohol producers

•      More valuable fatty acid mix from splitting

•      Logistically advantaged

•      Reduced processing steps

•      Sustainable source of renewable oil

   Bar and Liquid Soaps   

•      Enhanced bar soap performance (reduced skin sensitivity, enhanced foaming, etc.)

•      Sustainable source of renewable oil

Functional  Fluids    Lubricants   

•      Enhanced lubricity

•      Enhanced stability

•      Reduced processing

•      Meets food-grade standards with performance of mineral oil equivalents

•      Biodegradable

•      Sustainable source of renewable oil

   Dielectric Fluids   

•      High flash point (>350°C)

•      Enhanced stability

•      Longer equipment protection (transformers)

•      Reduced clean-up and hazard risks

•      Sustainable source of renewable oil

Fuels

Within the fuels market, our renewable oils can be sold as replacements for materials that are traditionally derived from petroleum or other conventional oils, or refined and sold as drop-in replacements for marine, motor vehicle and jet fuels. We can either manufacture the end product by contracting with refiners to produce fuels of targeted specifications, or sell our unrefined oils to refiners. Near term, our focus in fuels is providing oils that will be used as high-value fuel additives and blendstocks, an area which allows us to target attractive selling prices while offering enhanced performance and sustainability to customers.

Fuels and additives derived from our oils are compatible with the existing refining and distribution infrastructure, meet industry specifications, and can be used with factory-standard engines without modifications.

 

9


Table of Contents
Index to Financial Statements

We believe they are the first microalgae-based fuels to have been road tested, in both blended and unblended forms. The tests were successful, and performed over thousands of miles in a variety unmodified vehicles. In addition, we have ongoing long-term testing and demonstration work, an example of which is our partnership with Volkswagen.

Our fuels products range from drop-in replacement fuels, such as Soladiesel RD for on-road applications and Solajet for aviation use, to high-value fuel additives and blendstocks. We have entered and completed several large-scale programs with the Department of Defense and have delivered over one million liters of marine diesel and jet fuels to the U.S. Navy under multiple contracts. We partnered with United Airlines to provide renewable jet fuel for the first ever commercial flight utilizing microbe-derived biofuel. We intend to continue cultivating partnerships to develop tailored oil applications with a fuels focus as well as to deliver fuels or fuel blends that span marine, on-road, and aviation industries. Some of our fuels offerings are listed in the table below.

 

End Product    Industry Specification    Value  Proposition

Soladiesel BD

(fatty acid methyl ester (FAME))

  

•      ASTM D6751

•      EN 14214

  

•      Better cold temperature performance than commercially available biodiesel derived from planted seed crops

Soladiesel RD

(hydro-treated renewable diesel)

  

•      ASTM D975

•      EN 590

  

•      Higher cetane ratings than petroleum based diesel

Soladiesel HRD-76

(military grade hydrotreated renewable diesel)

  

•      HRD76 (Hydroprocessed Renewable F-76 Military Marine Diesel)

  

•      Largest supplier to the U.S. Navy of in-spec, microbially-derived HRD76

Solajet D7566

Solajet HRJ-5

(commercial and military grade hydrotreated renewable jet)

  

•      ASTM D7566

•      HRJ5 (Hydroprocessed Renewable JP-5 Navy Jet)

  

•      First microbially-derived jet fuel to meet key specifications

•      First Turbine Fuel Containing Synthesized Hydrocarbons to be used in a commercial flight in the U.S.

•      Oil can be refined and/or blended to meet other fuel specifications (HRJ8, JET A, JET A-1)

Foods

We believe that some of the largest opportunities and most valuable uses for our tailored oils and powdered ingredients are in food. We have developed microalgae-based food ingredients including tailored oils and whole algal powders that enhance the nutritional profile and functionality of food products for consumer packaged goods (CPG) companies. The products provide a wide range of health benefits while also offering a variety of functional benefits such as enhanced taste and texture, structuring, stability, and shelf life along with robust formulation and process flexibility.

We plan to commercialize our food products through a combination of direct sales, sales through distributors and sales through partners to nutraceutical and CPG companies, food service providers and private labels. We are also developing a range of next generation food oils and whole foods to serve new market opportunities and applications.

Tailored Food Oils

We are developing market opportunities for a range of tailored food oils that have the potential to improve upon conventionally utilized specialty fats and oils. Our tailored oil food ingredients offer a variety of health and

 

10


Table of Contents
Index to Financial Statements

functional benefits. Functional benefits include enhanced structuring capabilities, stability, and shelf life, as well as robust formulation, process flexibility and, in many cases, substantial health benefits compared with incumbent oils.

Key initial markets for our tailored oils include spray oil, premium oil and processed food applications. For example, our high stability high oleic oil is very rich in monounsaturated triglycerides and extremely low in polyunsaturated triglycerides. The properties of this oil profile provide substantial heart health benefits over incumbent oils such as soy, which has far higher levels of saturated fat. We expect this oil profile to provide market leading product stability, owing to the very low presence of polyunsaturates. In 2013, we received a “No Questions” notification from the U.S. FDA in response to our submission of notice of our self-affirmation that the first of our food oils should be considered generally regarded as safe (GRAS). This oil has also been classified as “Not-novel” in Europe. We have done safety testing on a number of our oils, with results indicating safety comparable to incumbent vegetable oils, and are in the process of meeting additional regulatory requirements for additional oils.

Powdered Ingredients

In addition to optimizing the composition of oils, we have also developed novel methods of preparing powdered forms of triglyceride oils. Our powdered ingredients are composed of whole algal cells, including the cell wall and the oils and other cellular products held within the whole algal cell.

The first examples of our powdered ingredients can be seen in our whole algal flour and whole algal protein products. We have fulfilled the regulatory requirements for each of these products in the U.S. and Europe, and both of these products can be sold into food applications today in those jurisdictions. These products contain whole algal cells that have been dried and processed for use as powdered food ingredients. The whole algal flour and whole algal protein products have been formulated to enhance the nutritional profile and functionality of food products. With these products, we can offer potential CPG customers myriad benefits, some of which include protein fortification, reduced saturated fat, reduced trans-fat and lower calories. Our microalgae-based powdered food ingredients can enhance or replace emulsifiers, fats and oils, polysaccharides, oligosaccharides and proteins. When used as a partial or complete replacement for ingredients such as eggs, butter, cream and oil, our products enable CPG companies, and other food processors, to offer products with significantly better nutrition, taste and texture parity and/or enhancement. As a result, our products align with current consumer trends, which include demand for products that are more nutritious without taste compromise, natural, sustainable ingredients and simpler ingredient panels.

Whole Algal Flour (WAF): Whole Algal Flour is multicomponent, whole food rich in healthy lipids that is able to efficiently replace other lipid sources. WAF is replete with healthy lipids that have a profile similar to olive oil. It is vegan, gluten-free, free of known allergens, low in saturated fat, cholesterol and trans-fat free. WAF can improve the nutritional profile of food products while maintaining the desirable sensory profile of those products. It can also be used in small quantities to enhance mouth feel without increasing viscosity. Key applications include bakery, ice cream, soups, sauces, beverage and bars.

Whole Algal Protein (WAP ): Whole Algal Protein is a naturally derived whole food source of vegan protein that is gluten free and free of known allergens. Whole Algal Protein is also rich in fiber, healthy lipids and micronutrients. WAP contains all essential amino acids and is highly digestible and formulates well into existing applications. Key initial applications include bars, beverages, protein powders as well as source of protein in mainstream foods and beverages.

Golden Chlorella High Protein (GCHP): Golden Chlorella High Protein is a microalgae powder rich in protein that offers a unique and highly beneficial nutrient profile. Highly stable with a mild flavor profile that is superior to traditional chlorella and other “greens” ingredients, GCHP has been shown to formulate well into a range of products including beverages, powder blends, bars and snacks.

 

11


Table of Contents
Index to Financial Statements

Solazyme Consumer Products

We have also developed branded consumer products. This is driven by our view that in certain instances, this will drive the highest returns from our unique, high performance intermediates/ingredients. Specifically, there are certain markets in which ingredient adoption timelines and value accrual to brands rather than performance ingredients create a strong incentive to sell branded products.

Skin and Personal Care

We have developed a portfolio of innovative and branded microalgae-based products. During our algal strain screening process, we discovered and isolated key compounds that microalgae synthesize to protect themselves against environmental hazards, such as UV exposure, changes in extremes of temperature, and dehydration. Our first major ingredient is Alguronic Acid ® , which we have formulated into a full range of skin care products with significant anti-aging benefits. For example, since March 2011, we have commercialized our brand Algenist ® , which is an anti-aging skin care line and available at Sephora S.A. and its affiliates (Sephora), QVC, Inc. and SpaceNK Limited. We have seen success in expanding our international distribution of Algenist ® and are currently selling in 17 countries including member countries of the EU, Mexico, Canada and China. In 2013, we further leveraged our innovative ingredient research and expertise by broadening the Algenist ® line to include products that use Microalgae Oil as a replacement for the essential oils currently used in skin care products. Some of our key Algenist ® products are outlined in the table below.

 

Representative Algenist ® Products
      Product   Description

 

LOGO

 

  Concentrated Reconstructing Serum   An anti-aging serum formulated with high concentrations of Alguronic Acid.

 

LOGO

 

  Complete Eye Renewal Balm   An eye cream formulated with Alguronic Acid, vitamin C, and caffeine, as well as cucumber, aloe and green tea extracts.

 

LOGO

 

  Firming & Lifting Cream   An anti-aging moisturizing cream formulated with Alguronic Acid.

 

12


Table of Contents
Index to Financial Statements
Representative Algenist ® Products
      Product   Description

 

LOGO

 

  Advanced Anti-Aging Repairing Oil   A face oil formulation containing Microalgae Oil.

 

LOGO

 

  Genius Cream   This moisturizer cream combines Alguronic Acid and Microalgae Oil, as well as a plant-based collagen.

In late 2013, we launched our second algal skin care line, EverDeep ® . EverDeep ® products are formulated with a new proprietary algal ingredient, Algasome TM complex, and are sold online and via telephone driven by direct-to-consumer “infomercial” broadcasts. The skin care line utilizes a continuity program and auto-delivery options to strengthen the link with customers to drive repeat sales.

Our Competitive Strengths

We harness the power of microalgae to yield substantial volumes of renewable oils and other bioproducts. Our key competitive advantages are:

 

   

Proprietary and innovative technology. Our technology platform creates a new paradigm that enables us to produce novel tailored oils that cannot be achieved through blending of existing conventional oils alone. We have made significant investments to protect the intellectual property and know-how related to our technology platform, including screening, classical strain development, targeted recombinant strain optimization, product and applications development and manufacturing capabilities.

 

   

Premium pricing for tailored products. While our cost structure allows us to access existing markets at prevailing prices, we also believe that the enhanced value of our tailored oils as compared to conventional oils should garner premium pricing. In industrial applications, our oils provide unique performance properties including enhanced lubricity, viscosity, pour point, and oxidative stability. Examples in food applications include oils with low levels of polyunsaturates for improved shelf and frying life and structuring fats, like algae-based butter, providing specific melting profiles.

 

   

Technology proven at scale. We have been operating our large-scale fermentations at multiple partner facilities since 2008 in 75,000-liter vessels and in our integrated biorefinery in Peoria, Illinois since 2012 in 125,000-liter vessels. In 2012, we completed our first fermentations at Archer-Daniels-Midland Company’s (ADM) Clinton, Iowa facility in approximately 500,000-liter vessels. We have exhibited linear scalability of our process from laboratory scale and in January 2014 we announced that we had commenced commercial-scale production at the Clinton Facility. We perform some of the downstream processing for Clinton at the facility of American Natural Processors, Inc. (ANP) in Galva, Iowa. Oils from the Clinton/Galva Facilities are now being sold domestically and are being shipped to Brazil for market development activity.

 

13


Table of Contents
Index to Financial Statements
   

Capital efficient access to manufacturing capacity. In structuring our capacity and feedstock partnerships, we have deployed a capital efficient strategy to source low-cost financing with our partners. For example, for our joint venture with Bunge Global Innovation, LLC in Brazil, over $100 million of capital expenditure related to investments for the 100,000 MT Solazyme Bunge Renewable Oils facility was approved for financing through an 8-year loan from the Brazilian Development Bank (BNDES) at an average interest rate of approximately 4% per annum. For our Iowa facilities, we partnered with ADM and ANP to retrofit part of ADM’s existing manufacturing facility in Clinton, Iowa and ANP’s existing manufacturing facility in Galva, Iowa, avoiding significant capital outlay associated with purchasing and installing commercial scale fermentation and downstream processing equipment.

 

   

Commercial products today . We have launched our Algenist ® and EverDeep ® brands within the skin care market. The Algenist ® line has grown to 21 SKUs with a number of additional product launches planned for 2014. Algenist ® has consistently shown strong growth since launch with 2013 sales up 21% year over year. We commenced commercial sales of our renewable, tailored products manufactured at the Clinton/Galva Facilities in January 2014 to customers in the metalworking and lubricants businesses and expect our Solazyme Bunge Renewable Oils Joint Venture to begin manufacturing and selling products from our purpose built facility in Brazil in 2014.

 

   

Feedstock and target market flexibility. Our technology platform provides us with the flexibility to choose from among multiple feedstocks on the input side and multiple specific products (and markets) on the output side, while using the same standard industrial fermentation equipment. A manufacturing facility utilizing a given plant-based sugar feedstock can produce oils with many different oil compositions. Conversely, we can produce the same oil compositions by processing a wide variety of plant-based sugar feedstock. This flexibility enables us to choose the optimal feedstock for any particular geography, while also enabling us to produce a wide variety of oils from the same manufacturing facility.

Manufacturing Operations

Our process is compatible with commercial-scale, widely-available fermentation and oil recovery equipment. We operate our lab and pilot fermentation and recovery equipment as scaled-down versions of our large commercial engineering designs, such as those used to supply large quantities of oil for our algae-derived fuel delivered for testing and certification programs with the U.S. Department of Defense. This allows us to more easily scale up to larger fermentation vessels. We have scaled up our technology platform and have successfully operated at lab (5-15 liter), pilot (600-1,000 liter), demonstration (75,000 liter) and commercial (approximately 120,000—500,000 liter and above) fermenter scale. The commercial scale achieved at ADM’s Clinton Facility is comparable to the fermentation equipment at the Solazyme Bunge Renewable Oils facility in Brazil.

 

   

Our pilot plant in South San Francisco, California, with recovery operations capable of handling material from both 600 and 1,000 liter fermenters, enables us to produce samples of our tailored oils for testing and optimization by our partners, as well as to test new process conditions at an intermediate scale.

 

   

Since 2007, we have operated in commercial-sized standard industrial fermentation equipment (75,000 liter) accessed through manufacturing partners. Our first fully integrated bio-refinery located at our facility in Peoria, Illinois, and partially funded with a U.S. Department of Energy (DOE) federal grant in December 2009 to demonstrate integrated commercial-scale production of renewable algal-based fuels, has a nameplate capacity of approximately two thousand tons of oil annually and provides an important platform for continued work on feedstock flexibility and scaling of new tailored oils into the marketplace. We have recently modified our Peoria Facility to also produce WAF and WAP in conjunction with other contract manufacturing operations.

 

   

In January 2014, we began commercial scale production of our oils at the Clinton/Galva Facilities in Iowa. Clinton uses corn sugars as a feedstock and has a nameplate capacity of 20,000 MT per year, which we are targeting to attain 12-18 months after startup. We have the option to expand the capacity to 40,000 MT per year with the potential to further expand production to 100,000 MT per year.

 

14


Table of Contents
Index to Financial Statements
   

We are currently completing the construction and commissioning of our 100,000 MT nameplate capacity purpose built production facility adjacent to Bunge’s Moema sugar mill in Orindiuva, Brazil. The facility was constructed as part of our Joint Venture with Bunge, and was financed with equal equity contributions by both Bunge and Solazyme and over $100 million in project financing from BNDES.

 

   

We utilize contract manufacturing and distribution to assist in the production and sales of our Algenist ® and EverDeep ® products. We closely monitor and advise these contract manufacturers to ensure that our products meet stringent quality standards.

Intellectual Property

Our success depends in part upon our ability to obtain and maintain intellectual property protection for our products and technologies, and to operate without infringing the proprietary rights of others. With respect to the former, our policy is to protect our proprietary position through filing for patent applications on inventions, filing for trademark protection on our product names and related materials and methods, and through trade secret protection when and where appropriate. We seek to avoid infringing the proprietary rights of others by: (1) monitoring patents and publications in our product areas; (2) monitoring the technological developments of others; and (3) evaluating and taking appropriate courses of action whenever we identify such developments.

As of December 31, 2013, we own 20 issued U.S. patents, six issued foreign patents and over 175 pending patent applications filed in the United States and in various foreign jurisdictions. The expiration dates of the patents are between 2023 and 2029. Patents that issue, if any, from our currently pending patent applications will expire between 2026 and 2032, twenty years from the date of filing. Our patents and patent applications claim and are directed to compositions such as custom oils, fuel products, chemicals, food products, cosmetics, strains of microbes, and gene sequences; methods of manufacturing finished goods and raw materials; and methods of using our raw materials and products. We also protect our proprietary information by requiring our employees, consultants, contractors and other advisors to execute nondisclosure and assignment of invention agreements upon commencement of their respective employments or engagements. Agreements with our employees also prohibit them from bringing the proprietary rights of third parties to us. In addition, we protect our proprietary information through creating written obligations of confidentiality with outside parties who are exposed to confidential information. Where appropriate we also employ material transfer agreements governing the use, intellectual property rights, and transfer of materials such as custom oils when sending them to third parties for purposes such as conversion into fuels, chemicals and consumer products.

We believe that the creation, when possible and appropriate, of multiple, overlapping mechanisms and forms of protection will offer the possibility of broadest and longest proprietary positions for our products and technologies. It is possible that our current and future patents may be successfully challenged or invalidated in whole or in part. It is also possible that we may not obtain issued patents from our filed applications, and may not be able to obtain patents covering other inventions we seek to protect. Due to uncertainties inherent in prosecuting patent applications, some patent applications may be rejected and we may subsequently abandon them. We may also abandon applications when we determine that a product or method is no longer of interest. It is also possible that we may develop products or technologies that will not be patentable or that the patents of others will limit or preclude our ability to do business. In addition, any patent issued to us may provide us with little or no competitive advantage, in which case we may abandon such patent or license it to another entity.

Government Regulation

Our development and production processes involve the use, generation, handling, storage, transportation and disposal of hazardous chemicals and radioactive and biological materials. We are subject to a variety of environmental, health and safety, federal, state, local and international laws, regulations and permit requirements governing, among other matters, the use, generation, manufacture, transportation, storage, handling and disposal of these materials, in the US, Brazil and other countries where we intend to operate or may operate or sell our

 

15


Table of Contents
Index to Financial Statements

products in the future. These laws, regulations and permits can cause delays, require expensive fees, pollution control equipment, capital expenditures or operational changes to limit actual or potential impact of our operations on the environment.

We are also subject to regulation by the Occupational Safety and Health Administration, or OSHA, the California and federal Environmental Protection Agency, or EPA, and to regulation under the Toxic Substance Control Act, or TSCA. OSHA, the California or federal EPA or other government agencies may adopt regulations that affect our research and development programs. In particular, our renewable chemical products may be subject to regulation by government agencies in our target markets. The EPA administers the requirements of the TSCA, which regulates the commercial use of chemicals. Before an entity can manufacture a chemical, it needs to determine whether that chemical is listed in the TSCA inventory. If the substance is listed, then manufacture can commence immediately. If not, then a pre-manufacture notice, or PMN, must be filed with the EPA, which has 90 days to review it. Some of the products we produce or plan to produce are already in the TSCA inventory. Others are not yet listed. A similar program exists under the European Chemicals Agency, or ECHA, called REACH. Under REACH, we are required to register some of our products with the ECHA, and this process could cause delays or involve significant costs.

The use of recombinant microbes like many of our microbial strains is subject to laws and regulations in many countries. In the US, the EPA regulates the commercial use of recombinant microbes as well as potential products from recombinant microbes. When used in an industrial process, our microalgae strains designed using recombinant technology may be considered new chemicals under TSCA, administered by the EPA. We will be required to comply with the EPA’s Microbial Commercial Activity Notice (MCAN) process and have filed MCANs for strains of recombinant microalgae that we use for our chemicals and fuels businesses, which have been dropped from review, allowing commercial use. In Brazil, engineered microbes are regulated by CTNBio. We have filed an application, and in the future may file additional applications, for approval from CTNBio to import and use engineered microbes in our Brazilian facilities for research and development purposes. In addition, we received commercial approval from CTNBio for one of our current microbial strains in October 2013. We expect to encounter regulations concerning engineered microbes in most if not all of the countries in which we may seek to make our fuel and chemical products, however, the scope and nature of these regulations will likely be different from country to country. In February 2014, CTNBio granted a CQB (Certificate of Quality in Biosafety) to the Moema plant for activities including industrial production, import and export, disposal and storage of our key production organisms.

Our fuel products are subject to regulation by various government agencies, including the EPA and the California Air Resources Board in the US and Agencia Nacional do Petroleo in Brazil. We have registered one fuel with the EPA and are preparing to secure approval for use of our diesel in Brazil. In addition, we may decide to register our fuel with the California Air Resources Board and the European Commission. Registration with each of these bodies is required for the sale and use of our fuels within their respective jurisdictions. Our jet fuels meet the standards set by ASTM D7566 and may therefore be used in commercial aviation.

The manufacture, sale and use of our foods products are regulated as food ingredients in the United States by the U.S Food and Drug Administration (FDA) under the federal Food, Drug, and Cosmetic Act. Food ingredients are broadly defined as any substance that may become a component, or otherwise affect the characteristics, of food. Food ingredients are regulated as food additives and must be approved through a formal Food Additive Petition (FAP) process or affirmed as substances generally recognized as safe, or GRAS. A substance can be listed or affirmed as GRAS by the FDA or self-affirmed by its manufacturer upon determination by independent qualified experts who generally agree that the substance is GRAS for a particular use. Although the FDA does not officially affirm the GRAS status of ingredients, it does review, at the notifier’s request, the notifier’s determination of ingredients’ GRAS status. FDA endeavors to respond to GRAS notices within 180 days by issuing a letter that either does not question the basis of the notifier’s determination of GRAS status or concludes that the notice does not provide a sufficient basis for a GRAS determination. Self-affirmation of GRAS status without FDA notification allows the marketing and sale of the ingredient, but reliance on self-

 

16


Table of Contents
Index to Financial Statements

affirmation alone may limit its marketability, as many food manufacturers require that the FDA issue a letter confirming that it does not question the notifier’s determination of GRAS status before such manufacturers will purchase food ingredients from third parties. We submitted a GRAS Notice to the FDA for our first algal oil in June 2011, and received a “No Questions” notification from the FDA in June 2012. We submitted a GRAS Notice for whole algal flour in the third quarter of 2012 and received a “No Questions” notification from the FDA in June 2013. We also have submitted a GRAS notice to the FDA for our whole algal protein and hope to receive a “No Questions” notification on this product in the future.

Food ingredients that are not suitable for the GRAS affirmation process are regulated as food additives and require the submission of a FAP to the FDA and the FDA’s approval prior to commercialization. The food additive petition process is generally expensive and time consuming, with approval, if secured, taking years. The petition must establish with reasonable certainty that the food additive is safe for its intended use at the level specified in the petition. If a food additive petition is submitted, the FDA may choose to reject the petition or deny any desired labeling claims. Furthermore, the FDA may require the establishment of regulations that necessitate costly and time-consuming compliance procedures. All products may also fall under the jurisdiction of the U.S. Department of Agriculture if the intended applications are for meat, dairy, organic or other specialty food areas.

The sale of ingredients for use in animal feed is regulated by agencies including the FDA Center for Veterinary Medicine, or CVM. CVM requirements for suitability must be met by providing data form studies.

Countries other than the U.S. also regulate the manufacture and sale of food ingredients. Regulations vary substantially from country to country, and we will be required to comply with applicable regulations in each country in which we choose to market our food ingredients. In February 2014, the Sao Paulo State Environmental Department granted a license to operate the Solazyme Bunge JV facility, which is necessary to begin commercial production.

Our skin and personal care products are also subject to regulation by various government agencies in the countries in which our products are sold. We completed several rounds of testing in connection with launching the Algenist ® and EverDeep ® product lines, including Human Repeat Insult Patch Testing. We will continue to evaluate regulatory requirements as we launch new skin and personal care products.

Employees

As of December 31, 2013, we had 271 full-time employees, excluding the employees of our joint venture. Our employees’ roles include research, process development, manufacturing, regulatory affairs, program management, finance, human resources, administration, sales and marketing and business development. None of our employees are covered by collective bargaining agreements and we consider relations with our employees to be good.

Investor Information

Our Annual Report on Form 10-K, Quarterly Reports on Form 10-Q, current reports on Form 8-K and any amendments to those reports are available free of charge on the Investor Relations section of our website at http://investors.solazyme.com/sec.cfm as soon as reasonably practicable after they are electronically filed with or furnished to the Securities and Exchange Commission (SEC). The public may read and copy any materials filed us with the SEC at the SEC’s Public Reference Room at 100 F Street, NE, Room 1580, Washington, DC 20549. The public may obtain information on the operation of the Public Reference Room by calling the SEC at 1-800-SEC-0330. The SEC maintains an Internet site that contains reports, proxy and information statements and other information regarding issuers that file electronically with the SEC at http://www.sec.gov. Except as expressly set forth in this Annual Report on Form 10-K, the contents of these websites are not incorporated into, or otherwise to be regarded as part of this report.

 

17


Table of Contents
Index to Financial Statements

Item 1A. Risk Factors.

You should carefully consider the risks described below before investing in our publicly-traded securities. Additional risks not presently known to us or that our management currently deems immaterial also may impair our business operations. If any of the risks described below were to occur, our business, financial condition, operating results, and cash flows could be materially adversely affected. In such an event, the trading price of our common stock could decline and you could lose all or part of your investment. In assessing these risks, you should also refer to the other information contained in this Report, including our consolidated financial statements and related notes. The risks discussed below also include forward-looking statements and our actual results may differ substantially from those discussed in these forward looking statements. See Management’s Discussion and Analysis of Financial Condition and Results of Operations—Forward Looking Statements.

Risks Related to Our Business and Industry

We have a limited operating history and have incurred significant losses to date, anticipate continuing to incur losses and may never achieve or sustain profitability.

We are an early stage company with a limited operating history. We only recently began commercializing our products. To date, a substantial portion of our revenues has consisted of funding from third party collaborative research agreements and government grants. We have generated only limited revenues from commercial sales, which have been principally derived from sales of our nutrition and skin and personal care products. Although we expect a significant portion of our future revenues to come from commercial sales in the food ingredients, chemicals and fuels markets, only a small portion of our revenues to date has been generated from market development activities in those markets.

We have incurred substantial net losses since our inception, including a net loss of $116.4 million during the year ended December 31, 2013. We expect these losses may continue as we expand our manufacturing capacity and build out our product pipeline. As of December 31, 2013, we had an accumulated deficit of $306.3 million. We expect to incur additional costs and expenses related to the continued development and expansion of our business, including research and development, the build-out and operation of our Peoria Facility, the construction and operation of the Solazyme Bunge JV production facility (described below), the retrofitting and operation of the Clinton/Galva Facilities (as described below) and other commercial facilities. As a result, our annual and quarterly operating losses may continue in the short term.

We, along with our development and commercialization partners, will need to develop products successfully, cost effectively produce them in large quantities, and market and sell them profitably. If we fail to become profitable, or if we are unable to fund our continuing losses, we may be unable to continue our business operations. There can be no assurance that we will ever achieve or sustain profitability.

We have generated limited revenues from the sale of our products, and our business may fail if we are not able to successfully commercialize these products.

We have had only limited product sales to date. If we are not successful in further advancing our existing commercial arrangements with strategic partners, developing new arrangements, or otherwise increasing our manufacturing capacity and securing reliable access to sufficient volumes of low-cost feedstock, we will be unable to generate meaningful revenues from our products. We are subject to the substantial risk of failure facing businesses seeking to develop products based on a new technology. Certain factors that could, alone or in combination, prevent us from successfully commercializing our products include:

 

   

our ability to secure reliable access to sufficient volumes of low-cost feedstock;

 

   

our ability to achieve commercial-scale production of our products on a cost effective basis and in a timely manner;

 

   

technical challenges with our production processes or with development of new products that we are not able to overcome;

 

18


Table of Contents
Index to Financial Statements
   

our ability to consistently manufacture our products within specifications;

 

   

our ability to establish and maintain successful relationships with development, feedstock, manufacturing and commercialization partners;

 

   

our ability to gain market acceptance of our products with customers and maintain customer relationships;

 

   

our ability to manage our growth;

 

   

our ability to secure and maintain necessary regulatory approvals for the production, distribution and sale of our products and to comply with applicable laws and regulations;

 

   

actions of direct and indirect competitors that may seek to enter the markets in which we expect to compete or that may seek to impose barriers to one or more markets that we intend to target; and

 

   

public concerns about the ethical, legal, environmental and social ramifications of the use of targeted recombinant technology, land use and the potential diversion of resources from food production.

The production of our microalgae-based products requires fermentable feedstock. The inability to obtain feedstock in sufficient quantities or in a timely and cost-effective manner may limit our ability to produce our products.

A critical component of the production of our microalgae-based products is access to feedstock in sufficient quantities and at an acceptable price to enable commercial production and sale. Other than as described below, we currently purchase feedstock, such as sugarcane-based sucrose and corn-based dextrose, for the production of our products at prevailing market prices. We are currently in discussions with additional potential feedstock partners.

We do not have any long-term supply agreements or other guaranteed access to feedstock other than (i) for the supply of feedstock to Solazyme Bunge Produtos Renováveis Ltda. (Solazyme Bunge Renewable Oils or the Solazyme Bunge JV) by our partner, Bunge Global Innovation, LLC and certain of its affiliates (Bunge), pursuant to our joint venture arrangement that includes a feedstock supply agreement, and (ii) pursuant to our strategic collaboration with Archer-Daniels-Midland Company (ADM) (Solazyme/ADM Collaboration) at the ADM facility in Clinton, Iowa (Clinton Facility). As we scale our production, we anticipate that the production of our microalgae-based products will require large volumes of feedstock, and we may not be able to contract with feedstock producers to secure sufficient quantities of feedstock at reasonable costs or at all. For example, corn-based dextrose feedstock for the Clinton Facility is being provided from ADM’s adjacent wet mill and sugarcane-based sucrose for the Solazyme Bunge JV facility in Moema, Brazil will be provided by Bunge. Corn and sugar are traded as commodities and are subject to price volatility. While we may seek to manage our exposure to fluctuations in the price of sugar and corn-based dextrose by entering into hedging transactions directly or through our joint venture or collaboration arrangements, we may not be successful in doing so. If we cannot access feedstock in the quantities we need at acceptable prices, we may not be able to successfully commercialize our food ingredients, chemicals, fuels and other products, and our business will suffer. We are currently in discussions with additional potential feedstock partners, but we cannot be sure that we will successfully execute additional long-term feedstock contracts on terms favorable to us, or at all. If we do not succeed in entering into long-term supply contracts or successfully hedge against our exposure to fluctuations in the price of feedstock, our costs and profit margins may fluctuate from period to period as we will remain subject to prevailing market prices.

Although our plan is to enter into partnerships, such as the Solazyme Bunge JV and the Solazyme/ADM Collaboration, with feedstock providers to supply the feedstock necessary to produce our products, we cannot predict the future availability or price of such feedstock or be sure that our feedstock partners will be able to supply such feedstock in sufficient quantities or in a timely manner. The prices of feedstock depend on numerous factors outside of our or our partners’ control, including weather conditions, government programs and regulations, changes in global demand, rising or falling commodities and equities markets, and availability of

 

19


Table of Contents
Index to Financial Statements

credit to producers. Crop yields and sugar content depend on weather conditions such as rainfall and temperature. Variable weather conditions have historically caused volatility in feedstock crop prices due to crop failures or reduced harvests. For example, excessive rainfall can adversely affect the supply of feedstock available for the production of our products by reducing the sucrose content of feedstock and limiting growers’ ability to harvest. Crop disease and pestilence can also occur from time to time and can adversely affect feedstock crop growth, potentially rendering useless or unusable all or a substantial portion of affected harvests. The limited amount of time during which feedstock crops keep their sugar content after harvest poses a risk of spoilage. Also, the fact that many feedstock crops are not themselves traded commodities limits our ability to substitute supply in the event of such an occurrence. If our ability to obtain feedstock crops is adversely affected by these or other conditions, our ability to produce our products will be impaired, and our business will be adversely affected. In the near term we believe Brazilian sugarcane-based sucrose will be an important feedstock for us. Along with the risks described above, Brazilian sugarcane prices may also increase due to, among other things, changes in the criteria set by the Conselho dos Produtores de Cana, Açúcar e Álcool (Council of Sugarcane, Sugar and Ethanol Producers), known as Consecana. Consecana is an industry association of producers of sugarcane, sugar and ethanol that sets market terms and prices for general supply, lease and partnership agreements and may change such prices and terms from time to time. Moreover, Brazil has a developed industry for producing ethanol from sugarcane, and if we have manufacturing operations in Brazil that do not have a partner providing the sugarcane feedstock, such as Bunge as part of the Solazyme Bunge JV, we will need to compete for sugarcane feedstock with ethanol producers. Such changes and competition could result in higher sugarcane prices and/or a significant decrease in the volume of sugarcane available for the production of our products, which could adversely affect our business and results of operations.

We have entered into, and plan to enter into other, arrangements with feedstock producers to co-locate production at their existing mills, and if we are not able to complete and execute on these arrangements in a timely manner and on terms favorable to us, our business will be adversely affected.

In April 2012, we entered into a Joint Venture Agreement with Bunge, forming the Solazyme Bunge JV, which is doing business as Solazyme Bunge Renewable Oils. The Joint Venture Agreement was amended in October 2013 to expand the field and product portfolio. The Solazyme Bunge JV will produce microalgae-based products in Brazil using our proprietary technology and sugarcane feedstock provided by Bunge. The Solazyme Bunge JV’s production facility is located adjacent to a sugarcane processing mill in Brazil that is owned by Bunge. The acquisition of the facility site by the Solazyme Bunge JV from the landowners is in process, is complex, is subject to multiple approvals from governmental authorities and will take time to complete. The construction of the Solazyme Bunge JV’s production facility began in June 2012, and commissioning is underway. We are targeting the production of commercially saleable product by the end of the first quarter of 2014, though such production could move into the second quarter. In addition, in May 2011, we entered a joint development agreement with Bunge that, among other things, advances our work on Brazilian sugarcane feedstocks and extends through September 2014. In May 2011, we entered into a Warrant Agreement, amended in August 2011, with Bunge Limited that vests upon the successful completion of milestones that target the completion of construction of the Solazyme Bunge JV facility with a nameplate capacity of 100,000 MT of output oil. We intend to continue to expand our manufacturing capacity by entering into additional agreements with feedstock producers that require them to invest some or all of the capital needed to build new production facilities to produce our products. In return, we expect to share in profits anticipated to be realized from the sale of these products. We are currently in discussions with additional potential feedstock and manufacturing partners.

In November 2012, we and ADM entered into a Strategic Collaboration Agreement (Collaboration Agreement), establishing the Solazyme/ADM Collaboration for the production of microalgae-based products at the Clinton Facility. The Clinton Facility will utilize our proprietary microbe-based catalysis technology. Feedstock for the facility will be provided from ADM’s adjacent wet mill. Under the terms of the Collaboration Agreement, we agreed to pay ADM annual fees for use and operation of a portion of the Clinton Facility, a portion of which may be paid in our common stock. In addition, we have granted to ADM a warrant covering 500,000 shares of our common stock, which vests in equal monthly installments over five years, commencing in

 

20


Table of Contents
Index to Financial Statements

November 2013. The initial target nameplate capacity of the facility is expected to be 20,000 MT per year of tailored triglyceride oil, which we are targeting to attain 12-18 months after commencement of commercial production, which occurred in January 2014. We have an option to expand the capacity to 40,000 MT per year, with the potential to further expand production to 100,000 MT per year. Since the third quarter of 2013, downstream processing of products manufactured at the Clinton Facility has been performed at a finishing facility in Galva, Iowa (Galva Facility), which is operated by our long-term partner, a wholly owned subsidiary of American Natural Processors, Inc. (Clinton/Galva Facilities). There can be no assurance that we will be able to meet our capacity target of 20,000 MT per year as the Clinton Facility is ramped up or that the capacity of the facility will be expanded. We and ADM are also working together to develop markets for the products produced at the Clinton Facility.

There can be no assurance that a sufficient number of other sugar or other feedstock mill owners will accept the opportunity to partner with us for the production of our microalgae-based products. Reluctance on the part of mill owners may be caused, for example, by their failure to understand our technology or product opportunities or their belief that greater economic benefits can be achieved from partnering with others. Mill owners may also be reluctant or unable to obtain needed capital; alternatively, if mill owners are able to obtain debt financing, we may be required to provide a guarantee. Limitations in the credit markets, such as those experienced in the recent economic downturn or historically in developing nations as a result of government monetary policies designed in response to very high rates of inflation, would impede or prevent this kind of financing and could adversely affect our ability to develop the production capacity needed to allow us to grow our business. Mill owners may also be limited by existing contractual obligations with other third parties, liability, health and safety concerns and additional maintenance, training, operating and other ongoing expenses.

Even if additional feedstock partners are willing to co-locate our production at their mills, they may do so only on economic terms that place more of the cost, or confer less of the economic return, on us than we currently anticipate. If we are not successful in negotiations with mill owners, our cost of securing additional manufacturing capacity may be higher than anticipated in terms of up-front costs, capital expenditure or lost future returns, and we may not gain the manufacturing capacity that we need to grow our business.

Our pursuit of new product opportunities may not be technologically feasible or cost effective, which would limit our ability to expand our product line and sources of revenues.

We have committed, and intend to continue to commit, substantial resources, alone or with collaboration partners, to the development and analysis of new tailored oils and other microalgae-based products by applying recombinant technology to our microalgae strains. There is no guarantee that we will be successful in creating new tailored oil profiles, or other microalgae-based products, that we, our partners or their customers desire. There are significant technological hurdles in successfully applying recombinant technology to microalgae, and if we are unsuccessful at engineering microalgae strains that produce desirable tailored oils and other microalgae-based products, the number and size of the markets we will be able to address will be limited, our expected profit margins could be reduced and the potential profitability of our business could be compromised.

The successful development of our business depends on our ability to efficiently and cost-effectively produce microalgae-based products at large commercial scale.

Two of the significant drivers of our production costs are the level of productivity and conversion yield of our microalgae strains. For example, with respect to oil, productivity is principally a function of the amount of oil that can be obtained from a given volume over a particular time period. Conversion yield refers to the amount of the desired oil that can be produced from a fixed amount of feedstock. We may not be able to meet our currently expected production cost profile as we bring large commercial manufacturing capacity online. If we cannot do so, our business could be materially and adversely affected.

Production of both current and future oils and other microalgae-based products will require that our technology and processes be scalable from laboratory, pilot and demonstration projects to large commercial-scale production.

 

21


Table of Contents
Index to Financial Statements

We do not have experience constructing, ramping up or managing large, commercial-scale manufacturing facilities. We may not have identified all of the factors that could affect our manufacturing processes. Our technology may not perform as expected when applied at large commercial scale, or we may encounter operational challenges for which we are unable to identify a workable solution. For example, contamination in the production process, equipment failure or accidents, problems with plant utilities, human error, issues arising from process modifications to reduce costs and adjust product specifications, and other similar challenges could decrease process efficiency, create delays and increase our costs. To date we have employed our technology using fermenters with a capacity of up to approximately 500,000 liters. However, we still need to demonstrate that we can reach our target cost structure including the achievement of target yields and productivities at approximately 500,000 liter scale in Iowa and approximately 625,000 liter scale in Brazil. We may not be able to scale up our production in a timely manner, on commercially reasonable terms, or at all. If we are unable to manufacture products at a large commercial scale, our ability to commercialize our technology will be adversely affected, and, with respect to any products that we do bring to market, we may not be able to achieve and maintain an acceptable production cost profile, which would adversely affect our ability to reach, maintain and increase the profitability of our business.

We rely in part on third parties for the production and processing of our products. If these parties do not produce and process our products at a satisfactory quality, in a timely manner, in sufficient quantities and at an acceptable cost, our development and commercialization efforts could be delayed or otherwise negatively impacted.

Other than our Peoria Facility, we do not own facilities that can produce and process our products other than at small scale. As such, we rely, and we expect to continue to rely, at least partially, on third parties (including partners and contract manufacturers) for the production and processing of our products. Currently, we have two manufacturing arrangements for industrial fermentation: an agreement for the manufacture of certain products by the Solazyme Bunge JV pursuant to a joint venture arrangement and the manufacture of products at the Clinton Facility. We also have manufacturing agreements relating to other aspects of our production process. Our current and anticipated future dependence upon our partners and contract manufacturers for the production and processing of our products may adversely affect our ability to develop products on a timely and competitive basis. The failure of any of our counterparties to provide acceptable products could delay the development and commercialization of our products. We or our partners will need to enter into additional agreements for the commercial development, manufacturing and sale of our products. There can be no assurance that we or our partners can do so on favorable terms, if at all. Even if we reach agreements with manufacturing partners to produce and process our products, initially the partners will be unfamiliar with our technology and production processes. We cannot be sure that the partners will have or develop the operational expertise needed to run the equipment and processes required to manufacture our products. Further, we may have limited control over the amount or timing of resources that any partner is able or willing to devote to production and processing of our products.

To date, our products have been produced and processed in quantities sufficient for our development work and initial commercial sales. For example, we delivered more than 400,000 liters (373 MT) of microalgae-derived military marine diesel and jet fuel to the US Navy in 2011. Even if there is demand for our products at a commercial scale, we or our partners may not be able to successfully increase the production capacity for any of our products in a timely or economic manner or at all. In addition, to the extent we are relying on contract manufacturers to produce and process our products, we cannot be sure that such contract manufacturers will have capacity available when we need their services, that they will be willing to dedicate a portion of their production and/or processing capacity to our products or that we will be able to reach acceptable price and other terms with them for the provision of their production and/or processing services. If we, our partners or our contract manufacturers are unable to increase the production capacity for a product when and as needed, the commercial launch of that product may be delayed, or there may be a shortage of supply, which could limit sales, cause us to lose customers and sales opportunities and impair the growth of our business.

In addition, if a facility or the equipment in a facility that produces and/or processes our products is significantly damaged, destroyed or otherwise becomes unavailable, we or our partners may be unable to replace the manufacturing

 

22


Table of Contents
Index to Financial Statements

capacity quickly or cost effectively. The inability to enter into manufacturing agreements, the damage or destruction of a facility upon which we or our partners rely for manufacturing or any other delays in obtaining supply would delay or prevent us and/or our partners from further developing and commercializing our products.

We may experience significant delays and/or cost overruns in financing, designing, constructing and ramping up large commercial manufacturing facilities, which could result in harm to our business and prospects.

Our business plan contemplates bringing significant commercial manufacturing capacity online over the next several years. In order to meet our capital requirements for those facilities, we may have to raise additional funds and may be unable to do so in a timely manner, in sufficient amounts and on terms that are favorable to us, if at all. If we fail to raise sufficient funds, our ability to finance and construct additional manufacturing facilities could be significantly limited. If this happens, we may be forced to delay the commercialization of our products and we will not be able to successfully execute our business plan, which would harm our business.

The Solazyme Bunge JV is currently constructing a production facility adjacent to Bunge’s Moema sugarcane mill in Brazil, and commissioning is underway. We are targeting the production of commercially saleable product by the end of the first quarter of 2014, though such production could move into the second quarter. The production facility is expected to have a name plate capacity of 100,000 MT of oil per year. In February 2013, the Solazyme Bunge JV entered a loan agreement with the Brazilian Development Bank (BNDES) for project financing. Funds borrowed under the loan agreement have supported the production facility in Brazil, including a portion of the construction costs of the facility. We have used a portion of our $35.0 million revolving facility with HSBC Bank, USA, National Association (HSBC) to support a bank guarantee of the BNDES loan. As a condition of the Solazyme Bunge JV drawing funds under the loan in excess of amounts supported by bank guarantees, we will be required to provide a corporate guarantee of a portion of the loan (in an amount that, when added to the amount supported by our bank guarantee, does not exceed our ownership percentage in the Solazyme Bunge JV). Negotiating the terms of the corporate guarantee documentation may take longer than anticipated and may contain terms that are not favorable to us. If we are unable to negotiate our corporate guarantee documentation on acceptable terms, the Solazyme Bunge JV may be unable to draw down the maximum amount available under the BNDES loan, it may have to seek additional financing and may not be able to raise sufficient additional funds on favorable terms, if at all. If the Solazyme Bunge JV is unable to secure additional financing, we will be required to fund our portion of the Solazyme Bunge JV’s capital requirements either from existing sources or seek additional financing. The acquisition of the facility site from the landowners is in process, is complex, is subject to multiple approvals of governmental authorities and will take time to complete. If the Solazyme Bunge JV is unable to acquire the facility site on reasonable terms, or at all, it may not be able to operate the production facility and may lose all or part of its investment in such facility.

We will need to construct, or otherwise secure access to, and fund, additional capacity significantly greater than what we are in the process of building as we continue to commercialize our products. Some of our customers may ultimately require that we acquire access to multiple production facilities in order to diversify our manufacturing base. We are targeting the production of commercially saleable product at the Solazyme Bunge JV facility by the end of the first quarter of 2014, though such production could move into the second quarter. We also expect to bring online additional facilities in the future. Although we intend to enter into arrangements with third parties to meet our capacity targets, it is possible that we will need to construct our own facility or facilities to meet a portion or all of these targets. We have limited experience in the construction of commercial production facilities and, if we decide to construct our own facility, we will need to secure necessary funding, complete design and other plans needed for the construction of such facility and secure the requisite permits, licenses and other governmental approvals, and we may not be successful in doing so. The construction of any such facility would have to be completed on a timely basis and within an acceptable budget. In addition, there may be delays related to the acquisition of facility sites, which could delay the development and commercialization of our products. Any facility, whether owned by a third party or by us, must perform as designed once it is operational. If we encounter significant delays, cost overruns, engineering problems, equipment damage, accidents, equipment supply constraints or other serious challenges in bringing any of these

 

23


Table of Contents
Index to Financial Statements

facilities online, we may be unable to meet our production goals in the time frame we have planned. In addition, we have limited experience in the management of manufacturing operations at large scale. We may not be successful in producing the amount and quality of oil or other microalgae-based products we anticipate in the facilities and our results of operations may suffer as a result. We have limited experience producing our products at commercial scale, and we will not succeed if we cannot maintain or decrease our production costs and effectively scale our technology and manufacturing processes.

If we fail to maintain and successfully manage our existing, or enter into new, strategic collaborations, we may not be able to develop and commercialize many of our products and achieve or sustain profitability.

Our ability to enter into, maintain and manage collaborations in our target markets is fundamental to the success of our business. We currently have joint venture, collaboration, research and development, supply and/or distribution agreements with various strategic partners. We currently rely on our partners, in part, for manufacturing and sales or marketing services and intend to continue to do so for the foreseeable future, and we intend to enter into other strategic collaborations to produce, market and sell other products we develop. However, we may not be successful in entering into collaborative arrangements with third parties for the production and sale and marketing of other products. Any failure to enter into collaborative arrangements on favorable terms could delay or hinder our ability to develop and commercialize our products and could increase our costs of development and commercialization.

In the chemicals and fuels markets, we have entered into a joint venture arrangement with Bunge that will focus on the manufacture of products in Brazil for sale in the Brazilian market, and development agreements with various other partners. In addition, we have entered into a strategic collaboration with ADM for the manufacture of products to be sold primarily to the industrial and nutritionals markets in North America, and have entered into a commercial supply agreement with Unilever. In the skin and personal care market, we have entered into arrangements with Sephora S.A. and its affiliates (Sephora), QVC, Inc. and others. There can be no guarantee that we can successfully manage these strategic collaborations. Under our agreement with Sephora, we bear a significant portion of the costs and risk of marketing the products, but do not exercise sole control of marketing strategy. In some cases, we will need to meet certain milestones to continue our activities with these partners. Moreover, the exclusivity provisions of certain strategic arrangements limit our ability to otherwise commercialize our products.

Pursuant to the agreements listed above and similar arrangements that we may enter into in the future, we may have limited or no control over the amount or timing of resources that any partner is able or willing to devote to our products or collaborative efforts. Any of our partners may fail to perform their obligations as expected. These partners may breach or terminate their agreements with us or otherwise fail to conduct their collaborative activities successfully and in a timely manner. Further, our partners may not develop products arising out of our arrangements or devote sufficient resources to the development, manufacture, marketing, or sale of our products. Dependence on collaborative arrangements will also subject us to other risks, including:

 

   

we may be required to relinquish important rights, including intellectual property, marketing and distribution rights;

 

   

we may disagree with our partners as to rights to intellectual property we develop, or their research programs or commercialization activities;

 

   

we may have lower revenues than if we were to market and distribute such products ourselves;

 

   

a partner could separately develop and market a competing product either independently or in collaboration with others, including our competitors;

 

   

a partner could divest assets that are critical to our or our joint venture’s operations to a third party that is less willing to cooperate with us or is less incentivized or able to manage such assets in a way that helps us achieve our operational and financial goals;

 

24


Table of Contents
Index to Financial Statements
   

our partners could become unable or less willing to expend their resources on research and development or commercialization efforts due to general market conditions, their financial condition or other circumstances beyond our control;

 

   

we may be unable to manage multiple simultaneous partnerships or collaborations; and

 

   

our partners may operate in countries where their operations could be adversely affected by changes in the local regulatory environment or by political unrest.

Moreover, disagreements with a partner or former partner could develop, and any conflict with a partner or former partner could reduce our ability to enter into future collaboration agreements and negatively impact our relationships with one or more existing partners. In addition, disagreements with a partner or former partner could result in disputes or litigation and could require substantial time and money to resolve. If any of these events occurs, or if we fail to maintain our agreements with our partners, we may not be able to commercialize our existing and potential products, grow our business or generate sufficient revenues to support our operations.

Additionally, our business could be negatively impacted if any of our partners undergoes a change of control or were to otherwise assign the rights or obligations under any of our agreements to a competitor of ours or to a third party who is not willing to work with us on the same terms or commit the same resources as the current partner.

Our relationship with our strategic partner ADM may not prove successful.

We have entered into the Solazyme/ADM Collaboration, which is focused on producing products at the Clinton Facility using our proprietary technology. Feedstock for the facility is being provided from ADM’s adjacent wet mill. Under the terms of the Collaboration Agreement, we will pay ADM annual fees for use and operation of a portion of the Clinton Facility, a portion of which may be paid in our common stock.

Our ability to generate value from the Solazyme/ADM Collaboration will depend, among other things, on our ability to work cooperatively with ADM for the production of our products at the Clinton Facility. We may not be able to do so. For example, under the Solazyme/ADM Collaboration, ADM has agreed to provide feedstock and utility services to the Clinton Facility as well as operating services. ADM does not have previous experience working with our technology, and we cannot be sure that ADM will be successful in producing our products in the amounts we may require, at a satisfactory quality and/or in a cost-effective manner. Subject to limited exceptions and adjustments, we are responsible for annual fees regardless of ADM’s success in producing our products in acceptable quantities, at satisfactory quality and at acceptable costs. If production capacity is expanded at the Clinton Facility, there may be delays or cost overruns related to the retrofitting and permitting of the Clinton Facility, which would delay the increased production and commercialization of our products and could increase our costs. Furthermore, the agreements governing our Solazyme/ADM Collaboration are complex and cover a range of future activities, and disputes may arise between us and ADM that could delay the production and commercialization of our products or cause the termination of the Solazyme/ADM Collaboration. Additionally, downstream processing of products produced at the Clinton Facility is being performed at the facilities of third-party manufacturing partners. Any business or operations interruption at the facilities of such third parties could delay the production and commercialization of our products and could increase our costs.

Our relationship with our strategic partner Bunge may not prove successful.

We have entered into a joint venture with Bunge that will focus on the production of certain microalgae-based products in Brazil. In connection with the establishment of the Solazyme Bunge JV, we entered into a development agreement and other agreements with Bunge and the Solazyme Bunge JV.

Our ability to generate value from the Solazyme Bunge JV will depend, among other things, on our ability to work cooperatively with Bunge and the Solazyme Bunge JV for the commercialization of the Solazyme Bunge

 

25


Table of Contents
Index to Financial Statements

JV’s products. We may not be able to do so. For example, under the joint venture, Bunge has agreed to provide feedstock as well as utility services to the production facility. We and Bunge have both agreed to provide various administrative services to the Solazyme Bunge JV, and Bunge will also provide working capital to the Solazyme Bunge JV through a revolving loan facility, with a portion of the repayment for start-up expenses to be guaranteed by us. Bunge does not have previous experience working with our technology, and we cannot be sure that the Solazyme Bunge JV will be successful in commercializing its products. In addition, there may be delays related to the acquisition of the facility site from the landowners and delays or cost overruns in connection with the construction of the Solazyme Bunge JV production facility. There may also be delays in our negotiation of the corporate loan guarantee to be entered into as a condition of the Solazyme Bunge JV drawing down amounts in excess of amounts supported by bank guarantees under the loan agreement with BNDES. In addition, we will be required to maintain the required license, granted by the Sao Paulo State Environmental Department, to operate the production facility. Any negative event with respect to these issues would delay the development and commercialization of the Solazyme Bunge JV products. Furthermore, the agreements governing our partnership are complex and cover a range of future activities, and disputes may arise between us and Bunge that could delay completion of the Solazyme Bunge JV facility and/or the expansion of the Solazyme Bunge JV’s capacity and the development and commercialization of the Solazyme Bunge JV’s products or cause the dissolution of the Solazyme Bunge JV.

Our joint venture with Roquette has been dissolved. We are currently in arbitration with Roquette as to several issues related to the dissolution of the joint venture. We may have other disputes with Roquette related to the joint venture and its business.

In 2010, we entered into a 50/50 joint venture with Roquette Frères, S.A. (Roquette). As part of this relationship, we and Roquette formed Solazyme Roquette Nutritionals, LLC (SRN) through which both we and Roquette agreed to pursue certain opportunities in microalgae-based products for the food, nutraceuticals and animal feed markets. On June 21, 2013, we and Roquette agreed to dissolve SRN. On July 18, 2013, SRN was dissolved. As a result of the dissolution, the joint venture and operating agreement between us and Roquette, and the license agreement, whereby we licensed to SRN certain of our intellectual property, automatically terminated.

SRN, we and Roquette are in the process of winding down the affairs of SRN. We and Roquette are currently engaged in an arbitration proceeding concerning several issues associated with the dissolution of SRN and the wind-down of its affairs. We cannot be sure that other disputes will not arise between us and Roquette related to the joint venture and its business. Such disagreements and disputes are costly, time-consuming to resolve and distracting to our management.

Disputes regarding our intellectual property rights, and the rights of others (including Roquette) to manufacture and sell the products included in the SRN joint venture could delay or negatively impact our commercialization of products in the markets SRN was targeting. Any such disputes could be costly, time-consuming to resolve and distracting to our management. In addition, if our commercialization in these markets is delayed or unsuccessful, our financial results could be negatively impacted.

We cannot be sure that our products will meet necessary standards or be approved or accepted by customers in our target markets.

If we are unable to convince our potential customers or end users of our products that we are a reliable supplier, that our products are comparable or superior to the products that they currently use, or that the use of our products is otherwise beneficial to them, we will not be successful in entering our target markets and our business will be adversely affected.

In the chemicals market, the potential customers for our or the Solazyme Bunge JV’s products are generally companies that have well-developed manufacturing processes and arrangements with suppliers for the chemical components of their products and may resist changing these processes and components. These potential customers

 

26


Table of Contents
Index to Financial Statements

frequently impose lengthy and complex product qualification procedures on their suppliers, influenced by consumer preference, manufacturing considerations, supplier operating history, regulatory issues, product liability and other factors, many of which are unknown to, or not well understood by, us. Satisfying these processes may take many months or years.

Although we produce products for the fuels market that comply with industry specifications, potential fuels customers may be reluctant to adopt new products. In addition, our fuels may need to satisfy product certification requirements of equipment manufacturers. For example, diesel engine manufacturers may need to certify that the use of diesel fuels produced from our oils in their equipment will not invalidate product warranties.

In the nutrition market, our food ingredients will compete with oils and other food ingredients currently in use. Potential customers may not perceive a benefit to microalgae-based ingredients as compared to existing ingredients or may be otherwise unwilling to adopt their use. If consumer packaged goods (CPG) companies do not accept our food ingredients as ingredients for their widely distributed finished products, or if end customers are unwilling to purchase finished products made using our products, we will not be successful in competing in the nutrition market and our business will be adversely affected.

In the skin and personal care market, our branded products are marketed directly to potential consumers, but we cannot be sure that consumers will continue to be attracted to our brands, be attracted to our new brands or products, or purchase our products on an ongoing basis. As a result, our branded products may not be successful, distribution partners may decide to discontinue marketing our products and our business will be adversely affected.

We have entered into a limited number of binding, definitive commercial supply agreements that contain minimum volume commitments. We have also entered contingent offtake agreements and non-binding letters of intent with third parties regarding purchase of our products, but these agreements do not unconditionally obligate the other party to purchase any quantities of any products at this time. There can be no assurance that our contingent offtake agreements and non-binding letters of intent will lead to unconditional definitive agreements to purchase our products.

We have limited experience in structuring arrangements with customers for the purchase of our microalgae-based products, and we may not be successful in this essential aspect of our business.

We expect that our customers will include large companies that sell skin and personal care products, food products and chemical products, as well as large users of oils for fuels. Because we began commercializing our skin and personal care products in the last few years, have only recently begun to commercialize food ingredient products on our own, and are still in the process of developing our products for the food ingredients, oils, chemicals, fuels and other markets, we have limited experience operating in our customers’ industries and interacting with the customers that we intend to target. Developing the necessary expertise may take longer than we expect and will require that we expand and improve our sales and marketing capability, which could be costly. These activities could delay our ability to capitalize on the opportunities that we believe our technology and products present, and may prevent us from successfully commercializing our products. Further, we ultimately aim to sell large amounts of our products, and this will require that we effectively negotiate and manage contracts for these purchase and sale relationships. The companies with which we aim to have arrangements are generally much larger than we are and have substantially longer operating histories and more experience in their industries than we have. As a result, we may not succeed in establishing relationships with these companies and, if we do, we may not be effective in negotiating or managing the terms of such relationships, which could adversely affect our future results of operations.

We may be subject to product liability claims and other claims of our customers and partners.

The design, development, production and sale of our products involve an inherent risk of product liability claims and the associated adverse publicity. Because some of our ultimate products in each of our target markets

 

27


Table of Contents
Index to Financial Statements

are used by consumers, and because use of those ultimate products may cause injury to those consumers and damage to property, we are subject to a risk of claims for such injuries and damages. In addition, we may be named directly in product liability suits relating to our products or third-party products integrating our products, even for defects resulting from errors of our partners, contract manufacturers or other third parties working with our products. These claims could be brought by various parties, including customers who are purchasing products directly from us or other users who purchase products from our customers or partners. We could also be named as co-parties in product liability suits that are brought against manufacturing partners that produce our products.

In addition, our customers and partners may bring suits against us alleging damages for the failure of our products to meet stated claims, specifications or other requirements. Any such suits, even if not successful, could be costly, disrupt the attention of our management and damage our negotiations with other partners and/or customers. Although we often seek to limit our product liability in our contracts, such limits may not be enforceable or may be subject to exceptions. Our current product liability and umbrella insurance for our business may be inadequate to cover all potential liability claims. Insurance coverage is expensive and may be difficult to obtain. Also, insurance coverage may not be available in the future on acceptable terms and may not be sufficient to cover potential claims. We cannot be sure that our contract manufacturers or manufacturing partners who produce our ultimate products will have adequate insurance coverage to cover against potential claims. If we experience a large insured loss, it may exceed our coverage limits, or our insurance carrier may decline to further cover us or may raise our insurance rates to unacceptable levels, any of which could impair our financial position and potentially cause us to go out of business.

We will face risks associated with our international business in developing countries and elsewhere.

For the foreseeable future, our business plan will likely subject us to risks associated with essential manufacturing, sales and operations in developing countries. We have limited experience to date manufacturing and selling internationally and such expansion will require us to make significant expenditures, including the hiring of local employees and establishing facilities, in advance of generating any revenue. The economies of many of the countries in which we or our joint ventures operate or will operate have been characterized by frequent and occasionally extensive government intervention and unstable economic cycles.

In addition, in Brazil, where the Solazyme Bunge JV is located, there are restrictions on the foreign ownership of land. As a result, the process for the acquisition by the Solazyme Bunge JV of the facility site from the landowners may be long, complicated and is subject to government approvals.

International business operations are subject to local legal, political, regulatory and social requirements and economic conditions and our business, financial performance and prospects may be adversely affected by, among others, the following factors:

 

   

political, economic, diplomatic or social instability;

 

   

land reform movements;

 

   

tariffs, export or import restrictions, restrictions on remittances abroad or repatriation of profits, duties or taxes that limit our ability to move our products out of these countries or interfere with the import of essential materials into these countries;

 

   

inflation, changing interest rates and exchange controls;

 

   

tax burden and policies;

 

   

delays or failures in securing licenses, permits or other governmental approvals necessary to build and operate facilities and use our microalgae strains to produce products;

 

   

the imposition of limitations on products or processes and the production or sale of those products or processes;

 

28


Table of Contents
Index to Financial Statements
   

uncertainties relating to foreign laws, including labor laws, regulations and restrictions, and legal proceedings;

 

   

foreign ownership rules and changes in regard thereto;

 

   

an inability, or reduced ability, to protect our intellectual property, including any effect of compulsory licensing imposed by government action;

 

   

successful compliance with US and foreign laws that regulate the conduct of business abroad, including the Foreign Corrupt Practices Act;

 

   

insufficient investment in developing countries in public infrastructure, including transportation infrastructure, and disruption of transportation and logistics services; and

 

   

difficulties and costs of staffing and managing foreign operations.

These and other factors could have a material adverse impact on our results of operations and financial condition.

Our international operations may expose us to the risk of fluctuation in currency exchange rates and rates of foreign inflation, which could adversely affect our results of operations.

We currently incur some costs and expenses in Euros and Brazilian Reais and expect in the future to incur additional expenses in these and other foreign currencies, and also derive a portion of our revenues in the local currencies of customers throughout the world. As a result, our revenues and results of operations are subject to foreign exchange fluctuations, which we may not be able to manage successfully. During the past few decades, the Brazilian currency in particular has faced frequent and substantial exchange rate fluctuations in relation to the US dollar and other foreign currencies. There can be no assurance that the Real or the Euro will not significantly appreciate or depreciate against the US dollar in the future. We bear the risk that the rate of inflation in the foreign countries where we incur costs and expenses or the decline in value of the US dollar compared to those foreign currencies will increase our costs as expressed in US dollars. Future measures by foreign governments to control inflation, including interest rate adjustments, intervention in the foreign exchange market and changes to the fixed value of their currencies, may trigger increases in inflation. We may not be able to adjust the prices of our products to offset the effects of inflation on our cost structure, which could increase our costs and reduce our net operating margins. If we do not successfully manage these risks through hedging or other mechanisms, our revenues and results of operations could be adversely affected.

We may encounter difficulties managing our growth, and we will need to properly prioritize our efforts in three distinct target markets as our business grows. If we are unable to do so, our business, financial condition and results of operations may be adversely affected.

Our business has grown rapidly. Continued growth may place a strain on our human and capital resources. Furthermore, we intend to conduct our business internationally and anticipate business operations in the United States, Europe, Latin America and elsewhere. These diversified, global operations place increased demands on our limited resources and may require us to substantially expand the capabilities of our administrative and operational resources and will require us to attract, train, manage and retain qualified management, technicians, scientists and other personnel. As our operations expand domestically and internationally, we will need to continue to manage multiple locations and additional relationships with various customers, partners, suppliers and other third parties across several product categories and markets.

Our growth is taking place across three distinct target markets: chemicals and fuels, nutrition, and skin and personal care. We will be required to prioritize our limited financial and managerial resources as we pursue particular development and commercialization efforts in each target market. Any resources we expend on one or more of these efforts could be at the expense of other potentially profitable opportunities. If we focus our efforts and resources on one or more of these markets and they do not lead to commercially viable products, our

 

29


Table of Contents
Index to Financial Statements

revenues, financial condition and results of operations could be adversely affected. Furthermore, as our operations continue to grow, the simultaneous management of development, production and commercialization across all three target markets will become increasingly complex and may result in less than optimal allocation of management and other administrative resources, increase our operating expenses and harm our operating results.

Our ability to effectively manage our operations, growth and various projects across our target markets will require us to make additional investments in our infrastructure to continue to improve our operational, financial and management controls and our reporting systems and procedures and to attract and retain sufficient numbers of talented employees, which we may be unable to do effectively. We may be unable to successfully manage our expenses in the future, which may negatively impact our gross margins or operating margins in any particular quarter.

In addition, we may not be able to improve our management information and control systems, including our internal control over financial reporting, to a level necessary to manage our growth and we may discover deficiencies in existing systems and controls that we may not be able to remediate in an efficient or timely manner.

Our success depends in part on recruiting and retaining key personnel and, if we fail to do so, it may be more difficult for us to execute our business strategy. We are currently a small organization and will need to hire additional personnel to execute our business strategy successfully.

Our success depends on our continued ability to attract, retain and motivate highly qualified management, business development, manufacturing and scientific personnel and directors, and on our ability to develop and maintain important relationships with leading academic institutions and scientists. We are highly dependent upon a number of key members of our senior management, including manufacturing, business development and scientific personnel, and on our directors. If any of such persons left, our business could be harmed. All of our employees and directors are at-will and may resign at anytime. The loss of the services of one or more of our key employees, or directors could delay or have an impact on the successful commercialization of our products. We do not maintain any key man insurance. Competition for qualified personnel in the biotechnology field is intense, particularly in the San Francisco Bay Area. We may not be able to attract and retain qualified personnel on acceptable terms given the competition for such personnel. If we are unsuccessful in our recruitment efforts, we may be unable to execute our strategy.

We may not be able to obtain regulatory approval for the sale of our microalgae-based products and the operation of production facilities, and, even if approvals are obtained, complying on an ongoing basis with the numerous regulatory requirements applicable to our various product categories and facilities will be time-consuming and costly.

The sale and/or use of diesel and jet fuels produced from our oils are subject to regulation by various government agencies, including the Environmental Protection Agency (EPA) and the California Air Resources Board in the United States. To date, we have registered only our Soladiesel RD ® fuel in the United States. We or our refining or commercialization partners or customers may be required to register our fuel in the United States, with the European Commission and elsewhere before selling our products.

Our chemical products may be subject to government regulation in our target markets. In the United States, the EPA administers the Toxic Substances Control Act (TSCA), which regulates the commercial registration, distribution, and use of chemicals. TSCA will require us to comply with the Microbial Commercial Activity Notice (MCAN) process to manufacture and distribute products made from our recombinant microalgae strains. An MCAN is not required for non-recombinant strains. To date, we have filed MCANs for certain of our recombinant microalgae strains, some of which have been dropped from review, and expect to file additional MCANs in the future.

Before we can manufacture or distribute significant volumes of a chemical, we need to determine whether that chemical is listed in the TSCA inventory. If the substance is listed, then manufacture or distribution can

 

30


Table of Contents
Index to Financial Statements

commence immediately. If not, then a pre-manufacture notice (PMN) must be filed with the EPA for a review period of up to 90 days excluding extensions. We have filed PMNs for certain of our products and expect to file additional PMNs in the future. Some of the products we produce or plan to produce are already eligible to be placed on the TSCA inventory. Others are not yet listed. We may not be able to expediently receive approval from the EPA to list the chemicals we would like to make on the TSCA registry, resulting in delays or significant increases in testing requirements. A similar program exists in the European Union, called REACH (Registration, Evaluation, Authorization, and Restriction of Chemical Substances). We are required to register some of our products with the European Commission, and this process could cause delays or significant costs. We have determined that some of our algal oils are exempt from REACH registration requirements. To the extent that other geographies, such as Brazil, may rely on the TSCA or REACH for chemical registration in their geographies, delays with the US or European authorities may subsequently delay entry into these markets as well. Furthermore, other geographies may have their own chemical inventory requirements, which may delay entry into these markets, irrespective of US or European approval.

Our nutrition products are subject to regulation by various government agencies, including the US Food and Drug Administration (FDA), state and local agencies and similar agencies outside the United States. Food ingredients are regulated either as food additives or as substances generally recognized as safe, or GRAS. A substance can be listed or affirmed as GRAS by the FDA or self-affirmed by its manufacturer upon determination that independent qualified experts would generally agree that the substance is GRAS for a particular use. A GRAS Notice of Determination for algal oil was submitted to the FDA, and notification was received from the FDA in June 2012 that it had no further questions. A GRAS Notice of Determination for whole algal flour was submitted to the FDA, and notification was received from the FDA that it had no further questions. If the FDA were to disagree with the conclusions in future GRAS Notices of Determination, they could ask that the products be voluntarily withdrawn from the market or could initiate legal action to halt their sale. Such actions by the FDA could have an adverse effect on our business, financial condition, and results of our operations. Food ingredients that are not GRAS are regulated as food additives and require FDA approval prior to commercialization. The food additive petition process is generally expensive and time consuming, with approval, if secured, taking years.

The sale of ingredients for use in animal feed is regulated by agencies including the FDA Center for Veterinary medicine (CVM). Regulatory requirements for suitability must be met by providing data from studies, which may cause delays and the incursion of additional costs.

Our skin and personal care products are subject to regulation by various government agencies both within and outside the United States. Such regulations principally relate to the ingredients, labeling, packaging and marketing of our skin and personal care products.

Changes in regulatory requirements, laws and policies, or evolving interpretations of existing regulatory requirements, laws and policies, may result in increased compliance costs, delays, capital expenditures and other financial obligations that could adversely affect our business or financial results.

We expect to encounter regulations in most if not all of the countries in which we may seek to sell our products, and we cannot be sure that we will be able to obtain necessary approvals in a timely manner or at all. If our products do not meet applicable regulatory requirements in a particular country or at all, then we may not be able to commercialize them and our business will be adversely affected. The various regulatory schemes applicable to our products will continue to apply following initial approval for sale. Monitoring regulatory changes and ensuring our ongoing compliance with applicable requirements will be time-consuming and may affect our results of operations. If we fail to comply with such requirements on an ongoing basis, we may be subject to fines or other penalties, or may be prevented from selling our products, and our business may be harmed.

The construction and operation of our, our partners’ or our joint ventures’ production facilities are likely to require government approvals. If we are not able to obtain or maintain the necessary approvals in a timely manner or at all, our business will be adversely affected. In February 2014, the Sao Paulo State Environmental Department granted a license to operate the Solazyme Bunge JV facility, which is necessary to begin commercial production.

 

31


Table of Contents
Index to Financial Statements

We may incur significant costs complying with environmental, health and safety laws and regulations, and failure to comply with these laws and regulations could expose us to significant liabilities.

We use hazardous chemicals and radioactive and biological materials in our business and are subject to a variety of federal, state, local and international laws and regulations governing, among other matters, the use, generation, manufacture, transportation, storage, handling, disposal of, and human exposure to, these materials both in the US and outside the US, including regulation by governmental regulatory agencies, such as the Occupational Safety and Health Administration and the EPA. We have incurred, and will continue to incur, capital and operating expenditures and other costs in the ordinary course of our business in complying with these laws and regulations.

Although we have implemented safety procedures for handling and disposing of these materials and waste products in an effort to comply with these laws and regulations, we cannot be sure that our safety measures will be compliant or capable of eliminating the risk of injury or contamination from the generation, manufacturing, use, storage, transportation, handling, disposal of, and human exposure to, hazardous materials. Failure to comply with environmental, health and safety laws could subject us to liability and resulting damages. There can be no assurance that violations of environmental, health and safety laws will not occur as a result of human error, accident, equipment failure or other causes. Compliance with applicable environmental laws and regulations may be expensive, and the failure to comply with past, present, or future laws could result in the imposition of fines, regulatory oversight costs, third party property damage, product liability and personal injury claims, investigation and remediation costs, the suspension of production, or a cessation of operations, and our liability may exceed our total assets. Liability under environmental laws, such as the Comprehensive Environmental Response Compensation and Liability Act in the United States, can impose liability for the full amount of damages, without regard to comparative fault for the investigation and cleanup of contamination and impacts to human health and for damages to natural resources. Contamination at properties we own and operate, and at properties to which we send hazardous materials, may result in liability for us under environmental laws and regulations.

Our business and operations will be affected by other new environmental, health and safety laws and regulations, which may affect our research and development and manufacturing programs, and environmental laws could become more stringent over time, requiring us to change our operations, or resulting in greater compliance costs and increasing risks and penalties associated with violations, which could impair our research, development or production efforts and harm our business. The costs of complying with environmental, health and safety laws and regulations, and any claims concerning noncompliance, or liability with respect to contamination in the future could have a material adverse effect on our financial condition or operating results.

Changes in government regulations, including subsidies and economic incentives, could have a material adverse effect on demand for our products, business or results of operations.

The market for renewable fuels is heavily influenced by foreign, federal, state and local government regulations and policies. Changes to existing, or adoption of new, domestic or foreign federal, state or local legislative initiatives that impact the production, distribution, sale or import and export of renewable fuels may harm our business. For example, in 2007, the Energy Independence and Security Act (EISA) of 2007 set targets for alternative sourced liquid transportation fuels (approximately 14 billion gallons in 2011, increasing to 36 billion gallons by 2022). Of the 2022 target amount, a minimum of 21 billion gallons must be advanced biofuels. In the US and in a number of other countries, these regulations and policies have been modified in the past and may be modified again in the future. For example, in 2013, the US Environmental Protection Agency proposed a reduction in the volume of total alternative fuel from the 2014 statutory target of 18.15 billion gallons to 15.21 billion gallons. Under this new proposed target, the advanced biofuel target would be reduced to 2.2 billion gallons from the 2014 statutory target of 3.75 billion gallons. The elimination of, or any additional reduction in, mandated requirements for fuel alternatives and additives to gasoline may cause demand for biofuels to decline and deter investment in the research, development or commercial adoption of renewable fuels.

In addition, the US Congress has passed legislation that extends tax credits to blenders of certain renewable fuel products. However, there is no assurance that this or any other favorable legislation will remain in place. For

 

32


Table of Contents
Index to Financial Statements

example, the biodiesel tax credit expired in December 2009 and its extension was not approved until March 2010. The most recent biodiesel tax credit expired in December 2013 and its extension has thus far not been approved. Any reduction in, phasing out or elimination of existing tax credits, subsidies and other incentives in the US and foreign markets for renewable fuels, or any inability of our customers to access such credits, subsidies and incentives, may adversely affect demand for our fuel products and increase the overall cost of commercialization of our renewable fuels, which would adversely affect our business.

In addition, market uncertainty regarding future policies may also affect our ability to develop new renewable products, license our technologies to third parties and sell products to end customers. Any inability to address these requirements and any regulatory or policy changes could have a material adverse effect on our business, financial condition and results of operations.

Conversely, government programs could increase investment and competition in the markets for our products. For example, various governments have announced a number of spending programs focused on the development of clean technology, including alternatives to petroleum-based fuels and the reduction of greenhouse gas (GHG) emissions, which could lead to increased funding for us or our competitors, or the rapid increase in the number of competitors within our markets.

Concerns associated with renewable fuels, including land usage, national security interests and food crop usage, are receiving legislative, industry and public attention. This could result in future legislation, regulation and/or administrative action that could adversely affect our business. When and how these requirements and any regulatory or policy changes are addressed could have a material adverse effect on our business, financial condition and results of operations.

Future government policies may adversely affect the supply of sugarcane, corn or cellulosic sugars, restricting our ability to use these feedstocks to produce our products, and negatively impact our revenues and results of operations.

We may face risks relating to the use of our targeted recombinant microalgae strains, and if we are not able to secure regulatory approval for the use of these strains or if we face material ethical, legal and social concerns about our use of targeted recombinant technology, our business could be adversely affected.

The use of microorganisms designed using targeted recombinant technology, such as some of our microalgae strains, is subject to laws and regulations in many states and countries, some of which are new and still evolving and interpreted by fact specific application. In the United States, the EPA regulates the commercial use of microorganisms designed using targeted recombinant technology as well as potential products derived from them.

We expect to encounter regulations of microorganisms designed using targeted recombinant technology in most if not all of the countries in which we may seek to establish manufacturing operations, and the scope and nature of these regulations will likely be different from country to country. For example, in the US, when used in an industrial process, our microalgae strains designed using targeted recombinant technology may be considered new chemicals under the TSCA, administered by the EPA. We will be required to comply with the EPA’s process. In Brazil, microorganisms designed using targeted recombinant technology are regulated by the National Biosafety Technical Commission, or CTNBio. In March 2013, we submitted an application for approval from CTNBio to use a specific microalgae strain designed using targeted recombinant technology in a contained environment in order to use these microalgae for research and development and commercial production purposes in any facilities we establish in Brazil. We obtained approval for this application from CTNBio in October 2013. In February 2014, CTNBio granted a CQB (Certificate of Quality in Biosafety) to the Moema plant for activities including industrial production, import and export, disposal and storage of our key production organisms. If we cannot meet the applicable requirements in Brazil and other countries in which we intend to produce microalgae-based products, or if it takes longer than anticipated to obtain such approvals, our business could be adversely affected.

 

33


Table of Contents
Index to Financial Statements

The subject of organisms designed using targeted recombinant technology has received negative publicity, which has aroused public debate. Public attitudes about the safety and environmental hazards of, and ethical concerns over, genetic research and microorganisms designed using targeted recombinant technology could influence public acceptance of our technology and products. In addition, shifting public attitudes regarding, and potential changes to laws governing, ownership of genetic material could harm our intellectual property rights with respect to our genetic material and discourage collaborators from supporting, developing, or commercializing our products, processes and technologies. Governmental reaction to negative publicity concerning organisms designed using targeted recombinant technology could result in greater government regulation of or trade restrictions on imports of genetic research and derivative products. If we and/or our collaborators are not able to overcome the ethical, legal, and social concerns relating to the use of targeted recombinant technology, our products and processes may not be accepted or we could face increased expenses, delays or other impediments to their commercialization.

We expect to face competition for our products in the chemicals and fuels markets from providers of products based on petroleum, plant oils and animal fats and from other companies seeking to provide alternatives to these products, many of whom have greater resources and experience than we do. If we cannot compete effectively against these companies or products, we may not be successful in bringing our products to market or further growing our business.

In the chemical market, we will compete with the established providers of oils currently used in chemical products. Producers of these incumbent products include global oil companies, including those selling agricultural products such as palm oil, palm kernel oil, castor bean oil and sunflower oil, large international chemical companies and other companies specializing in specific products or essential oils. We may also compete in one or more of these markets with manufacturers of other products such as highly refined petrochemicals, synthetic polymers and other petroleum-based fluids and lubricants as well as new market entrants offering renewable products.

In the transportation fuels market, we expect to compete with independent and integrated oil refiners, large oil and gas companies and, in certain fuels markets, with other companies producing advanced biofuels. The refiners compete with us by selling conventional fuel products, and some are also pursuing hydrocarbon fuel production using non-renewable feedstocks, such as natural gas and coal, as well as production using renewable feedstocks, such as vegetable oil and biomass. We also expect to compete with companies that are developing the capacity to produce diesel and other transportation fuels from renewable resources in other ways. These include advanced biofuels companies using specific engineered enzymes that they have developed to convert cellulosic biomass, which is non-food plant material such as wood chips, corn stalks and sugarcane bagasse, into fermentable sugars and ultimately, renewable diesel and other fuels. Biodiesel companies convert vegetable oils and animal oils into diesel fuel and some are seeking to produce diesel and other transportation fuels using thermochemical methods to convert biomass into renewable fuels.

We believe the primary competitive factors in both the chemicals and fuels markets are product price, product performance, sustainability, availability of supply and compatibility of products with existing infrastructure.

The oil companies, large chemical companies and well-established agricultural products companies with whom we expect to compete are much larger than we are, have, in most cases, well-developed distribution systems and networks for their products, have valuable historical relationships with the potential customers we are seeking to serve and have much more extensive sales and marketing programs in place to promote their products. Some of our competitors may use their influence to impede the development and acceptance of our products. Our limited resources relative to many of our competitors may cause us to fail to anticipate or respond adequately to new developments and other competitive pressures. In the nascent markets for renewable chemicals and fuels, it is difficult to predict which, if any, market entrants will be successful, and we may lose market share to competitors producing new or existing renewable products.

 

34


Table of Contents
Index to Financial Statements

We expect to face competition for our nutrition and skin and personal care products from other companies in these fields, many of whom have greater resources and experience than we do. If we cannot compete effectively against these companies or their products, we may not be successful in selling our products or further growing our business.

We expect that our nutrition products will compete with providers in both the specialty and mass food ingredient markets. Many of these companies, such as Cargill, Incorporated, Monsanto Company, Syngenta AG and Roquette S.A., are larger than we are, have well-developed distribution systems and networks for their products and have valuable historical relationships with the potential customers and distributors we hope to serve. We may also compete with companies seeking to produce nutrition products based on renewable oils, including DSM Food Specialties and DuPont Nutrition & Health. Our success in the development of nutrition products will depend on our ability to effectively compete with established companies and successfully commercialize our products.

In the skin and personal care market, we expect to compete with established companies and brands with loyal customer followings. The market for skin and personal care products is characterized by strong established brands, loyal brand following and heavy brand marketing. We will compete with companies with well-known brands such as Kinerase ® , Perricone MD ® , and StriVectin ® . These companies have greater sales and marketing resources than us. We will also compete in the mass consumer market. Some of our competitors in this market have well-known brands such as Meaningful Beauty ® and Principal Secret ® and have substantially greater sales and marketing resources than us. We have limited experience in the skin and personal care market. We will need to continue to devote substantial resources to the marketing of our products and there can be no assurance that we will be successful.

A decline in the price of petroleum and petroleum-based products, plant oils or other commodities may reduce demand for our products and may otherwise adversely affect our business.

We believe that some of the present and projected demand for renewable fuels results from relatively recent increases in the cost of petroleum and certain plant oils. We anticipate that most of our oils, and in particular those used to produce fuels, will be marketed as alternatives to corresponding products based on petroleum and plant oils. If the price of any of these oils falls, we may be unable to produce tailored oils or other products that are cost-effective alternatives to their petroleum or plant oil-based counterparts. Declining oil prices, or the perception of a future decline in oil prices, may adversely affect the prices we can obtain from our potential customers or prevent potential customers from entering into agreements with us to buy our products. During sustained periods of lower oil prices we may be unable to sell our products, which could materially and adversely affect our operating results.

Petroleum prices have been extremely volatile, and this volatility is expected to persist. Lower petroleum prices over extended periods of time may change the perceptions in government and the private sector that cheaper, more readily available energy alternatives should be developed and produced. If petroleum prices were to decline from present levels and remain at lower levels for extended periods of time, the demand for renewable fuels could be reduced, and our business and revenue may be harmed.

Prices of plant oils have also experienced significant volatility. If prices for oils such as palm kernel were to materially decrease in the future, there may be less demand for oil alternatives, which could reduce demand for our products and harm our business. The prices of commodities that serve as food ingredients have also been volatile. To the extent that the prices of these commodities decline and remain at lower levels for extended periods of time, the demand for our nutrition products may be reduced, and our ability to successfully compete in this market may be harmed.

Our information technology systems, processes and sites may suffer a significant breach or disruption that may adversely affect our ability to conduct our business.

Our information technology systems, some of which are dependent on services provided by third parties, provide critical data and services for internal and external users, including procurement and inventory

 

35


Table of Contents
Index to Financial Statements

management, transaction processing, financial, commercial and operational data, human resources management, legal and tax compliance information and other information and processes necessary to operate and manage our business. Our information technology and infrastructure may experience attacks by hackers, breaches or other failures or disruptions that could compromise our systems and the information stored there. While we have implemented security measures and disaster recovery plans designed to protect the security and continuity of our networks and critical systems, these measures may not adequately prevent adverse events such as breaches or failures from occurring or mitigate their severity if they do occur. If our information technology systems are breached, damaged or fail to function properly due to any number of causes, such as security breaches or cyber based attacks, systems implementation difficulties, catastrophic events or power outages, and our security, contingency or disaster recovery plans do not effectively mitigate these occurrences on a timely basis, we may experience a material disruption in our ability to manage our business operations. We may also be subject to legal claims or proceedings, liability under laws that protect the privacy of personal information, potential regulatory penalties and damage to our reputation. These impacts may adversely impact our business, results of operations and financial condition, as well as our competitive position.

Our facilities in California are located near an earthquake fault, and an earthquake or other natural disaster or resource shortage could disrupt our operations.

Important documents and records, such as hard copies of our laboratory books and records for our products and some of our manufacturing operations, are located in our corporate headquarters in South San Francisco, California, near active earthquake zones. In the event of a natural disaster, such as an earthquake, drought or flood, or localized extended outages of critical utilities or transportation systems, we do not have a formal business continuity or disaster recovery plan, and could therefore experience a significant business interruption. In addition, California from time to time has experienced shortages of water, electric power and natural gas. Future shortages and conservation measures could disrupt our operations and could result in additional expense. Although we maintain business interruption insurance coverage, we do not maintain earthquake or flood coverage.

Risks Related to Our Intellectual Property

Our competitive position depends on our ability to effectively obtain and enforce patents related to our products, manufacturing components and manufacturing processes. If we or our licensors fail to adequately protect this intellectual property, our ability and/or our partners’ ability to commercialize products could suffer.

Our success depends in part on our ability to obtain and maintain patent protection sufficient to prevent others from utilizing our manufacturing components, manufacturing processes or marketing our products, as well as to successfully defend and enforce our patents against infringement by others. In order to protect our products, manufacturing components and manufacturing processes from unauthorized use by third parties, we must hold patent rights that cover our products, manufacturing components and manufacturing processes.

The patent position of biotechnology and bio-industrial companies can be highly uncertain because obtaining and determining the scope of patent rights involves complex legal and factual questions. The standards applied by the US Patent and Trademark Office and foreign patent offices in granting patents are not always applied uniformly or predictably. There is no uniform worldwide policy regarding patentable subject matter, the scope of claims allowable in biotechnology and bio-industrial patents, or the formal requirements to obtain such patents. Consequently, patents may not issue from our pending patent applications. Furthermore, in the process of seeking patent protection or even after a patent is granted, we could become subject to expensive and protracted proceedings, including patent interference, opposition, post-grant review and re-examination proceedings, which could invalidate or narrow the scope of our patent rights. As such, we do not know nor can we predict the scope and/or breadth of patent protection that we might obtain on our products and technology.

Changes either in patent laws or in interpretations of patent laws in the United States and other countries may diminish the value of our intellectual property rights. In the US, depending on the decisions and actions

 

36


Table of Contents
Index to Financial Statements

taken by the US Congress, the federal courts, and the US Patent and Trademark Office, the laws and regulations governing patents could change in unpredictable ways that would weaken our ability to obtain new patents or to enforce our existing patents and patents that we might obtain in the future. In foreign jurisdictions, depending on the decisions and actions taken by the foreign government, the judicial system of the jurisdiction, and its patent office, the laws and regulations governing patents could change in unpredictable ways that could weaken our ability to obtain new patents or to enforce our existing patents or patents that we might obtain in the future.

The America Invents Act (AIA), which was signed into law on September 16, 2011, brought a number of changes to the US patent system and affects the way patents are prosecuted, challenged and litigated. Among the changes that went into effect September 16, 2012, one of the most significant involves the implementation of a reformed post-grant review system. Other changes, which went into effect on March 16, 2013, include the transition from a “first-to-invent” to “first-to-file” system that attempts to harmonize the US with most of the world. Lack of precedential interpretation of the new provisions of the AIA through specific cases or through guidelines promulgated by the US Patent and Trademark Office and the lack of binding precedent from the courts increase the uncertainty of the impact of the AIA. Together, these changes may increase the costs of prosecution and enforcement of US patents. While it is currently unclear what impact these changes will have on the operation of our business, they may favor companies able to dedicate more resources to patent filings and challenges.

Risks associated with enforcing our intellectual property rights in the United States.

If we were to initiate legal proceedings against a third party to enforce a patent claiming one of our technologies, the defendant could counterclaim that our patent is invalid and/or unenforceable or assert that the patent does not cover its manufacturing processes, manufacturing components or products. Proving patent infringement may be difficult, especially where it is possible to manufacture a product by multiple processes or when a patented process is performed by multiple parties. Patent litigation is also costly, time-consuming and distracting to our management. Furthermore, in patent litigation in the United States or elsewhere, defendant counterclaims alleging both invalidity and unenforceability are commonplace. Although we believe that we have conducted our patent prosecution in accordance with the duty of candor and in good faith, the outcome following legal assertions of invalidity and unenforceability during patent litigation is unpredictable. With respect to the validity of our patent rights, we cannot be certain, for example, that there is no invalidating prior art, of which we and the patent examiner were unaware during prosecution. If a defendant were to prevail on a legal assertion of invalidity and/or unenforceability, we would not be able to exclude others from practicing the inventions claimed therein. Such a loss of patent protection could have a material adverse effect on our business. Defendant counterclaims of antitrust or other anti-competitive conduct are also commonplace.

Even if our patent rights are found to be valid and enforceable, patent claims that survive litigation may not cover commercially viable products or prevent competitors from importing or marketing products similar to our own, or using manufacturing processes or manufacturing components similar to our own.

Although we believe we have obtained valid assignments of patent rights from all inventors, if an inventor did not adequately assign their patent rights to us, a third party could obtain a license to the patent from such inventor. This could preclude us from enforcing the patent against such third party.

We may not be able to enforce our intellectual property rights throughout the world.

The laws of some foreign countries where we intend to produce and use our proprietary strains in collaboration with sugar mills or other feedstock suppliers do not protect intellectual property rights to the same extent as the laws of the United States. Many companies have encountered significant problems in protecting and defending intellectual property rights in certain foreign jurisdictions. The legal systems of certain countries, including Brazil and developing countries, do not favor the enforcement of patents and other intellectual property protection, particularly those relating to biotechnology and/or bio-industrial technologies. This could make it difficult for us to stop the infringement of our patents or misappropriation of our intellectual property rights in

 

37


Table of Contents
Index to Financial Statements

these countries. Proceedings to enforce our patent rights in certain foreign jurisdictions are unpredictable and could result in substantial costs and divert our efforts and attention from other aspects of our business. Accordingly, our efforts to protect our intellectual property rights in such countries may be inadequate.

Third parties may misappropriate our proprietary strains, information, or trade secrets despite a contractual obligation not to do so.

Third parties (including joint venture, collaboration, development and feedstock partners and former partners, contract manufacturers, and other contractors and shipping agents) often have custody or control of our proprietary microbe strains. If our proprietary microbe strains were stolen, misappropriated or reverse engineered, they could be used by other parties who may be able to use our strains or reverse-engineered strains for their own commercial gain. It is difficult to prevent misappropriation or subsequent reverse engineering. In the event that our proprietary microbe strains are misappropriated, it could be difficult for us to challenge the misappropriation or prevent reverse engineering, especially in countries with limited legal and intellectual property protection.

Confidentiality agreements with employees and third parties may not prevent unauthorized disclosure of proprietary information and trade secrets.

In addition to patents, we rely on confidentiality agreements to protect our technical know-how and other proprietary information. Confidentiality agreements are used, for example, when we talk to potential strategic partners. In addition, each of our employees signed a confidentiality agreement upon joining our company. Nevertheless, there can be no guarantee that an employee or an outside party will not make an unauthorized disclosure or use of our proprietary confidential information. This might happen intentionally or inadvertently. It is possible that a competitor will make use of such information, and that our competitive position will be compromised, in spite of any legal action we might take against persons making such unauthorized disclosures.

We also keep as trade secrets certain technical and proprietary information where we do not believe patent protection is appropriate, desirable or obtainable. However, trade secrets are difficult to protect. Although we use reasonable efforts to protect our trade secrets, our employees, consultants, contractors, outside scientific collaborators, partners, former partners and other advisors may unintentionally or willfully disclose our trade secrets to competitors or otherwise use misappropriated trade secrets to compete with us. It can be expensive and time consuming to enforce a claim that a third party illegally obtained and is using our trade secrets. Furthermore, the outcome of such claims is unpredictable. In addition, courts outside the US may be less willing to or may not protect trade secrets. Moreover, our competitors may independently design around our intellectual property or develop equivalent knowledge, methods and know-how without misappropriating or otherwise violating our trade secret rights. Where a third party independently designs around our intellectual property or develops equivalent knowledge, methods and know-how without misappropriating or otherwise violating our trade secret rights, they may be able to seek patent protection for such equivalent knowledge, methods and know-how. This could prohibit us from practicing our trade secrets.

Claims by patent holders that our products or manufacturing processes infringe their patent rights could result in costly litigation or could require substantial time and money to resolve, whether or not we are successful, and an unfavorable outcome in these proceedings could have a material adverse effect on our business.

Our ability to commercialize our technology depends on our ability to develop, manufacture, market and sell our products without infringing the proprietary rights of patent holders or their authorized agents. An issued patent does not guarantee us the right to practice or utilize the patented inventions or commercialize the patented product. Third parties may have blocking patents that may prevent us from commercializing our patented products and utilizing our patented manufacturing components and manufacturing processes. In the event that we are made aware of blocking third party patents, we cannot be sure that licenses to the blocking third-party patents would be available or obtainable on terms favorable to us or at all.

 

38


Table of Contents
Index to Financial Statements

Numerous US and foreign issued patents and pending patent applications, which are owned by third parties, relate to (1) the production of bio-industrial products, including oils, chemicals and biofuels, and (2) the use of microalgae strains, such as microalgae strains containing genes to alter oil composition. As such, there could be existing valid patents that our manufacturing processes, manufacturing components, or products may inadvertently infringe. There could also be existing invalid or unenforceable patents that could nevertheless be asserted against us and would require expenditure of resources to defend. In addition, there are pending patent applications that are currently unpublished and therefore unknown to us that may later result in issued patents that are infringed by our products, manufacturing processes or other aspects of our business.

We may be exposed to future litigation based on claims that our products, manufacturing processes or manufacturing components infringe the intellectual property rights of others. There is inevitable uncertainty in any litigation, including patent litigation. Defending against claims of patent infringement is costly and time consuming, regardless of the outcome. Thus, even if we were to ultimately prevail, or to settle at an early stage of litigation, such litigation could burden us with substantial unanticipated costs. Some of our competitors are larger than we are and have substantially greater resources. They are, therefore, likely to be able to sustain the costs of complex patent litigation longer than we could. In addition, the costs and uncertainty associated with patent litigation could have a material adverse effect on our ability to continue our internal research and development programs, in-license needed technology, or enter into strategic partnerships that would help us commercialize our technologies. In addition, litigation or threatened litigation could result in significant demands on the time and attention of our management team, distracting them from the pursuit of other company business.

If a party successfully asserts a patent or other intellectual property rights against us, we might be barred from using certain of our manufacturing processes or manufacturing components, or from developing and commercializing related products. Injunctions against using specified processes or components, or prohibitions against commercializing specified products, could be imposed by a court or by a settlement agreement between us and a third party. In addition, we may be required to pay substantial damage awards to the third party, including treble or enhanced damages if we are found to have willfully infringed the third party’s intellectual property rights. We may also be required to obtain a license from the third party in order to continue manufacturing and/or marketing the products that were found to infringe. It is possible that the necessary license will not be available to us on commercially acceptable terms, or at all. This could limit our ability to competitively commercialize some or all of our products.

During the course of any patent litigation, there could be public announcements of the results of hearings, rulings on motions, and other interim proceedings in the litigation. If securities analysts or investors regard these announcements as negative, the perceived value of our products, technology or intellectual property could be diminished. Accordingly, the market price of our common stock may decline.

We have received government funding in connection with the development of certain of our proprietary technologies, which could negatively affect our intellectual property rights in such technologies.

Some of our proprietary technology was developed with US federal government funding. When new technologies are developed with US government funding, the government obtains certain rights in any resulting patents, including a nonexclusive license authorizing the government to use the invention for non-commercial purposes. These rights may permit the government to disclose our confidential information to third parties and to exercise “march-in” rights to use or allow third parties to use our patented technology. The government can exercise its march-in rights if it determines that action is necessary because we fail to achieve practical application of the US government-funded technology, because action is necessary to alleviate health or safety needs, to meet requirements of federal regulations, or to give preference to US industry. In addition, US government-funded inventions must be reported to the government and US government funding must be disclosed in any resulting patent applications. In addition, our rights in such inventions are subject to government license rights and foreign manufacturing restrictions. Any exercise by the government of such rights could harm our competitive position or impact our operating results.

 

39


Table of Contents
Index to Financial Statements

In addition, some of our technology was funded by a grant from the state of California. Inventions funded by this grant may be subject to forfeiture if we do not seek to patent or practically apply them. Any such forfeiture could have a materially adverse effect on our business. For proprietary technology developed with funding from the State of California, certain confidential information may be disclosed to third parties by California. Our rights in such inventions are subject to State of California license and march-in rights. Any exercise by the State of California of such rights could harm our competitive position or impact our operating results.

Risks Related to Our Finances and Capital Requirements

Our financial results could vary significantly from quarter to quarter and are difficult to predict.

Our revenues and results of operations could vary significantly from quarter to quarter because of a variety of factors, many of which are outside of our control. As a result, comparing our results of operations on a period-to-period basis may not be meaningful. Factors that could cause our quarterly results of operations to fluctuate include:

 

   

achievement, or failure to achieve, technology or product development milestones needed to allow us to enter target markets on a cost effective basis;

 

   

delays or greater than anticipated expenses associated with the completion of new manufacturing facilities, and the time to complete scale up of production following completion of a new manufacturing facility;

 

   

our capital requirements or capital requirements of our joint ventures;

 

   

our ability to effectively manage larger working capital positions as we increase commercial production and distribution of our products;

 

   

disruptions in the production process at any facility where we produce our products, including due to equipment failure or accidents;

 

   

the timing, size and mix of sales to customers for our products;

 

   

increases in price or decreases in availability of feedstocks;

 

   

fluctuations in the price of, and demand for, products based on petroleum or other oils for which our products are alternatives;

 

   

the unavailability of contract manufacturing capacity altogether or at anticipated cost;

 

   

fluctuations in foreign currency exchange rates;

 

   

seasonal production and sale of our products;

 

   

the effects of competitive pricing pressures, including decreases in average selling prices of our products;

 

   

unanticipated expenses associated with changes in governmental regulations and environmental, health and safety requirements;

 

   

reductions or changes to existing fuel, chemical, nutrition or skin and personal care regulations and policies;

 

   

departure of key employees;

 

   

business interruptions, such as earthquakes and other natural disasters;

 

   

our ability to integrate businesses that we may acquire;

 

   

risks associated with the international aspects of our business; and

 

   

changes in general economic, industry and market conditions, both domestically and in foreign markets in which we operate.

 

40


Table of Contents
Index to Financial Statements

Due to these factors and others the results of any quarterly or annual period may not meet our expectations or the expectations of our investors and may not be meaningful indications of our future performance.

We may require additional financing in the future and may not be able to obtain such financing on favorable terms, if at all, which could force us to delay, reduce or eliminate our research and development or commercialization activities.

To date, we have financed our operations primarily through our initial public offering, completed in June 2011, private placements of our equity and convertible debt securities, credit facilities, government grants and funding from strategic partners. In January 2013 we issued $125.0 million aggregate principal amount of convertible senior subordinated notes due 2018, which bear interest at a rate of 6.00% per year, payable in cash semi-annually. We entered into a loan and security agreement with HSBC that provides for a $35.0 million revolving facility for working capital and letters of credit. While we plan to enter into relationships with partners or collaborators for them to provide some portion or all of the capital needed to build production facilities, we may determine that it is more advantageous for us to provide some portion or all of the financing for new production facilities. Some of our previous funding has come from government grants; however, our future ability to obtain government grants is uncertain due to the competitive bid process and other factors.

We may have to raise additional funds through public or private debt or equity financings to meet our capital requirements, including our portion of joint venture funding requirements. For example, although the Solazyme Bunge JV entered a loan agreement with BNDES for project financing funding to support the joint venture’s production facility in Brazil, including a portion of the construction costs of the facility, and has drawn on the funds, if we are unable to finalize the corporate guarantee documentation on acceptable terms, the Solazyme Bunge JV will be unable to draw down amounts under the loan in excess of amounts supported by bank guarantees and may have to seek additional financing. If the Solazyme Bunge JV is unable to secure additional financing, we will be required to fund our portion of the Solazyme Bunge JV’s capital requirements from existing sources or seek additional financing. In addition, our working capital requirements and the working capital requirements of the Solazyme Bunge JV are likely to increase as we and the Solazyme Bunge JV increase and begin production, respectively, due to an increase in inventory and the manufacture out-of-spec product during the ramp-up of commercial production. We may not be able to raise sufficient additional funds on terms that are favorable to us, if at all. If we fail to raise sufficient funds and continue to incur losses, our ability to fund our operations, take advantage of strategic opportunities, develop and commercialize products or technologies, or otherwise respond to competitive pressures could be significantly limited. If this happens, we may be forced to delay or terminate research and development programs or the commercialization of products resulting from our technologies, curtail or cease operations or obtain funds through collaborative and licensing arrangements that may require us to relinquish commercial rights, or grant licenses on terms that are not favorable to us. If adequate funds are not available, we will not be able to successfully execute our business plan or continue our business.

Servicing our debt will require a significant amount of cash, and we may not have sufficient cash flow from our business to pay amounts due under our indebtedness, including our convertible notes.

Our ability to make scheduled payments of the principal of, to pay interest on or to refinance our indebtedness, including our convertible notes, depends on our future performance, which is subject to economic, financial, competitive and other factors beyond our control. Our business may not generate cash flow from operations in the future sufficient to service our debt and make necessary capital expenditures. If we are unable to generate such cash flow, we may be required to adopt one or more alternatives, such as selling assets, restructuring debt or obtaining additional equity capital on terms that may be onerous or highly dilutive. Our ability to refinance our indebtedness will depend on the capital markets and our financial condition at such time. We may not be able to engage in any of these activities or engage in these activities on desirable terms, which could result in a default on our debt obligations.

 

41


Table of Contents
Index to Financial Statements

Despite our current debt levels, we may still incur substantially more debt or take other actions that would intensify the risks discussed above.

Despite our current consolidated debt levels, we and our subsidiaries may be able to incur substantial additional debt in the future, subject to the restrictions contained in our debt instruments, some of which may be secured debt. We are not restricted under the terms of the indenture governing the convertible notes from incurring additional debt, securing existing or future debt, recapitalizing our debt or taking a number of other actions that are not limited by the terms governing the notes. Our existing credit facility with HSBC contains certain restrictions on our ability to incur additional indebtedness, but if the facility matures or is repaid, we may not be subject to such restrictions under the terms of any subsequent indebtedness.

We have received government grant funding and entered contracts with government agencies, and may pursue government grant funding or contracts in the future. Our receipt of government funds through grants and contracts subjects us to additional regulatory oversight.

We have received government grants and have entered contracts with government agencies in the past. Activities funded by a government grant or pursuant to government contracts are subject to audits by government agencies. As part of an audit, these agencies may review our performance, cost structures and compliance with applicable laws, regulations and standards. Grant funds must be applied by us toward the research and development programs specified by the granting agency, rather than for all of our programs generally. If any of our grant-funded costs are found to be allocated improperly, the costs may not be reimbursed and any costs already reimbursed may have to be refunded. Accordingly, an audit could result in an adjustment to our revenues and results of operations. We are also subject to additional regulations based on our receipt of government grant funding and entry into government contracts. If we fail to comply with the requirements under our grants or contracts, we may face penalties or other negative consequences, and in such event we may not be awarded government funding or contracts in the future.

If we engage in any acquisitions, we will incur a variety of costs and may potentially face numerous risks that could adversely affect our business and operations.

If appropriate opportunities become available, we may seek to acquire additional businesses, assets, technologies or products to enhance our business. In connection with any acquisitions, we could issue additional equity or equity-linked securities such as our convertible notes, which would dilute our stockholders, incur substantial debt to fund the acquisitions, or assume significant liabilities.

Acquisitions involve numerous risks, including problems integrating the purchased operations, technologies or products, unanticipated costs and other liabilities, diversion of management’s attention from our core businesses, adverse effects on existing business relationships with current and/or prospective collaborators, customers and/or suppliers, risks associated with entering markets in which we have no or limited prior experience and potential loss of key employees. Acquisitions may also require us to record goodwill and non-amortizable intangible assets that will be subject to impairment testing on a regular basis and potential periodic impairment charges, incur amortization expenses related to certain intangible assets, and incur write offs and restructuring and other related expenses, any of which could harm our operating results and financial condition. If we fail in our integration efforts with respect to any of our acquisitions and are unable to efficiently operate as a combined organization, our business and financial condition may be adversely affected.

Raising additional funds may cause dilution to our stockholders or require us to relinquish valuable rights.

If we elect to raise additional funds through equity offerings or offerings of equity-linked securities, our stockholders would likely experience dilution. Debt financing, if available, may subject us to restrictive covenants that could limit our flexibility in conducting future business activities. For example, the loan and security agreement we entered into with HSBC in March 2013 contains financial covenants that, if breached, would require us to secure our obligations thereunder. To the extent that we raise additional funds through

 

42


Table of Contents
Index to Financial Statements

collaboration and licensing arrangements, it may be necessary for us to share a portion of the margin from the sale of our products. We may also be required to relinquish or license on unfavorable terms our rights to technologies or products that we otherwise would seek to develop or commercialize ourselves.

If we fail to maintain an effective system of internal controls, we might not be able to report our financial results accurately or prevent fraud; in that case, our stockholders could lose confidence in our financial reporting, which would harm our business and could negatively impact the price of our stock.

Effective internal controls are necessary for us to provide reliable financial reports and prevent fraud. In addition, Section 404 of the Sarbanes-Oxley Act of 2002 requires us and our independent registered public accounting firm to evaluate and report on our internal control over financial reporting, and have our chief executive officer and chief financial officer certify as to the accuracy and completeness of our financial reports. The process of implementing our internal controls and complying with Section 404 is expensive and time consuming, and requires significant attention from management. We cannot be certain that these measures will ensure that we implement and maintain adequate controls over our financial processes and reporting in the future.

Our management has concluded that there are no material weaknesses in our internal controls over financial reporting as of December 31, 2013. However, there can be no assurance that our controls over financial processes and reporting will be effective in the future or that material weaknesses or significant deficiencies in our internal controls will not be discovered in the future. Because of its inherent limitations, internal control over financial reporting may not prevent or detect fraud or misstatements. Failure to implement required new or improved controls, or difficulties encountered in their implementation, could harm our results of operations or cause us to fail to meet our reporting obligations. If we or our independent registered public accounting firm discover a material weakness, the disclosure of that fact, even if quickly remedied, could reduce the market’s confidence in our financial statements and harm our stock price.

Risks Relating to Securities Markets and Investment in Our Stock

The price of our common stock may be volatile.

The volatility of our common stock may affect the price of our common stock, and the sale of substantial amounts of our common stock could adversely affect the price of our common stock. Stock markets have experienced extreme volatility that has often been unrelated to the operating performance of particular companies. These broad market fluctuations may adversely affect the trading price of our common stock. In addition, the average daily trading volume of the securities of small companies, particularly small technology companies, can be very low. Limited trading volume of our stock may contribute to its future volatility. Price declines in our common stock could result from general market and economic conditions and a variety of other factors, including any of the risk factors described in this Annual Report on Form 10-K.

These broad market and industry factors may seriously harm the market price of our common stock, regardless of our operating performance. The market price of our common stock could also be affected by possible sales of the common stock by investors who view our convertible notes as a more attractive means of equity participation in us and by hedging or arbitrage trading activity that we expect to develop involving the common stock.

Our certificate of incorporation, our bylaws and Delaware law contain provisions that could discourage another company from acquiring us and may prevent attempts by our stockholders to replace or remove our current management.

Provisions of Delaware law (where we are incorporated), our certificate of incorporation and bylaws may discourage, delay or prevent a merger or acquisition that stockholders may consider favorable, including transactions in which you might otherwise receive a premium for your shares. In addition, these provisions may

 

43


Table of Contents
Index to Financial Statements

frustrate or prevent any attempts by our stockholders to replace or remove our current management by making it more difficult for stockholders to replace or remove our board of directors. These provisions include:

 

   

authorizing the issuance of “blank check” preferred stock without any need for action by stockholders;

 

   

requiring supermajority stockholder voting to effect certain amendments to our certificate of incorporation and bylaws;

 

   

eliminating the ability of stockholders to call special meetings of stockholders;

 

   

prohibiting stockholder action by written consent;

 

   

establishing advance notice requirements for nominations for election to the board of directors or for proposing matters that can be acted on by stockholders at stockholder meetings; and

 

   

dividing our board of directors into three classes so that only one third of our directors will be up for election in any given year.

In addition, we are subject to Section 203 of the Delaware General Corporation Law, which, under certain circumstances, may make it more difficult for a person who would be an “interested stockholder,” as defined in Section 203, to effect various business combinations with us for a three-year period. Our certificate of incorporation and bylaws do not exclude us from the restrictions imposed under Section 203. These provisions could impede a merger, takeover or other business combination involving us or discourage a potential acquirer from making a tender offer for our common stock, which, under certain circumstances, could reduce the market price of our common stock.

Being a public company increases our expenses and administrative burden.

As a public company, we incur significant legal, accounting and other expenses. For example, as a public company, we have adopted internal and disclosure controls and procedures and bear all of the internal and external costs of preparing and distributing periodic public reports in compliance with our obligations under applicable securities laws.

In addition, changing laws, regulations and standards relating to corporate governance and public disclosure, including the Sarbanes-Oxley Act of 2002 and related regulations implemented by the SEC and the NASDAQ Global Select Market, create uncertainty for public companies, increasing legal and financial compliance costs and making some activities more time consuming. We evaluate and monitor developments with respect to new and proposed rules and cannot predict or estimate the amount of additional costs we may incur or the timing of such costs. These laws, regulations and standards are subject to varying interpretations, in many cases due to their lack of specificity, and, as a result, their application in practice may evolve over time as new guidance is provided by regulatory and governing bodies. This could result in continuing uncertainty regarding compliance matters and higher costs necessitated by ongoing revisions to disclosure and governance practices. We intend to invest resources to comply with evolving laws, regulations and standards, and this investment may result in increased general and administrative expenses and a diversion of management’s time and attention from revenue-generating activities to compliance activities. If our efforts to comply with new laws, regulations and standards differ from the activities intended by regulatory or governing bodies due to ambiguities related to practice, regulatory authorities may initiate legal proceedings against us and our business may be harmed. These factors could also make it more difficult for us to attract and retain qualified members of our board of directors, particularly to serve on our audit committee and compensation committee, and attract and retain qualified executive officers. If these requirements divert our management’s attention from other business concerns, they could have a material adverse effect on our business, financial condition and results of operations.

 

44


Table of Contents
Index to Financial Statements

If securities or industry analysts do not continue to publish research or publish inaccurate or unfavorable research about our business, our stock price and trading volume could decline.

The trading market for our common stock depends in part on the research and reports that securities or industry analysts publish about us or our business. If securities or industry analysts do not continue coverage of our company, the trading price for our stock would be negatively impacted. If one or more of the analysts who cover us downgrade our stock or publish inaccurate or unfavorable research about our business, our stock price would likely decline. If one or more of these analysts cease coverage of our company or fail to publish reports on us regularly, demand for our stock could decrease, which might cause our stock price and trading volume to decline.

We do not anticipate paying cash dividends, and accordingly, stockholders must rely on stock appreciation for any return on their investment.

We do not anticipate paying cash dividends in the foreseeable future. As a result, only appreciation of the price of our common stock, which may never occur, would provide a return to stockholders. Investors seeking cash dividends should not invest in our common stock.

 

45


Table of Contents
Index to Financial Statements
Item 1B. Unresolved Staff Comments.

None.

 

Item 2. Properties.

We currently lease an aggregate of approximately 96,000 square feet of office and laboratory facilities, including a pilot plant, in South San Francisco, California. The South San Francisco location is comprised of two buildings and is covered by a single amended sublease agreement that expires in February 2015.

In May 2011, we purchased the Peoria Facility in Peoria, Illinois. Solazyme Brasil Óleos Renováveis e Bioprodutos Ltda. leases approximately 14,100 square feet of space in Campinas, Brazil that is used as general office and lab space pursuant to a lease that expires in April 2016.

We believe that our current facilities are suitable and adequate to meet our current needs. As our needs change and as our business grows, we intend to build, lease or acquire additional manufacturing capacity on our own and with partners. We believe that additional space and facilities will be available.

 

Item 3. Legal Proceedings.

From time to time, we may be involved in litigation relating to claims arising out of our operations. We are not currently involved in any material legal proceedings.

 

Item 4. Mine Safety Disclosures.

Not applicable.

 

46


Table of Contents
Index to Financial Statements

PART II

 

Item 5. Market for Registrant’s Common Equity, Related Stockholder Matters and Issuer Purchases of Equity Securities

1. On October 24, 2013, pursuant to a Research and Development Agreement with Warner Babcock Institute for Green Chemistry LLC (WBI), we issued 39,578 shares of our common stock to WBI. As of December 31, 2013, all of these shares had fully vested. Pursuant to the Research and Development Agreement, WBI is providing research and development services to us.

2. On November 4, 2013, we issued 423,278 shares of our common stock to Archer-Daniels-Midland Company (ADM) upon the exercise by ADM of a warrant to receive $4,500,000, payable at our election in cash, stock or a combination thereof, for use and operation of a portion of ADM’s facility in Clinton, Iowa under the Strategic Collaboration Agreement between us and ADM.

The issuances of securities described above were deemed to be exempt from registration under the Securities Act in reliance on Section 4(2) of the Securities Act and Regulation D promulgated thereunder as transactions by an issuer not involving a public offering. The recipients of securities in each such transaction represented their intention to acquire the securities for investment only and not with a view to or for sale in connection with any distribution thereof and appropriate legends were affixed to the electronic records representing such securities in such transactions. All recipients received adequate information about us.

Market Information

Our common stock is traded on The NASDAQ Global Select Market, or NASDAQ, under the symbol “SZYM.” The following table sets forth the high and low sales prices per share of the common stock as reported on NASDAQ. Such prices represent inter dealer prices without retail markup, markdown or commission and may not necessarily represent actual transactions.

 

Fiscal 2012

   High      Low  

First Quarter

   $ 16.00       $ 10.16   

Second Quarter

     16.31         9.40   

Third Quarter

     14.34         10.92   

Fourth Quarter

     11.59         6.45   

Fiscal 2013

   High      Low  

First Quarter

   $ 9.49       $ 6.81   

Second Quarter

     12.89         7.15   

Third Quarter

     13.09         10.20   

Fourth Quarter

     12.10         8.00   

As of February 28, 2014 there were 92 stockholders of record of our common stock. A substantially greater number of stockholders may be beneficial holders, whose shares are held of record by banks, brokers and other financial institutions in “street name.”

Dividend Policy

We have never declared or paid any dividends on our common stock or any other securities. We currently intend to retain our future earnings, if any, for use in the expansion and operation of our business and therefore do not anticipate paying cash dividends on our common stock in the foreseeable future. Any future determination relating to our dividend policy will be made at the discretion of our board of directors, based upon our financial condition, results of operations, contractual restrictions, capital requirements, business prospects and other factors our board of directors may deem relevant. In addition, the terms of our loan facility require that we obtain consent from the lender prior to any payment of dividends.

 

47


Table of Contents
Index to Financial Statements

Use of Proceeds from Public Offering of Common Stock

On June 2, 2011, we closed our initial public offering. We sold 12,621,250 shares of common stock at a price to the public of $18.00 per share, which included 600,000 shares offered by selling stockholders and 1,646,250 shares that the underwriters had the option to purchase to cover over-allotments. This offer and sale of our common stock in the initial public offering were registered under the Securities Act pursuant to a registration statement on Form S-1 (File No. 333-172790), which was declared effective by the SEC on May 26, 2011. The principal underwriters of the initial public offering were Morgan Stanley and Co. Incorporated, Goldman, Sachs & Co., Jefferies, Pacific Crest Securities and Lazard Capital Markets. We raised approximately $201.2 million in net proceeds after deducting underwriting discounts and commissions of $15.1 million and other offering costs of $4.3 million. No offering costs were paid directly or indirectly to any of our directors or officers (or their associates) or persons owning ten percent or more of any class of our equity securities or to any other affiliates, other than payments in the ordinary course of business to officers for salaries and to non-employee directors as compensation for board or board committee service. There has been no material change in the planned use of proceeds from our initial public offering as described in our final prospectus filed with the SEC pursuant to Rule 424(b).

Stock Performance Graph

The following graph compares our total common stock return with the total return for (i) the S&P SmallCap 600 Index and (ii) the NASDAQ Clean Edge Green Energy Index for the period from May 27, 2011 (the date our common stock commenced trading on the NASDAQ) through December 31, 2013. The figures represented below assume an investment of $100 in our common stock at the closing price of $20.71 on May 27, 2011 and in the S&P SmallCap Index and the NASDAQ Clean Edge Green Energy Index on May 27, 2011 and the reinvestment of dividends into shares of common stock. The comparisons in the table are required by the SEC and are not intended to forecast or be indicative of possible future performance of our common stock. This graph shall not be deemed “soliciting material” or to be “filed” for purposes of Section 18 of the Exchange Act or otherwise subject to the liabilities under that Section, and shall not be deemed to be incorporated by reference into any of our filings under the Securities Act or the Exchange Act.

 

LOGO

 

48


Table of Contents
Index to Financial Statements
Item 6. Selected Financial Data

In the tables below, we provide our selected historical financial data. We derived the selected statement of operations data for the years ended December 31, 2013, 2012, and 2011 and the selected balance sheet data as of December 31, 2013 and 2012 from our audited consolidated financial statements and related notes included in Item 8 of this Annual Report on Form 10-K. We derived the selected statement of operations data for the years ended December 31, 2010 and 2009 and the selected balance sheet data as of December 31, 2011, 2010 and 2009 from our audited consolidated financial statements and related notes not included in this Annual Report on Form 10-K. You should read this data together with our consolidated financial statements and related notes in Item 8 of this Annual Report on Form 10-K and “Management’s Discussion and Analysis of Financial Condition and Results of Operations” included elsewhere in this Annual Report on Form 10-K. Our historical results are not necessarily indicative of the results that may be expected in the future.

 

    Year Ended December 31,  
    2013     2012     2011     2010     2009  
    (In thousands, except share and per share data)  

Statement of Operations Data:

         

Total revenues

  $ 39,750      $ 44,108      $ 38,966      $ 37,970      $ 9,161   
 

 

 

   

 

 

   

 

 

   

 

 

   

 

 

 

Cost of product revenue

    6,385        5,311        2,420        —          —     

Research and development

    66,572        66,384        45,613        34,227        12,580   

Sales, general and administrative

    62,933        57,516        41,426        17,422        9,890   
 

 

 

   

 

 

   

 

 

   

 

 

   

 

 

 

Total costs and operating expenses (1)

    135,890        129,211        89,459        51,649        22,470   
 

 

 

   

 

 

   

 

 

   

 

 

   

 

 

 

Loss from operations

    (96,140     (85,103     (50,493     (13,679     (13,309

Total other income (expense), net

    (20,249     1,971        (3,408     (2,601     (361
 

 

 

   

 

 

   

 

 

   

 

 

   

 

 

 

Net loss

    (116,389     (83,132     (53,901     (16,280     (13,670

Accretion of redeemable convertible preferred stock

                  (60     (140     (145
 

 

 

   

 

 

   

 

 

   

 

 

   

 

 

 

Net loss attributable to Solazyme, Inc. common stockholders

  $ (116,389   $ (83,132   $ (53,961   $ (16,420   $ (13,815
 

 

 

   

 

 

   

 

 

   

 

 

   

 

 

 

Basic and diluted net loss per share attributable to Solazyme, Inc. common stockholders (2)

  $ (1.81   $ (1.37   $ (1.35   $ (1.42   $ (1.38
 

 

 

   

 

 

   

 

 

   

 

 

   

 

 

 

Shares used in computation of basic and diluted net loss per share (2)

    64,211,958        60,509,048        39,934,013        11,540,494        10,030,495   
 

 

 

   

 

 

   

 

 

   

 

 

   

 

 

 

 

(1) Includes stock-based compensation expense of $18.7 million, $15.4 million, $10.9 million, $2.0 million and $0.5 million for the years ended December 31, 2013, 2012, 2011, 2010 and 2009, respectively.
(2) See notes to our consolidated financial statements for an explanation of the method used to calculate basic and diluted net loss per share of common stock and the weighted-average number of shares used in computation of the per share amounts.

 

    As of December 31,  
    2013     2012     2011     2010     2009  
    (In thousands)  

Balance Sheet Data:

         

Cash and cash equivalents

  $ 54,977      $ 30,818      $ 28,780      $ 32,497      $ 19,845   

Marketable securities

    112,544        118,187        214,944        49,533        15,043   

Working capital

    166,523        140,341        229,681        73,152        29,693   

Total assets

    258,705        217,024        285,224        93,984        41,891   

Indebtedness

    93,522        14,968        20,252        229          

Redeemable convertible preferred stock

                         128,313        68,459   

Accumulated deficit

    (306,317     (189,928     (106,796     (52,835     (36,415

Total stockholders’ equity (deficit)

    138,948        183,311        240,558        (50,067     (36,164

 

49


Table of Contents
Index to Financial Statements
Item 7. Management’s Discussion and Analysis of Financial Condition and Results of Operations.

Forward-Looking Statements

The following discussion and analysis should be read together with our audited consolidated financial statements and the other financial information appearing elsewhere in this Annual Report on Form 10-K. This discussion contains forward-looking statements reflecting our current expectations and involves risks and uncertainties. In some cases, you can identify forward-looking statements by terminology such as “may,” “will,” “should,” “expect,” “plan,” “anticipate,” “believe,” “estimate,” “predict,” “intend,” “potential” or “continue” or the negative of these terms or other comparable terminology. For example, statements regarding our expectations as to future financial and operating performance, future selling prices and margins for our products, attributes and performance of our products, manufacturing capacity, expense levels and liquidity sources are forward-looking statements. Our actual results and the timing of events may differ materially from those discussed in our forward-looking statements as a result of various factors, including those discussed below and those discussed in the section entitled “Risk Factors” included in this Annual Report on Form 10-K and in our other filings with the Securities and Exchange Commission (SEC).

Overview

We make renewable oils and other bioproducts. Our proprietary technology uses highly optimized microalgae in an industrial fermentation process to transform a growing range of abundant plant-based sugars into high-value triglyceride oils and other bioproducts.

We tailor the composition of our oils and bioproducts to address specific customer requirements, offering superior performance characteristics and value, compared with conventionally sourced products. We anticipate that the average selling prices (ASPs) of our products will capture the enhanced value that results from tailoring compositions of oils that enable heightened performance. As such, we expect our products to generate attractive margins in our target markets. Our main commercial focus is on selling oil-based products, including oils and algal meal products, to companies that use them as intermediates and ingredients.

We initiated our commercialization efforts several years ago by launching low-volume, high-margin branded skin and personal care products. We are currently selling into this market with two branded skin care offerings, our Algenist ® and EverDeep ® lines, and we intend to develop additional products. As we expand into large-scale, high-volume commercial production, we expect to sell our oil-based intermediate and ingredients products more broadly to customers in the chemicals, fuels and food markets starting in the first quarter of 2014. We expect while the margins on these intermediate and ingredients products will be lower than those launched initially, our sales volumes will be higher as we expand our large-scale production. We have entered into sales agreements and partnership agreements to advance commercialization efforts. In addition to development agreements to fund development work and new product application testing, we expect that our partners will enter into long-term purchase agreements with us. We are currently engaged in development activities with multiple partners.

The inherent flexibility of our technology platform and the broad usage of triglyceride oils and functional fluids across multiple industries allows us to approach a wide range of customers across a wide range of end markets. We have many oils in various stages of development that can address multiple end markets.

We are also developing food oils targeted at the nutritional markets. The tailored food oils are formulated to offer a variety of functional benefits such as enhanced structuring capabilities, stability, and shelf life while providing robust formulation and process flexibility. In addition to tailoring the composition of oils, we have also developed novel methods of preparing powdered forms of triglyceride oils. Our powdered ingredients are composed of whole algal cells, including the cell wall and the oils and other cellular products held within the whole algal cell.

 

50


Table of Contents
Index to Financial Statements

Our process is compatible with commercial-scale and widely-available fermentation equipment. We operate our lab and pilot fermentation and recovery equipment as scaled-down versions of our large commercial engineering designs. This allows us to more easily scale up to larger fermentation vessels. We have scaled up our technology platform and have successfully operated at lab (5-15 liter), pilot (600-1,000 liter), demonstration (120,000 liter) and commercial (approximately 500,000 liter and above) fermenter scale. The fermentation equipment used to achieve commercial scale at Archer-Daniels-Midland Company’s (ADM) Clinton Facility is comparable to the fermentation equipment at the Solazyme Bunge Renewable Oils facility in Brazil. Our existing manufacturing operations are as follows:

 

   

Our pilot plant in South San Francisco, California, with recovery operations capable of handling material from both 600 and 1,000 liter fermenters, enables us to produce samples of our tailored oils for testing and optimization by our partners, as well as to test new process conditions at an intermediate scale.

 

   

In 2012, we announced successful commissioning of our first fully integrated bio-refinery (IBR) at our Peoria, Illinois facility, to produce algal oil. The IBR was partially funded with a federal grant that we received from the U.S. Department of Energy (DOE) in December 2009 to demonstrate integrated commercial-scale production of renewable algae-derived fuels. The Peoria Facility has a nameplate capacity of two million liters of oil annually and provides an important platform for continued work on feedstock flexibility and scaling of new tailored oils into the marketplace. We have recently modified our Peoria Facility to produce WAF and WAP in conjunction with select contract manufacturing operations.

 

   

In April 2012, we executed a Joint Venture Agreement with Bunge Global Innovation, LLC and certain of its affiliates (collectively, Bunge), one of the largest sugarcane processing companies in Brazil, establishing a joint venture (Solazyme Bunge JV) to construct and operate a production facility adjacent to Bunge’s sugarcane mill in Moema, Brazil. We are currently completing the construction and commissioning of our 100,000 MT purpose-built production facility at Bunge’s Moema sugar mill in Orindiuva, Brazil. See “Significant Partner Agreements.”

 

   

In November 2012, we executed a strategic collaboration agreement with ADM to produce tailored triglyceride oil products at ADM’s facility in Clinton, Iowa (the Clinton Facility). In January 2014, we began commercial scale production of our products at the Clinton Facility. See “Significant Partner Agreements.”

 

   

We utilize contract manufacturing to assist in the production of our Algenist ® and EverDeep ® products and we closely monitor and advise these contract manufacturers to help ensure that our products meet stringent quality standards. We also produce some product ingredients at our Peoria Facility.

Through fiscal year 2013, our revenues have been generated from research and development programs and commercial sale of our skin and personal care products. Our research and development programs have been conducted primarily under key agreements with government agencies and strategic partners to fund development work and perform application testing. We focus our innovation efforts on creating a broad suite of tailored products that meet defined market needs. We intend to continue to work closely with our partners and customers to understand their requirements and design products to specifically address their needs.

We have developed a portfolio of innovative and branded microalgae-based consumer products. Our first major ingredient was Alguronic Acid ® , which was formulated into a full range of skin care products. Since its launch in March 2011, we have commercialized Algenist ® , which is an anti-aging skin care line primarily through Sephora S.A. and its affiliates (Sephora) and QVC. We have seen success in expanding our international distribution and are currently selling in over 1,300 retail stores in 17 countries including member countries of the EU, Mexico, Canada and China. In 2013, we further leveraged our innovative ingredient research and expertise by broadening the Algenist ® line to include products that use Microalgae Oil as a replacement for the essential oils currently used in skin care products.

 

51


Table of Contents
Index to Financial Statements

In November 2013, we launched our second skin care line, EverDeep ® . EverDeep ® uses a new proprietary ingredient, Algasome™ complex, and is sold online and via telephone driven by direct-to-consumer “infomercial” broadcasts. The skin care line utilizes a continuity program and auto-delivery options to strengthen the link with customers to drive repeat sales.

Significant Partner Agreements

We currently have joint venture, joint development, supply and distribution arrangements with various strategic partners. We expect to enter into additional partnerships in each of our target markets to advance commercialization of our products and to expand our upstream and downstream capabilities. Upstream, we expect partners to provide research and development funding, capital for commercial manufacturing capacity and/or secure access to feedstock. Downstream, we expect partners to provide expanded distribution channels, product application testing, marketing expertise and/or long-term purchase commitments. Our current principal partnership and strategic arrangements include:

Bunge . In May 2011, we entered into a Joint Development Agreement (the JDA) with Bunge that has been extended through September 2014. Pursuant to the JDA, we and Bunge are jointly developing microbe-derived oils, and exploring the production of such oils from Brazilian sugarcane feedstock.

In anticipation of the Solazyme Bunge JV’s formation, in May 2011, we granted Bunge Limited a warrant (the Warrant) to purchase 1,000,000 shares of our common stock at an exercise price of $13.50 per share. The Warrant vests based on a number of milestones connected with the construction and initial operation of the Solazyme Bunge JV Plant. As of December 31, 2013, the warrant was vested as to 75% of the shares underlying the Warrant. The Warrant expires in May 2021.

In April 2012, we and Bunge formed the Solazyme Bunge JV to build, own and operate a commercial-scale renewable tailored oils production facility (the Solazyme Bunge JV Plant) adjacent to Bunge’s Moema sugarcane mill in Brazil. The Solazyme Bunge JV Plant, which will leverage our technology and Bunge’s sugarcane milling and natural oil processing capabilities, will produce microalgae-based products. In addition, the Solazyme Bunge JV Plant has been designed to be expanded for further production in line with market demand. We expect this production facility to have annual production capacity of 100,000 MT of oil. Construction of the Solazyme Bunge JV Plant commenced in the second quarter of 2012 and was financed with equal equity contributions by both Bunge and Solazyme and over $100 million of project financing from the Brazilian BNDES. Commissioning is underway, and we are targeting production of commercially saleable product by the end of the first quarter of 2014, though such production could move into the second quarter. As a condition of the Solazyme Bunge JV drawing funds under the loan in excess of amounts supported by bank guarantees, we may be required to provide a corporate guarantee of a portion of the loan (in an amount that, when added to the amount supported by our bank guarantee, does not exceed our ownership percentage in the Solazyme Bunge JV).

In addition to forming the Solazyme Bunge JV in April 2012, we entered into a Development Agreement with the Solazyme Bunge JV to continue research and development activities that are intended to benefit the Solazyme Bunge JV, including activities in the areas of strain development, molecular biology and process development. The Development Agreement provides that the Solazyme Bunge JV will pay us a technology maintenance fee in recognition of our ongoing research investment in technology that would benefit the Solazyme Bunge JV. We also entered into a Technology Service Agreement with the Solazyme Bunge JV under which the Solazyme Bunge JV will pay us for technical services related to the operations of the plant, including, but not limited to, engineering support for Plant operations, operation procedure consultation, product analysis and microbe performance monitoring and assessment. In the third quarter of 2013, the Solazyme Bunge JV also agreed to pay us to support its commercial activities, including, but not limited to, facilitating supply agreements on behalf of the Solazyme Bunge JV and providing regulatory support.

In November 2012, we entered into a joint venture expansion framework agreement with Bunge. This framework agreement sets forth the intent of the partners to expand joint venture-owned oil production capacity

 

52


Table of Contents
Index to Financial Statements

from the current 100,000 MT under construction in Brazil to 300,000 MT by 2016 at select Bunge owned and operated processing facilities worldwide. We and Bunge amended the Joint Venture agreement in October 2013 to expand the field and product portfolio of the Solazyme Bunge JV. We and Bunge intend to work together through joint market development to bring new, healthy, edible oils to the Brazilian market.

Refer to Note 7 and Note 10 in the accompanying notes to our consolidated financial statements for further discussion of the Bunge JDA, Joint Venture Agreement and Warrant.

ADM . In November 2012, we entered into a strategic collaboration agreement with ADM, establishing a collaboration for the production of tailored triglyceride oil products at the Clinton Facility. The Clinton Facility is producing tailored triglyceride oil products using our proprietary microbe-based catalysis technology. Feedstock for the facility is provided by ADM’s adjacent wet mill. Under the terms of the strategic collaboration agreement, we will pay ADM annual fees for use and operation of a portion of the Clinton Facility, a portion of which may be paid in our common stock. In addition, in January 2013 we granted to ADM a warrant to purchase 500,000 shares of our common stock, which vests in equal monthly installments over five years, commencing in November 2013. In addition, in March 2013 we issued a series of warrants to ADM for payment in stock, in lieu of cash, at our election, of future annual fees for use and operation of a portion of the Clinton Facility. This facility uses corn sugars as a feedstock and currently has an initial target nameplate capacity of 20,000 MT per year of tailored triglyceride oil products, which we are targeting to attain 12-18 months after commencement of commercial production, which occurred in January 2014. We have an option to expand the capacity to 40,000 MT per year with the potential to further expand production to 100,000 MT per year. We are also working together with ADM to develop markets for the products produced at the Clinton Facility. Since the third quarter of 2013, downstream processing has been performed at a finishing facility in Galva, Iowa (Galva Facility), which is operated by our long-term partner, a wholly owned subsidiary of American Natural Processors, Inc. In January 2014, we began commercial scale production of our oils at the Clinton/Galva Facilities.

Mitsui . In February 2013, we entered into a multi-year agreement with Mitsui & Co., Ltd. (Mitsui) to jointly develop triglyceride oils for use primarily in the oleochemical industry. The agreement includes further development of our myristic oil, a valuable raw material in the oleochemical industry, and additional oils that we are developing for the oleochemical and industrial sectors. End use applications may include renewable, high-performance polymer additives for plastic applications, lubricants and toiletry and household products.

Chevron . We have entered into multiple research and development agreements with Chevron to conduct research related to algal technology in the fields of diesel fuel, lubes and additives and blendstocks. Under the terms of the most recent agreement, we successfully completed all defined deliverables against the active Chevron research program which was funded through June 30, 2012.

U.S. Navy . In September 2010, we entered into a firm fixed price research and development contract with the Department of Defense (DoD), through the Defense Logistics Agency, Fort Belvoir, VA (DLA), to provide marine diesel fuel. We agreed to produce up to 567,812 liters of HRF-76 marine diesel for the U.S. Navy’s testing and certification program. This contract was the third contract that we have entered into with the DoD and the largest of the three. We completed two earlier contracts to research, develop and demonstrate commercial-scale production of microalgae-based advanced biofuels to establish appropriate status for future commercial procurements. We completed the first phase of our 567,812 liter contract in July 2011, with the delivery of 283,906 liters of HRF-76 marine diesel to the U.S. Navy for its testing and certification program. In August 2011, the DoD exercised its option to pursue the second phase of the DoD contract, which called for the delivery of the remainder of the 283,906 liters of HRF-76 marine diesel for the U.S. Navy’s testing and certification program. We completed the second phase of the contract in June 2012, with the delivery of 283,906 liters of HRF-76 marine diesel to the U.S. Navy.

In November 2011, Dynamic Fuels, LLC (Dynamic) was awarded a contract to supply the U.S. Navy with 450,000 gallons (1,703,000 liters) of renewable fuels. The contract involved supplying the U.S. Navy with 100,000 gallons (379,000 liters) of jet fuel (Hydro-treated Renewable JP-5 or HRJ-5) and 350,000 gallons

 

53


Table of Contents
Index to Financial Statements

(1,325,000 liters) of marine distillate fuel (Hydro-Treated Renewable F-76 or HRD-76). We were named a subcontractor and we entered into a subcontractor agreement with Dynamic effective January 2012 to supply Dynamic with algal oil to help fulfill Dynamic’s contract with the U.S. Navy to deliver fuel by May 2012. We delivered our commitment of algal oil pursuant to this subcontract in February 2012. The fuel was used as part of the U.S. Navy’s Green Strike Group demonstration at the 2012 Rim of the Pacific Exercise, the world’s largest international maritime warfare exercise. The Great Green Fleet was powered by a 50/50 blend of biofuel and conventional petroleum-based fuel.

Roquette . In November 2010, we entered into a joint venture agreement with Roquette. The purpose of the Solazyme Roquette JV was to engage in manufacturing, distribution, sales, marketing and support of products and services related to the use of microalgae to which we have not applied our targeted recombinant technology in a fermentation production process to produce materials for use in the following fields: (1) human foods and beverages; (2) animal feed; and (3) nutraceuticals. In June 2013, we and Roquette agreed to dissolve the Solazyme Roquette JV and on July 18, 2013, the Solazyme Roquette JV was dissolved.

Algenist ® Distribution Partners. In December 2010, we entered into a distribution contract with Sephora EMEA to distribute our Algenist ® product line in Sephora EMEA stores in certain countries in Europe and select countries in the Middle East and Asia. In January 2011, we also made arrangements with Sephora Americas to sell our Algenist ® product line in Sephora Americas stores (which currently includes locations in the United States and Canada). In October 2011, we launched our Algenist ® product line at Sephora inside jcpenney stores in the United States. In March 2011, we entered into an agreement with QVC, Inc. (QVC) and launched the sale of our Algenist ® product line through QVC’s multimedia platform.

Unilever. In October 2011, we entered into a joint development agreement with Unilever (our fourth agreement altogether), which expanded our current research and development efforts. In September 2013, we and Unilever extended this joint development agreement through September 30, 2014 and entered into a commercial supply agreement for at least 10,000 MT of our tailored algal oil.

Financial Operations Overview

Our total revenues were $39.0 million, $44.1 million, and $39.8 million in 2011, 2012, and 2013, respectively. Since our commercialization of the Algenist ® skin care line in March of 2011, our product revenues have increased each year partially offsetting the reduction in license fee revenue and government program revenues as we completed our work with the DOE and DoD in 2012. In addition, revenues from our development agreements with strategic partners fluctuate depending on timing of the program execution and structure. In general, we expect that the mix of our research and development program (R&D) revenues will be lower as a percentage of total Revenues as we continue to commercialize our products. We will continue to work with our strategic partners under our existing and new R&D agreements to enable us to be a global market leader in the design and production of renewable oils and specialty bioproducts. We expect a larger percentage of our total revenues to be generated from product sales as we ramp up our manufacturing production volume to nameplate capacity.

We incurred net losses of $54.0 million, $83.1 million, and $116.4 million in 2011, 2012, and 2013, respectively. In the near term, we anticipate that we will continue to incur net losses as we ramp up our manufacturing capacity and continue our development activities to further build on our library of tailored oils and powders that address the chemicals and fuels, nutrition and skin and personal care markets, continue work on feedstock flexibility and scaling of new tailored oils, nutrition ingredients and skin and personal care products in the marketplace and support commercialization activities for our products. In addition, as we continue to scale our capacity in current facilities or by entering into new manufacturing capacity and joint venture agreements, we may incur additional net losses associated with the build-out and initial operations of those new production facilities.

 

54


Table of Contents
Index to Financial Statements

Revenues

We are commercializing our products as intermediates/ingredients or Solazyme Consumer Products. Intermediates/Ingredients encompasses a portfolio of ingredient products targeted at customers in the chemicals, fuels and foods markets. Within Solazyme Consumer Products, we are currently selling consumer brands into the skin and personal care market with two branded skin care offerings, our Algenist ® and EverDeep ® lines. Prior to commercialization of Algenist ® in 2011, our revenues were primarily from collaborative research and government grants. Through the end of 2013, our product revenues have been entirely from the sale of products into the skin and personal care market providing us with the highest gross margin within our target markets. We expect to sell more broadly into the chemicals, fuels and food markets starting in the first quarter of 2014. In 2013, four of our largest partners, Mitsui, QVC, Sephora and the Solazyme Bunge JV each accounted for more than 10% of our total revenues, and collectively accounted for 72% of our total revenues.

 

   

Research and Development Program Revenues

Revenues from research and development (R&D) programs are recognized in the period during which the related costs are incurred, provided that the conditions under which the government grants and agreements were provided have been met and only perfunctory obligations are outstanding. We currently have active R&D programs with commercial partners and governmental agencies. These R&D programs are entered into pursuant to agreements and grants that generally provide payment for certain types of expenditures in return for research and development activities over a contractually defined period. Revenues related to R&D programs include reimbursable expenses and payments received for full-time equivalent employee services recognized over the related performance periods for each of the contracts. We are required to perform research and development activities as specified in each respective agreement based on the terms and performance periods set forth in the agreements as outlined above. R&D program revenues represented 50%, 63%, and 69% of our total revenues for 2013, 2012, and 2011, respectively. Revenues from government grants and agreements represented 1%, 52%, and 46% of total R&D revenues in 2013, 2012, and 2011, respectively. Revenues from commercial and strategic partner development agreements represented 99%, 48%, and 54% of total R&D revenues in 2013, 2012, and 2011, respectively.

 

   

Product Revenues

Product revenues consist of revenues from products sold commercially into each of our target markets.

We began our commercialization in the skin and personal care markets within Solazyme Consumer Products. Starting in 2011, we recognized revenues from the sale of our first commercial product line, Algenist ® , which we distributed to the skin and personal care end market through arrangements with Sephora S.A. and its affiliates (Sephora), QVC and Space NK in 17 countries including the U.S., member countries of the EU, Mexico, Canada and China, as well as direct-to-consumer sales via the Internet. In November 2013, we launched our second algal skin care line, EverDeep ® . We expect our product revenues to increase as the demand for our Algenist ® and EverDeep ® product lines grow and as we commercialize our portfolio of products targeted at customers in the chemicals, fuels and foods markets.

Product revenues represented 50%, 37%, and 18% of our total revenues for 2013, 2012, and 2011, respectively.

 

   

License Fees

Recognition of license fees is dependent on the specific terms of the license agreement. To date, license fee revenue has consisted of up-front, one-time, non-refundable fees for licensing our technology for commercialization to Solazyme Roquette Nutritionals and these fees have been recognized when cash was received. License fees represented 0%, 0% and 13% of our total revenues in 2013, 2012 and 2011, respectively.

 

55


Table of Contents
Index to Financial Statements

Costs and Operating Expenses

Costs and operating expenses consist of cost of product revenue, research and development expenses and sales, general and administrative expenses. Personnel-related expenses, including non-cash stock-based compensation, costs associated with our strategic collaboration agreements as well as other third-party contractors and contract manufacturers, reimbursable equipment and costs associated with government contracts, consultants and facility costs, comprise the significant components of these expenses.

 

   

Cost of Product Revenue

To date, cost of product revenue consists primarily of third-party contractor costs associated with packaging, distribution and production of Algenist ® products, internal labor, shipping, supplies and other overhead costs associated with production of Alguronic Acid ® , a microalgae-based active ingredient, and microalgae oil used in our Algenist ® product line. We expect our total cost of product revenue to increase in correlation with increased product sales as the demand for our Algenist ® and EverDeep ® product lines grow and as we commercialize our portfolio of products targeted at customers in the chemicals, fuels and foods markets.

 

   

Research and Development

Research and development expenses consist of costs incurred for internal projects as well as partner-funded collaborative research and development activities with commercial and strategic partners and governmental and JV entities (partners). Research and development expenses consist primarily of personnel and related costs including non-cash stock-based compensation, costs associated with our strategic collaboration agreements as well as other third-party contract manufacturers, reimbursable equipment and costs associated with government contracts, consultants, facility costs and overhead, depreciation and amortization of property and equipment used in development, and laboratory supplies.

We expense our research and development costs as they are incurred. Our research and development programs are undertaken to advance our overall industrial biotechnology platform that enables us to produce tailored, high-value oils. Although our partners fund certain development activities, they benefit from advances in our technology platform as a whole, including costs funded by other development programs. Therefore, costs for such activities have not been separated as these costs have all been determined to be part of our total research and development related activity.

Our research and development efforts are directed at (1) identifying, isolating and further optimizing strains of microalgae to achieve high cell densities, high yield converting sugar to product and high productivity rates compared to other alternatives; (2) tailoring the oil outputs to meet specific market needs; (3) product and process development projects aimed at reducing the cost of oil production; and (4) scale-up of commercial scale production at the Clinton/Galva Facilities as well as product and process development activities in our Peoria Facility. Our research and development projects also include activities as specified in our government grants and contracts and development agreements with commercial and strategic partners. We expect to continue to use our Peoria Facility for joint development activities, to provide samples for market development as well as for commercial production for products such as WAF and WAP.

 

   

Sales, General and Administrative

Sales, general and administrative expenses consist primarily of personnel and related costs including non-cash stock-based compensation related to our executive management, corporate administration, sales and marketing functions, professional services and administrative and facility overhead expenses. These expenses also include costs related to our business development and sales functions, including marketing programs. Professional services consist primarily of consulting, external accounting, legal and investor relations fees associated with operating as a publicly-traded company. We expect sales, general and administrative expenses to increase as we incur additional costs related to commercializing our business, including our growth and expansion in Brazil.

 

56


Table of Contents
Index to Financial Statements

Other Income (Expense), Net

Interest and Other Income

Interest and other income consist primarily of interest income earned on marketable securities and cash balances. Our interest income will vary for each reporting period depending on our average investment balances during the period and market interest rates.

Interest Expense

Interest expense consists primarily of interest related to our debt. As of December 31, 2013 and 2012, our outstanding debt, net of debt discounts, was approximately $93.5 million and $15.0 million, respectively.

Gain (Loss) from Change in Fair Value of Warrant Liability

Gain (loss) from change in fair value of warrant liability consists primarily of the change in the fair value of redeemable convertible preferred stock warrants and a common stock warrant issued to Bunge Limited. The warrant liability is remeasured to fair value at each balance sheet date and/or upon vesting, and the change in the then-current aggregate fair value of the warrants is recorded as a gain or loss from the change in the fair value in our consolidated statement of operations. The warrant liability is reclassified to additional paid-in capital upon conversion of redeemable preferred stock, or vesting of common warrant shares. In April 2012, the first and second tranches of the common stock warrant issued to Bunge Limited had vested, and the related warrant liability of $4.6 million was reclassified to additional paid-in capital and was no longer adjusted to fair value. The third tranche of the common stock warrant issued to Bunge Limited was unvested as of December 31, 2013, and will be adjusted based on contractual terms and remeasured to fair value at each balance sheet date until the warrant shares have vested.

Loss from Change in Fair Value of Derivative Liability

Loss from change in fair value of derivative liability consists of the change in the fair value of the embedded derivative related to the early conversion feature of the Notes issued in January 2013.

Income (Loss) from Equity Method Investments, Net

Income (loss) from the equity method investment in the Solazyme Bunge JV is recorded in our income statement as “Income (Loss) from Equity Method Investments, Net”.

In the year ended December 31, 2013 we recorded a loss of $1.4 million to Income (loss) from equity method investments, net related to the dissolution of the Solazyme Roquette JV.

Income Taxes

Since inception, we have incurred net losses and have not recorded any U.S. federal, state or non-U.S. income tax provisions. We have recorded a full valuation allowance against deferred tax assets as it is more likely than not that they will not be realized.

Critical Accounting Policies and Estimates

Our discussion and analysis of our financial condition and results of operations is based upon our consolidated financial statements, which have been prepared in accordance with accounting principles generally accepted in the United States. The preparation of our consolidated financial statements requires us to make estimates, assumptions and judgments that affect the reported amounts of assets, liabilities, revenues, expenses and related disclosures. The results of our analysis form the basis for making assumptions about the carrying

 

57


Table of Contents
Index to Financial Statements

values of assets and liabilities that are not readily apparent from other sources. Our actual results may differ from these estimates under different assumptions or conditions. We evaluate our estimates, assumptions and judgments on an ongoing basis.

We believe the following critical accounting policies involve significant areas of management’s judgments and estimates in the preparation of our consolidated financial statements.

Revenue Recognition

We currently recognize revenues from R&D programs that consist of government programs, collaborative research and development agreements with commercial and strategic partners and related parties, as well as from commercial sales of our products. Revenues are recognized when all of the following criteria are met: persuasive evidence of an arrangement exists, delivery has occurred or services have been rendered, the fee is fixed or determinable and collectability is reasonably assured.

If collaborative research and development or sales agreements contain multiple elements, we evaluate whether the components of each arrangement represent separate units of accounting. We have determined that all of our revenue arrangements should be accounted for as a single unit of accounting. Application of revenue recognition standards requires subjective determination and requires management to make judgments about the fair values of each individual element and whether it is separable from other aspects of the contractual relationship.

For each source of revenue, we apply the above revenue recognition criteria in the following manner:

Government Program Revenues

Revenues from government programs are recognized in the period during which the related costs are incurred, provided that the conditions under which the government program activities were provided have been met and only perfunctory obligations are outstanding.

Collaborative Research and Development Revenues

Revenues from collaborative research and development are recognized as the services are performed consistent with the performance requirements of the agreement. In cases where the planned levels of research and development fluctuate over the research term, we recognize revenues using the proportionate performance method based upon actual efforts to date relative to the amount of expected effort to be incurred by us. When up-front payments are received and the planned levels of research and development do not fluctuate over the research term, revenues are recorded on a ratable basis over the arrangement term, up to the amount of cash received. When up-front payments are received and the planned levels of research and development fluctuate over the research term, revenues are recorded using the proportionate performance method, up to the amount of cash received. Where arrangements include milestones that are determined to be substantive and at risk at the inception of the arrangement, revenues are recognized upon achievement of the milestone and are limited to those amounts for which collectability is reasonably assured. If these conditions are not met, we defer the milestone payment and recognize it as revenue over the estimated period of performance under the contract as we complete our performance obligations.

Product Revenue

Product revenue is recognized when all of the following criteria are satisfied: persuasive evidence of an arrangement exists; risk of loss and title transfers to the customer; the price is fixed or determinable; and collectability is reasonably assured. Products are sold with a right of return for expired, discontinued, damaged or non-compliant products. Algenist ® and EverDeep ® products have an approximate three year shelf life from their

 

58


Table of Contents
Index to Financial Statements

manufacture date. We give credit for returns by issuing a credit memo at the time of product return or, in certain cases, by allowing a customer to decrease the amount of subsequent payments to us for the amount of the return. We reserve for estimated returns of products at the time revenues are recognized. To estimate our return reserve, we analyze our own actual product return data, data from our customers regarding their inventory levels and historical return rates of our products, and other known factors, such as our customers’ return policies to their end consumers, which is typically 30 to 90 days. We monitor our actual performance by comparing our actual return rates against estimated rates, and adjust our estimated return rates as necessary. In addition, we estimate a reserve for products that do not meet internal quality standards. Actual returns of Algenist ® and EverDeep ® products may differ from estimates that we used to calculate such reserves.

We continually evaluate collectability of our accounts receivable related to product sales, and to date our customers have remitted full payments in a timely manner. Accordingly, we expect full collection of our accounts receivable balance related to product sales and therefore have not established any reserves for uncollectible accounts receivable.

Convertible Preferred Stock Warrants

Prior to our initial public offering, the freestanding warrants to purchase shares of our convertible preferred stock were classified as liabilities on our consolidated balance sheets at fair value because the warrants could conditionally obligate us to redeem the underlying convertible preferred stock at some point in the future. The warrants were subject to remeasurement at each balance sheet date, and any change in fair value was recognized as a component of Other Income (Expense), in the consolidated statement of operations. We estimated the fair value of these warrants at the respective balance sheet dates utilizing an option-based model to allocate an estimated business enterprise value to the various classes of our equity stock and related warrants. Prior to our initial public offering, the assumptions used to estimate the business enterprise value and allocation of value to the classes of equity stock and related warrants were highly judgmental. We used our initial public offering price for the final measurement of these freestanding warrants.

In 2012 and 2011, we recorded a gain of $2.3 million and charges of $3.6 million, respectively, in Other Income (Expense), to reflect the change in the fair value of the warrants. Upon the close of our initial public offering in June 2011, the then-aggregate fair value of the related preferred stock warrant liability of $6.6 million was reclassified to additional paid-in capital and we no longer record any related period fair value adjustments.

Convertible Debt and Embedded Derivative

In January 2013, we issued $125.0 million aggregate principal amount of Notes. The terms of the Notes include, among others, that if a conversion occurs prior to November 1, 2016 (other than conversions in connection with certain fundamental changes where we may be required to increase the conversion rate as described in Note 11 to the consolidated financial statements) in addition to the shares deliverable upon conversion, holders are entitled to receive an early conversion payment equal to $83.33 per $1,000 principal amount of Notes surrendered for conversion that may be settled, at our election, in cash or, subject to satisfaction of certain conditions, in shares of our common stock. As of December 31, 2013, $43.2 million of the Notes had been converted into approximately 5.2 million shares of our common stock and were reclassified from long-term debt to stockholders’ equity in our consolidated balance sheets. We elected to settle the early conversion payments related to the Notes in shares of our common stock, and accordingly issued approximately 0.3 million shares of our common stock as of December 31, 2013.

We evaluated the embedded derivative resulting from the early conversion payment feature within the indenture for bifurcation from the notes. The early conversion feature was not deemed clearly and closely related to the Notes and was bifurcated as an embedded derivative. We estimated the fair value of this embedded derivative liability using a Monte Carlo simulation model and classified it as a non-current liability in our consolidated balance sheets with a corresponding debt discount that is netted against the principal amount of the

 

59


Table of Contents
Index to Financial Statements

Notes. The fair value of the embedded derivative is remeasured to fair value at each balance sheet date, with a resulting non-cash gain or loss related to the change in the fair value of the derivative liability. Early conversion payments in cash or common stock are also recorded to the change in the fair value of the derivative liability upon the early conversion of the Notes.

Stock-Based Compensation

We recognize compensation expense related to stock-based compensation, including the awarding of employee stock options and restricted stock units, based on the grant date estimated fair value. We amortize the fair value of the employee stock options on a straight-line basis over the requisite service period of the award, which is generally the vesting period.

We estimate the fair value of stock-based compensation awards using the Black-Scholes option pricing model, which requires the following inputs: expected life, expected volatility, risk-free interest rate, expected dividend yield rate, exercise price and closing price of our common stock on the date of grant. Due to our limited history of grant activity, we calculate our expected term utilizing the “simplified method” permitted by the SEC, which is the average of the total contractual term of the option and its vesting period.

We account for stock options issued to non-employees based on their estimated fair value determined using the Black-Scholes option-pricing model. We account for restricted stock units and restricted stock awards issued to nonemployees based on the estimated fair value of our common stock. The measurement of stock-based compensation for nonemployees is subject to periodic adjustments as the underlying equity instruments vest, and the resulting change in value, if any, is recognized in our consolidated statements of operations during the period the related services are rendered.

Our stock-based compensation expense is expected to increase in the future as we recognize expense related to unvested stock-based awards and we issue additional stock-based awards to attract and retain employees and nonemployee consultants.

Income Taxes

We are subject to income taxes in both the U.S. and a foreign jurisdiction, and we use estimates in determining our provisions for income taxes. We use the asset and liability method of accounting for income taxes, whereby deferred tax asset or liability account balances are calculated at the balance sheet date using current tax laws and rates in effect for the year in which the differences are expected to affect taxable income.

Recognition of deferred tax assets is appropriate when realization of such assets is more likely than not. We record a valuation allowance against our net deferred tax assets if it is more likely than not that some portion of the deferred tax assets will not be fully realizable. This assessment requires judgment as to the likelihood and amounts of future taxable income by tax jurisdiction. At December 31, 2013 and 2012, we had a full valuation allowance against all of our net deferred tax assets.

Effective January 1, 2007, we adopted Financial Accounting Standards Board (FASB) Accounting Standards Codification (ASC) ASC 740-10, Income Taxes , to account for uncertain tax positions. As of December 31, 2013 and 2012, we had no significant uncertain tax positions requiring recognition in our consolidated financial statements. We do not expect the total amount of unrecognized income tax benefits will change significantly in the next 12 months.

We assess all material positions taken in any income tax return, including all significant uncertain positions, in all tax years that are still subject to assessment or challenge by relevant taxing authorities. Assessing an uncertain tax position begins with the initial determination of the position’s sustainability and is measured at the largest amount of benefit that is greater than 50 percent likely of being realized upon ultimate settlement. As of each balance sheet date, unresolved uncertain tax positions must be reassessed, and we will determine whether (1) the factors underlying the sustainability assertion have changed and (2) the amount of the recognized tax

 

60


Table of Contents
Index to Financial Statements

benefit is still appropriate. The recognition and measurement of tax benefits requires significant judgment. Judgments concerning the recognition and measurement of a tax benefit might change as new information becomes available.

Results of Operations

Comparison of Year Ended December 31, 2013 and 2012

Revenues

 

     Year ended December 31,  
     2013      2012      $ Change  
     (In thousands)  

Revenues:

        

Research and development programs

   $ 19,788       $ 27,649       $ (7,861

Net product revenue

     19,962         16,459         3,503   
  

 

 

    

 

 

    

 

 

 

Total revenues

   $ 39,750       $ 44,108       $ (4,358
  

 

 

    

 

 

    

 

 

 

R&D program revenue decreased by $7.9 million in 2013 compared to 2012, due to a $14.1 million decrease in government program revenues, partially offset by a $6.3 million increase in revenues primarily from development agreements with the Solazyme Bunge JV and strategic partners.

Our government program revenues decreased in 2013 compared to the same period in 2012, primarily due to the completion of the integrated biorefinery build out at our Peoria Facility in mid-2012 under the DOE grant, delivery of our commitment of algal oil under the Dynamic Fuels subcontract in the first half of 2012 and completion of the second phase of our 2011 DoD fuels testing and certification contract in June 2012. The grant awarded by the DOE has funded $21.8 million of the build-out, equipment costs and certain research and development costs associated with our integrated biorefinery program at our Peoria Facility. We successfully commissioned the integrated biorefinery at our Peoria Facility in the second quarter of 2012 and anticipate that the remaining objectives under the program will be completed as outlined in the program by the end of the third quarter of 2014. We are fully funding the remaining costs to complete the objectives of the DOE award.

Our revenues from development agreements with strategic partners and the Solazyme Bunge JV increased due to timing of the development work performed and achievement of contract milestones defined in these agreements. We are currently engaged in development activities with multiple strategic partners and the Solazyme Bunge JV and expect that our R&D program revenues will continue, as we continue this work and add new strategic partners. In addition to funding development work and performing application testing, we expect that our partners will enter into long-term purchase agreements with us and that revenue from product sales from these purchase agreements will become a higher percentage of total revenues over time. In the near term, we don’t expect government program revenues to increase. As we enter into new agreements with strategic partners or government programs, we expect that quarterly trends may fluctuate based on the timing of program activities.

Net product revenue increased primarily due to new Algenist ® product offerings and increased consumer demand. The launch of our second algal skin care line, EverDeep ® in late 2013 contributed slightly to the increase in product revenues. EverDeep ® products are sold online and via telephone driven by direct-to-consumer “infomercial” broadcasts leveraging a continuity program and auto-delivery options to strengthen the link with customers to drive repeat sales.

The inherent flexibility of our technology platform and the broad usage of triglyceride oils across multiple industries, allows us to approach a wide range of customers across myriad end markets. We expect our product revenues to increase as we commercialize our intermediate/ingredient products encompassing a portfolio of products targeted at customers in the chemicals, fuels and foods markets. We also expect an increase in our mix of product revenues to total revenues as we expand our manufacturing capacity and related oil product offerings in the chemical, fuels and foods markets.

 

61


Table of Contents
Index to Financial Statements

Cost of Product Revenues

 

     Year ended December 31,  
     2013      2012      $ Change  
     (In thousands)  

Cost of revenue:

        

Product

   $ 6,385       $ 5,311       $ 1,074   
  

 

 

    

 

 

    

 

 

 

Gross profit:

        

Product

   $ 13,577       $ 11,148       $ 2,429   
  

 

 

    

 

 

    

 

 

 

Cost of product revenue increased by $1.1 million in 2013 compared to 2012 primarily due almost exclusively to increased sales of Algenist ® products. Gross margin percentage on product sales remained constant at 68% in 2013 and 2012.

Beginning in the first quarter of 2014, we commenced commercial-scale production at the Clinton Facility. We expect our cost of production will increase as we start commercial production for the chemicals, fuels and foods markets and that production volume will ramp up over the next 12 to 18 months, as we work toward our target nameplate capacity of 20,000 MT. We also expect that our cost of production as a percentage of revenue will be higher in the early stages of production, but will ease and flatten as production volume increases to nameplate capacity.

Operating Expenses

 

     Year ended December 31,  
     2013      2012      $ Change  
     (In thousands)  

Operating expenses:

        

Research and development

   $ 66,572       $ 66,384       $ 188   

Sales, general and administrative

     62,933         57,516         5,417   
  

 

 

    

 

 

    

 

 

 

Total operating expenses

   $ 129,505       $ 123,900       $ 5,605   
  

 

 

    

 

 

    

 

 

 

Research and Development Expenses

Our research and development expenses increased by $0.2 million in 2013 compared to 2012, due primarily to $10.6 million of increased costs incurred to scale up the Clinton/ Galva Facilities as well as increased personnel-related and facilities-related costs of $5.1 million and $1.6 million, respectively, offset by decreased DOE and DoD R&D program costs and outside contract manufacturing costs of $15.1 million and $2.1 million, respectively.

Personnel-related and facilities-related costs increased as a result of headcount growth to support the Clinton, Galva and Solazyme Bunge JV activities as well as Peoria manufacturing and collaborative research activities. Personnel-related costs include non-cash stock-based compensation expense of $5.9 million in 2013 compared to $3.9 million in 2012.

R&D program and third-party contractor costs decreased in 2013 compared to 2012 primarily due to decreased costs as a result of the completion of both the construction of the integrated biorefinery program and the second phase of our 2011 DoD fuels testing and certification contract in 2012. We plan to continue to make investments in research and development for the foreseeable future as we continue (1) to identify, isolate and further optimize strains of microalgae to achieve high cell densities, high yield converting sugar to product and high productivity rates compared to other alternatives; (2) to tailor the oil outputs to meet specific market needs; (3) product and process development projects aimed at reducing the cost of oil production; and (4) to scale-up

 

62


Table of Contents
Index to Financial Statements

commercial production at the Clinton Facility as well as product and process development activities in our Peoria Facility. We do not expect a significant increase in our research and development expenses in the near term as we scale up to commercial production.

Sales, General and Administrative Expenses

Our sales, general and administrative expenses increased by $5.4 million in 2013 compared to 2012, primarily due to increased personnel-related and facilities-related costs of $5.6 million and $0.5 million, respectively, increased marketing and promotional costs of $0.2 million, partially offset by decreased outside service costs of $0.8 million. Personnel-related and facilities-related costs increased due to headcount growth primarily related to commercialization of our products. Personnel-related costs include non-cash stock-based compensation of $12.7 million in 2013 compared to $11.5 million in 2012. We expect our sales, general and administrative expenses to increase as we hire additional personnel and enhance our infrastructure to support the anticipated commercialization into the chemicals, fuels and food markets domestically and in Brazil.

Other Income (Expense), Net

 

     Year ended December 31,  
     2013     2012     $ Change  
     (In thousands)  

Other income (expense):

      

Interest and other income, net

   $ 1,369      $ 2,072      $ (703

Interest expense

     (7,136     (561     6,575   

Loss from equity method investments

     (8,237     (1,824     6,413   

Gain from change in fair value of warrant liability

     147        2,284        (2,137

Loss from change in fair value of derivative liability

     (6,392            6,392   
  

 

 

   

 

 

   

 

 

 

Total other income (expense), net

   $ (20,249   $ 1,971      $ (22,220
  

 

 

   

 

 

   

 

 

 

Interest and Other Income, net

Interest and other income, net decreased by $0.7 million in 2013 compared to 2012, primarily due to decreased investment yields on investment balances. We expect our interest and other (expense) income, net to fluctuate with changes in our cash and investment balances.

Interest expense

Interest expense increased by $6.6 million in 2013 compared to 2012, due to $7.7 million of increased interest expense resulting primarily from the issuance of the Notes in January 2013, partially offset by $1.1 million of interest expense capitalized to our investment in the Solazyme Bunge JV. We expect interest expense and amortization of debt discounts and debt issue costs to decrease slightly due to the early conversion of Notes during 2013 (see Note 11 to our consolidated financial statements).

Loss from Equity Method Investment

Loss from equity method investment increased by $6.4 million in 2013 compared to 2012, primarily due to the increase in our proportionate share of the net loss from the Solazyme Bunge JV of $5.0 million and a $1.4 million loss related to the dissolution of the Solazyme Roquette JV. We expect the loss from our equity method investment to increase as the Solazyme Bunge JV completes plant construction and begins scale up of commercial-scale production in Brazil.

 

63


Table of Contents
Index to Financial Statements

Gain from Change in Fair Value of Warrant Liability

There was a $0.1 million gain from the change in fair value of warrant liability in 2013 compared to a $2.3 million gain from the change in fair value of warrant liability in 2012. The change in fair value of warrant liability is related to the fair value of the unvested warrant issued to Bunge Limited. The warrant vests in three separate tranches, each contingent upon the achievement of specific performance-based milestones related to the formation and operations of the Solazyme Bunge JV. The unvested warrant shares were recorded as a liability on our consolidated balance sheet beginning in the second quarter of 2012, the unvested portion of the warrant continues to be remeasured to fair value at each balance sheet date and reclassified to additional paid-in capital upon vesting. In the second quarter of 2012, 750,000 warrant shares vested and were reclassified to additional paid-in capital. We expect that the gain or loss from the change in the fair value of the warrant liability will fluctuate with the change in our stock price and other factors.

Loss from Change in Fair Value of Derivative Liability

Loss from change in fair value of derivative liability of $6.4 million in 2013 was due to the change in the fair value of the embedded derivative related to the early conversion feature of the Notes issued in January 2013 of $4.4 million and fair value adjustments related to early conversions made in 2013 of $2.0 million. At each reporting period, we remeasure this embedded derivative at fair value which is included as a component of Convertible Debt on our consolidated balance sheets. We used a Monte Carlo simulation model to estimate the fair value of the embedded derivative related to the early conversion feature of the Notes. Changes in certain inputs into the model may have a significant impact on changes in the estimated fair value of the embedded derivative. We expect that the loss from the change in the fair value of the derivative liability will fluctuate with the change in our stock price and other certain inputs to the Monte Carlo simulation model and upon early conversion by Note holders.

Results of Operations

Comparison of Year Ended December 31, 2012 and 2011

Revenues

 

     Year ended December 31,  
     2012      2011      $ Change  
     (In thousands)  

Revenues:

        

Research and development programs

   $ 27,649       $ 26,793       $ 856   

Net product revenue

     16,459         7,173         9,286   

License Fee

             5,000         (5,000
  

 

 

    

 

 

    

 

 

 

Total revenues

   $ 44,108       $ 38,966       $ 5,142   
  

 

 

    

 

 

    

 

 

 

Our total revenues increased by $5.1 million in 2012 compared to 2011, due primarily to a $9.3 million increase in Algenist ® product revenue (which launched in March 2011) and $0.9 million increase in R&D program revenue, offset in part by a $5.0 million decrease in license fees related to an up-front non-refundable fee for licensing our technology to Solazyme Roquette Nutritionals. The decrease in license fee revenue was expected per the terms of the Solazyme Roquette JV joint venture agreement. Net Algenist ® product sales increased due to increased consumer demand, as well as additional product offerings.

R&D program revenues increased by $0.9 million, due to a $2.1 million increase in government program revenues, offset by a $1.2 million decrease in revenues from our development agreements with strategic partners.

Our government program revenues increased in 2012 compared to the same period in 2011, primarily due to increased activities associated with our DOE and California Energy Commission (CEC) grants in 2012, partially

 

64


Table of Contents
Index to Financial Statements

offset by the successful completion of the second phase of our 2011 DoD fuels testing and certification contract in June 2012. The grant awarded by the DOE is funded up to $21.8 million of the build-out, equipment costs and certain research and development costs associated with our integrated biorefinery program at our Peoria Facility. We successfully commissioned the integrated biorefinery in our Peoria Facility in the second quarter of 2012 and completed the IBR construction activities in 2012. In October 2011, the CEC agreed to fund up to $1.5 million for continuing research and development at our South San Francisco pilot plant facility through early 2015.

Our revenues from development agreements with strategic partners decreased in 2012 due to timing of agreements that ended offset by new agreements entered into since the second half of 2011.

Cost of Product Revenues

 

     Year ended December 31,  
     2012      2011      $ Change  
     (In thousands)  

Cost of revenue:

        

Product

   $ 5,311       $ 2,420       $ 2,891   
  

 

 

    

 

 

    

 

 

 

Gross profit:

        

Product

   $ 11,148       $ 4,753       $ 6,395   
  

 

 

    

 

 

    

 

 

 

Cost of product revenue increased in 2012 compared to 2011 primarily due to increased sales of Algenist ® products, which launched in March 2011. Gross margin percentage on product sales increased slightly from 66.0% in 2011 to 68.0% in 2012.

Operating Expenses

 

     Year Ended December 31,  
     2012      2011      $ Change  
     (In thousands)  

Operating expenses:

        

Research and development

   $ 66,384       $ 45,613       $ 20,771   

Sales, general and administrative

     57,516         41,426         16,090   
  

 

 

    

 

 

    

 

 

 

Total operating expenses

   $ 123,900       $ 87,039       $ 36,861   
  

 

 

    

 

 

    

 

 

 

Research and Development Expenses

Our research and development expenses increased by $20.8 million in 2012 compared to 2011, due primarily to increased personnel-related and facilities-related costs of $9.2 million and $3.9 million, respectively, and increased R&D program and third- party contractor costs of approximately $7.6 million. Personnel-related and facilities-related costs increased as a result of headcount growth to support Peoria manufacturing and collaborative research activities. Personnel-related costs include non-cash stock-based compensation expense of $3.9 million in 2012 compared to $2.3 million in 2011. R&D program and third-party contractor costs increased primarily due to increased costs to complete the construction of the integrated biorefinery pursuant to the DOE grant, increased costs related to R&D programs with our commercial partners and operating costs related to the Peoria Facility.

Sales, General and Administrative Expenses

Our sales, general and administrative expenses increased by $16.1 million in 2012 compared to 2011, primarily due to increased personnel-related and facilities-related costs of $7.4 million and $2.0 million,

 

65


Table of Contents
Index to Financial Statements

respectively, associated with headcount growth, increased marketing and promotional costs of $5.0 million and increased consulting costs of $1.7 million. Personnel-related costs include non-cash stock-based compensation of $11.5 million in 2012 compared to $8.6 million in 2011.

Other Income (Expense), Net

 

     Year Ended December 31,  
     2012     2011     $ Change  
     (In thousands)  

Other income (expense):

      

Interest and other income, net

   $ 2,072      $ 871      $ 1,201   

Interest expense

     (561     (642     (81

Loss from equity method investments

     (1,824            1,824   

Gain (loss) from change in fair value of warrant liabilities

     2,284        (3,637     (5,921
  

 

 

   

 

 

   

 

 

 

Total other income (expense), net

   $ 1,971      $ (3,408   $ (5,379
  

 

 

   

 

 

   

 

 

 

Interest and Other Income, net

Interest and other income, net increased by $1.2 million in 2012 compared to 2011, primarily due to $0.8 million of increased interest income earned as a result of higher average investment balances resulting from the proceeds we received upon the closing of our initial public offering in June 2011 and the $15.0 million term loan drawn down from our Silicon Valley Bank credit facility, net of cash used for operations, and $0.2 million of increased gains on sales of marketable securities.

Interest expense

Interest expense decreased by $0.1 million in 2012, primarily due to the lower outstanding balance on our debt during the year.

Loss from Equity Method Investment

Loss from equity method investment increased by $1.8 million, which represents our proportionate share of the net loss from the Solazyme Bunge JV.

Gain (Loss) from Change in Fair Value of Warrant Liability

Loss from the change in fair value of warrant liability decreased by $5.9 million in 2012 compared to 2011. The $3.6 million loss from change in fair value of warrant liabilities in 2011 represents the non-cash loss from the change in fair value of warrants as we remeasured the warrants through the closing date of our initial public offering. Upon the close of our initial public offering in June 2011, all outstanding warrants to purchase shares of preferred stock were converted into shares of our common stock or common stock warrants and are no longer measured to fair value. In the second quarter of 2011, we granted Bunge Limited a warrant to purchase 1,000,000 shares of our common stock at an exercise price of $13.50 per share. The warrant vests in three separate tranches, each contingent upon the achievement of specific performance-based milestones related to the formation and operations of the Solazyme Bunge JV. The unvested warrant shares are classified as a liability on our consolidated balance sheet beginning in the second quarter of 2012, and remeasured to fair value at each balance sheet date and reclassified to additional paid-in capital upon vesting. In 2012, 750,000 warrant shares vested and were reclassified to additional paid-in capital. The value of the remaining unvested warrant shares decreased since the initial recording of the warrant liability in the second quarter of 2012, resulting in a $2.3 million non-cash gain related to the change in the fair value of the warrant liability.

 

66


Table of Contents
Index to Financial Statements

Liquidity and Capital Resources

 

     December 31,
2013
     December 31,
2012
 
     (In thousands)  

Cash and cash equivalents

   $ 54,977       $ 30,818   

Marketable securities

     112,544         118,187   

Cash, cash equivalents and marketable securities increased by $18.5 million in 2013, primarily due to $119.2 million of net cash proceeds received from the issuance of the Notes (net of $5.3 million of debt discounts and $0.5 million of debt issue costs) and $10.4 million of proceeds received from borrowings under the loan and security agreement entered into with HSBC (the HSBC facility), partially offset by cash used in operating activities of $74.8 million, $14.9 million of repayments under loan agreements, $12.4 million of capital contributed primarily to the Solazyme Bunge JV and $10.2 million of property and equipment purchases.

The following table shows a summary of our cash flows for the periods indicated:

 

     Year ended December 31,  
     2013     2012     2011  
     (In thousands)  

Net cash used in operating activities

   $ (74,790   $ (67,571   $ (34,905

Net cash (used in) provided by investing activities

     (20,341     72,234        (182,831

Net cash provided by (used in) financing activities

     119,379        (2,570     214,344   

Since our inception, we have incurred significant net losses, and, as of December 31, 2013, we had an accumulated deficit of $306.3 million. We anticipate that we will continue to incur net losses as we continue the scale-up of our manufacturing activities, support commercialization activities for our products and continue to support our research and development activities. In addition, we may acquire additional manufacturing facilities, expand or build out our current manufacturing facilities and/or build additional manufacturing facilities. We are unable to predict the extent of any future losses or when we will become profitable, if at all. We expect to continue making investments in research and development and manufacturing, and expect selling, general and administrative expenses to increase as we begin and ramp up commercialization. As a result, we will need to generate significant revenues from product sales, collaborative research and joint development activities, licensing fees and other revenue arrangements to achieve profitability. To date, our sources for capital are as follows:

Strategic Partners and Government

In January 2010, we obtained a grant from the DOE to receive up to $21.8 million for reimbursement of expenses incurred towards building, operating, and optimizing a pilot-scale integrated biorefinery, which has allowed us to develop integrated U.S.-based production capabilities at the Peoria Facility to make oil for algae-derived biofuel. Under the terms of the grant, we are responsible for funding an additional $8.4 million. We anticipate that the remaining objectives under the program will be completed as outlined in the program by the end of the third quarter of 2014.

We purchased the Peoria Facility in May 2011. We began fermentation operations in the fourth quarter of 2011 and successfully commissioned our integrated biorefinery in June 2012, funded in part by the DOE grant described above. In connection with the closing of the Peoria Facility acquisition, we entered into a promissory note, mortgage and security agreement with the seller in the initial amount of $5.5 million. In March 2013, we paid in full the outstanding principal on this promissory note.

In April 2012, we entered into the Solazyme Bunge JV, which is jointly capitalized by us and Bunge, to construct and operate an oil production facility in Brazil that will utilize our proprietary technology to produce oil products from sugar feedstock provided by Bunge. Through February 2014, we contributed approximately

 

67


Table of Contents
Index to Financial Statements

$28.8 million in capital to the Solazyme Bunge JV, and we may need to contribute additional capital to this project. In February 2013, the Solazyme Bunge JV entered a loan agreement with the Brazilian Development Bank (BNDES) under which it may borrow up to R$245.7 million (approximately USD $104.0 million based on the exchange rate as of December 31, 2013). As a condition of the Solazyme Bunge JV drawing funds under the loan in excess of amounts supported by bank guarantees, we may be required to provide a corporate guarantee for a portion of the loan (in an amount that when added to the amount supported by our bank guarantee does not to exceed our ownership percentage in the Solazyme Bunge JV). The BNDES funding is supporting the Solazyme Bunge JV’s first commercial-scale production facility in Brazil, which will reduce the capital requirements funded directly by us and Bunge. We expect to scale up additional manufacturing capacity in a capital- efficient manner by signing additional agreements whereby our partners will invest capital and operational resources in building manufacturing capacity, while also providing access to feedstock. We expect to evaluate the optimal amount of capital expenditures that we agree to fund on a case-by-case basis. These events may require us to access additional capital through equity or debt offerings. If we are unable to access additional capital, our growth may be limited due to the inability to build out additional manufacturing capacity.

In November 2012, we entered into a strategic collaboration agreement with ADM, whereby we have agreed to pay ADM annual fees for use and operation of a portion of its commercial scale facility in Clinton, Iowa, a portion of which may be paid in our common stock. In addition, in March 2013 we issued a series of warrants to ADM for payment in stock, in lieu of cash, at our election, of future annual fees for use and operation of a portion of the Clinton Facility. In January 2013 and November 2013, we made payments to ADM in both common stock and cash.

Commercial Banks

On May 11, 2011, we entered into a loan and security agreement with Silicon Valley Bank (the bank) that provided for a $20.0 million credit facility (the SVB facility) consisting of (i) a $15.0 million term loan (the term loan) and (ii) a $5.0 million revolving facility (the SVB revolving facility). In the first quarter of 2013, the SVB facility was terminated when we paid in full the outstanding principal and interest on the term loan using proceeds from the revolving facility with HSBC Bank, USA, National Association (HSBC) we entered into in March 2013 as described below.

On March 26, 2013, we entered into a credit facility with HSBC (the HSBC facility), which provides for a $30.0 million revolving facility for working capital, letters of credit denominated in U.S. dollars or a foreign currency and other general corporate purposes, and in May 2013 we entered into an amendment to increase the HSBC facility to $35.0 million. Also on March 26, 2013, we drew down approximately $10.4 million under the HSBC facility to repay the outstanding term loan plus accrued interest under the SVB facility. The HSBC facility is unsecured unless (i) we take action that could cause or permit obligations under the HSBC facility not to constitute senior debt (as defined in the indenture related to the Notes dated as of January 24, 2013 by and between us and Wells Fargo Bank, National Association, as trustee), (ii) we breach financial covenants that require us and our subsidiaries to maintain cash and unrestricted cash equivalents at all times of not less than $35.0 million plus one hundred ten percent of the aggregate dollar equivalent amount of outstanding advances and letters of credit under the HSBC facility, or (iii) there is a payment default under the HSBC facility or bankruptcy or insolvency events relating to us. As of December 31, 2013, $10.4 million was outstanding under the HSBC facility and we were in compliance with all the financial covenants under the loan. A portion of the HSBC facility supports the bank guarantee issued to BNDES in May 2013. Therefore, $9.6 million of the HSBC facility remained available as of December 31, 2013.

Private and Public Offerings

In January 2013, we issued $125.0 million aggregate principal amount of Notes in a private offering to qualified institutional buyers pursuant to Rule 144A under the Securities Act of 1933, as amended. The Notes bear interest at a fixed rate of 6.00% per year, payable semiannually in arrears on August 1 and February 1 of

 

68


Table of Contents
Index to Financial Statements

each year, beginning on August 1, 2013. The Notes are convertible into our common stock and will mature on February 1, 2018, unless earlier repurchased or converted. We may not redeem the Notes prior to maturity. The initial conversion price is approximately $8.26 per share of common stock and, under certain circumstances, the Note holders will be entitled to additional payments upon conversion. The Notes are convertible at the option of the holders at any time prior to February 1, 2018 into shares of our common stock at the then-applicable conversion rate. The conversion rate is initially 121.1240 shares of common stock per $1,000 principal amount of Notes. In the event the Notes are converted prior to November 1, 2016 (other than conversions in connection with certain fundamental changes described below), in addition to the shares deliverable upon conversion, the holders are entitled to receive an early conversion payment of $83.33 per $1,000 principal amount of Notes surrendered for conversion that may be settled, at our election, in cash or, subject to satisfaction of certain conditions, in shares of our common stock. If we undergo a fundamental change (as defined in the indenture entered into with the trustee), Note holders may require that we repurchase for cash all or part of their Notes at a purchase price equal to 100% of the principal amount of the Notes to be repurchased, plus accrued and unpaid interest to, but excluding, the fundamental change repurchase date. In addition, if fundamental changes occur, we may be required in certain circumstances to increase the conversion rate for any Notes converted in connection with such fundamental changes by a specified number of shares of our common stock. Certain Note holders elected to convert their Notes during 2013 and, as of December 31, 2013, we had issued approximately 5.5 million shares of our common stock to settle both the Note conversions and early conversion payments. We had $81.8 million aggregate principal amount of Notes outstanding as of December 31, 2013.

In February 2014, we filed a shelf registration statement whereby securities may be offered by us or by selling security holders in amounts, at prices and on terms determined at the time of the offering.

We believe that our current cash, cash equivalents, marketable securities, revenue from product sales and net proceeds from the Notes issued in January 2013 will be sufficient to fund our current operations for at least the next 12 months. However, our liquidity assumptions may prove to be wrong, and we could utilize our available financial resources sooner than we currently expect. We may elect to raise additional funds within this period of time through public or private debt or equity financings and/or additional collaborations.

Our future capital requirements and the adequacy of available funds will depend on many factors, including those set forth under “Risk Factors” elsewhere in this Annual Report on Form 10-K. We may not be able to secure additional financing to meet our funding requirements on acceptable terms, if at all. If we raise additional funds by issuing equity securities, dilution to our existing stockholders may result. If we are unable to obtain additional funds, we will have to reduce our operating costs and delay our manufacturing and research and development programs.

Cash Flows from Operating Activities

Cash used in operating activities of $74.8 million in 2013 reflects a loss of $116.4 million, and a net change of $0.4 million in our net operating assets and liabilities, partially offset by aggregate non-cash charges of $42.0 million. Non-cash charges included stock-based compensation, loss from equity method investments, revaluation of our derivative liability, depreciation and amortization, net amortization of premiums on marketable securities and debt discount and loan fee amortization. We expect stock-based compensation and revaluation of our derivative liability to fluctuate with the change in our stock price and other factors. We expect loss from equity method investments and depreciation to increase as construction and commissioning of the Solazyme Bunge JV Plant is completed, production of commercially saleable product at the Solazyme Bunge JV Plant begins and the Clinton/Galva Facilities are ramped up.

The net change in our operating assets and liabilities was primarily a result of increased accounts receivable and unbilled revenue of $5.2 million, increased deferred revenues of $2.0 million, increased inventories of $2.9 million, increased accounts payable and accrued liabilities of $3.4 million and decreased other assets of $3.3 million. Accounts receivable and unbilled revenue increased primarily due to billing related to research and development agreements entered into in 2013 and timing of payments received on accounts receivables from

 

69


Table of Contents
Index to Financial Statements

strategic partners. Deferred revenues increased due primarily to the timing of payments received under our R&D programs. Inventories increased due to the expansion of and increased demand in our skin care line. The net increase in accounts payable and accrued liabilities was due primarily to increased scale-up activities at the Clinton Facility and interest accrued on the Notes. We expect increased working capital requirements as we commercialize our portfolio of products in the chemical, fuels and food markets.

Cash used in operating activities of $67.6 million in 2012 reflect a loss of $83.1 million, and a net change of $5.5 million in our net operating assets and liabilities, partially offset by aggregate non-cash charges of $21.1 million. Non-cash charges primarily included $15.4 million of stock-based compensation, $3.5 million of depreciation and amortization, $2.5 million of net amortization of premiums on marketable securities, $2.3 million gain on revaluation of warrant liability and $1.8 million of loss from an equity method investment. The net change in our operating assets and liabilities was primarily a result of increases in inventories of $3.8 million, decreased deferred revenue of $2.7 million, a net decrease in accounts payable and accrued liabilities of $1.4 million, decrease in accounts receivable of $0.7 million, decrease in unbilled revenue of $0.7 million and a $0.6 million decrease in prepaid expenses and other current assets. Inventories increased due to increased production of Algenist ® product to meet higher customer demand. Deferred revenue decreased primarily due to timing of payments received on R&D programs. Accounts payable and accrued liabilities decreased primarily due to payments made to third-party contract manufacturers that we no longer use as a result of the operations at our Peoria Facility. Accounts receivable and unbilled revenues decreased due primarily to the completion of government programs during 2012. Prepaid expenses decreased primarily due to payments received from our Solazyme Roquette JV to settle other receivables due to us.

Cash used in operating activities of $34.9 million in 2011 reflect a loss of $53.9 million, partially offset by aggregate non-cash charges of $18.3 million and a net change of $0.7 million in our net operating assets and liabilities. Non-cash charges primarily included $10.9 million of stock-based compensation, $3.6 million related to the change in fair value of our warrant liability, $1.9 million of net accretion of premiums on marketable securities and $1.7 million of depreciation and amortization. The net change in our operating assets and liabilities was primarily a result of increases in our accounts payable and accrued liabilities of $8.2 million and an increase in deferred revenue of $1.7 million, offset by the increase in inventories of $3.1 million, an increase in accounts receivable of $3.4 million, an increase in prepaid expenses and other current assets of $2.3 million and an increase of $0.4 million in unbilled revenue. Accounts payable and accrued liabilities increased primarily due to vendor liabilities associated with the DOE program, payroll related liabilities associated with increased headcount, vendor liabilities associated with third-party manufacturing contracts, and vendor liabilities for engineering work related to the Solazyme Bunge JV. Deferred revenue increased due primarily to timing of payments received on research and development programs. Inventory increased primarily due to the manufacture of Algenist ® products. Accounts receivable and unbilled revenues increased due to revenue earned on our research and development programs and Algenist ® product sales in the fourth quarter of 2011. Prepaid expenses and other current assets increased primarily due to a receivable from our Solazyme Roquette JV and increased interest receivables.

Cash Flows from Investing Activities

In 2013, cash used in investing activities was $20.3 million, primarily as a result of $3.4 million of net marketable securities maturities, $12.4 million of capital contributed to the Solazyme Bunge JV and the Solazyme Roquette JV, $10.2 million of capital expenditures related primarily to equipment installed at the Clinton Facility, and $1.1 million of interest capitalized related to the Solazyme Bunge JV.

In 2012, cash provided by investing activities was $72.2 million, primarily as a result of $94.8 million of net marketable securities maturities, partially offset by $12.6 million of capital expenditures related primarily to the construction of our Peoria Facility and $10.0 million of capital contributed to the Solazyme Bunge JV.

In 2011, cash used in investing activities was $182.8 million, primarily as a result of $167.6 million of net marketable securities purchases, $15.2 million of net capital expenditures related primarily to the purchase of the Peoria Facility and property and equipment.

 

70


Table of Contents
Index to Financial Statements

Cash Flows from Financing Activities

In 2013, cash provided by financing activities was $119.4 million, primarily due to $119.2 million of proceeds received from the issuance of the Notes, net of debt discounts and debt issue costs, $10.4 million of loan proceeds received from HSBC and $4.8 million received from common stock issuances pursuant to our equity plans, partially offset by $14.9 million of principal debt payments.

In 2012, cash used in financing activities was $2.6 million, primarily due to $5.4 million of repayments under loan agreements, partially offset by proceeds of $2.9 million received from common stock issuances pursuant to our equity plans.

In 2011, cash provided by financing activities was $214.3 million, primarily due to the net proceeds of $197.4 million received from our initial public offering, after deducting underwriting discounts and commissions and other offering costs paid in 2011, a $15.0 million term loan received from Silicon Valley Bank, $1.6 million received on promissory notes to stockholders and $0.9 million of proceeds from the exercise of stock options, partially offset by $0.3 million of debt repayments.

Contractual Obligations and Commitments

The following is a summary of our contractual obligations and commitments as of December 31, 2013:

 

    Total     2014     2015     2016     2017     2018     2019 and
beyond
 

Principal payments on long-term debt

  $ 92,218      $ 65      $ 10,374      $      $      $ 81,779      $   

Interest payments on long-term debt, fixed rate

    22,444        5,202        4,975        4,907        4,907        2,453     

Non-cancellable operating leases

    10,605        3,981        6,624                               

Purchase obligations

    452        452                                      
 

 

 

   

 

 

   

 

 

   

 

 

   

 

 

   

 

 

   

 

 

 

Total

  $ 125,719      $ 9,700      $ 21,973      $ 4,907      $ 4,907      $ 84,232      $     —   
 

 

 

   

 

 

   

 

 

   

 

 

   

 

 

   

 

 

   

 

 

 

This table does not reflect (1) a lease agreement entered into in May 2011 for facility space in Brazil; the lease term is five years, commencing on April 1, 2011 and expiring on April 1, 2016; the rent is 30,500 Brazilian Real (approximately $13,000 based on the exchange rate at December 31, 2013) per month and is subject to an annual inflation adjustment; this lease is cancelable at any time, subject to a maximum three month rent penalty, (2) fees expected to be incurred related to the bank guarantee issued to BNDES in May 2013, and (3) that portion of the expenses that we expect to incur, up to $0.6 million from January through September 30, 2014, in connection with research activities under the DOE program for which we will not be reimbursed.

We currently lease approximately 96,000 square feet of office and laboratory space in South San Francisco, California. Operating leases also include annual fees to use and operate a portion of the Clinton/ Galva Facilities, a portion of which may be paid in our common stock.

Off-Balance Sheet Arrangements

For information about variable interest entities and guarantees, refer to Note 7 and Note 12, respectively, in the accompanying notes to our consolidated financial statements.

Recent Accounting Pronouncements

Refer to Note 2 in the accompanying notes to our consolidated financial statements for a discussion of recent accounting pronouncements.

 

71


Table of Contents
Index to Financial Statements
Item 7A. Quantitative and Qualitative Disclosures about Market Risk.

We are exposed to financial market risks, primarily changes in interest rates, currency exchange rates and commodity prices. All of the potential changes noted below are based on sensitivity analyses performed on our financial positions as of December 31, 2013. Actual results may differ materially.

Interest Rate Risk

Our exposure to market risk for changes in interest rates relates primarily to our investment portfolio and our outstanding debt obligations. We generally invest our cash in investments with short maturities or with frequent interest reset terms. Accordingly, our interest income fluctuates with short-term market conditions. As of December 31, 2013, our investment portfolio consisted primarily of corporate debt obligations, U.S. government agency securities, asset-backed and mortgaged-backed securities, municipal bonds and money market funds, which are held for working capital purposes. We believe we do not have material exposure to changes in fair value as a result of changes in interest rates. Our marketable securities were comprised primarily of fixed-term securities as of December 31, 2013. Due to the short-term nature of these instruments, we do not believe that there would be a significant negative impact to our consolidated financial position or results of operations as a result of interest rate fluctuations in the financial markets. On March 26, 2013 we entered into the HSBC revolving facility, which bears a variable interest rate based on LIBOR during the two-year funding period. As of December 31, 2013, the HSBC loan had a balance of $10.4 million. A 1.0% increase or decrease in the underlying interest rate for this obligation would increase or decrease interest expense by approximately $0.1 million annually, assuming debt remains constant at December 31, 2013 levels. Our other outstanding debt as of December 31, 2013 consists of fixed-rate debt, and therefore, is not subject to fluctuations in market interest rates.

Foreign Currency Risk

Our operations include manufacturing and sales activities primarily in the United States, as well as research activities primarily in the United States. We are actively expanding outside the United States, in particular in Brazil through our Solazyme Bunge JV. We also sell our Algenist ® products in Europe and conduct operations in Brazil. As we expand internationally, our results of operations and cash flows will become increasingly subject to fluctuations due to changes in foreign currency exchange rates. For example, our operations in Brazil and / or potential expansion elsewhere in Latin America or increasing Euro denominated product sales to European distributors, will result in our use of currencies other than the U.S. dollar. In addition, the local currency is the functional currency of our Brazil subsidiary and the Solazyme Bunge JV (an unconsolidated joint venture). The assets and liabilities of the Brazil subsidiary are translated from its functional currency to U.S. dollars at the exchange rate in effect at the balance sheet date, with resulting foreign currency translation adjustments recorded in accumulated other comprehensive income (loss) in the consolidated statements of comprehensive loss. The assets and liabilities of the Solazyme Bunge JV are also translated to U.S. dollars similar to our Brazil subsidiary, and we adjust our investment in the Solazyme Bunge JV and cumulative translation adjustment in equity for our ownership portion of the cumulative translation gain or loss recognized on the Solazyme Bunge JV’s financial statements. As a result, our comprehensive income (loss), cash flows and expenses are subject to fluctuations due to changes in foreign currency exchange rates. In periods when the U.S. dollar declines in value as compared to the foreign currencies in which we incur expenses, our foreign-currency based expenses increase when translated into U.S. dollars. We have not hedged our foreign currency since the exposure has not been material to our historical operating results. Although substantially all of our sales are currently denominated in U.S. dollars, future fluctuations in the value of the U.S. dollar may affect the price competitiveness of our products outside the United States. We may consider hedging our foreign currency risk as we continue to expand internationally.

Commodity Price Risk

Our exposure to market risk for changes in commodity prices currently relates primarily to our purchases of plant sugar feedstock. We have not historically hedged the price volatility of plant sugar feedstock. In the future, we may manage our exposure to this risk by hedging the price volatility of feedstock, principally through futures contracts, and entering into joint venture agreements that would enable us to obtain secure access to feedstock.

 

72


Table of Contents
Index to Financial Statements
Item 8. Financial Statements and Supplementary Data.

CONSOLIDATED FINANCIAL STATEMENTS

Solazyme, Inc.

Index

 

REPORTS OF INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM

     74   

Consolidated Balance Sheets

     76   

Consolidated Statements of Operations

     77   

Consolidated Statements of Comprehensive Loss

     78   

Consolidated Statements of Redeemable Convertible Preferred Stock and Stockholders’ Equity (Deficit)

     79   

Consolidated Statements of Cash Flows

     82   

Notes to the Consolidated Financial Statements

     83   

 

73


Table of Contents
Index to Financial Statements

REPORT OF INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM

To the Board of Directors and Stockholders of

Solazyme, Inc.

South San Francisco, California

We have audited the accompanying consolidated balance sheets of Solazyme, Inc. and subsidiaries (the “Company”) as of December 31, 2013 and 2012, and the related consolidated statements of operations, comprehensive loss, redeemable convertible preferred stock and stockholders’ equity (deficit) and cash flows for each of the three years in the period ended December 31, 2013. These financial statements are the responsibility of the Company’s management. Our responsibility is to express an opinion on the financial statements based on our audits.

We conducted our audits in accordance with the standards of the Public Company Accounting Oversight Board (United States). Those standards require that we plan and perform the audit to obtain reasonable assurance about whether the financial statements are free of material misstatement. An audit includes examining, on a test basis, evidence supporting the amounts and disclosures in the financial statements, assessing the accounting principles used and significant estimates made by management, as well as evaluating the overall financial statement presentation. We believe that our audits provide a reasonable basis for our opinion.

In our opinion, such consolidated financial statements present fairly, in all material respects, the financial position of Solazyme, Inc. and subsidiaries as of December 31, 2013 and 2012, and the results of their operations and their cash flows for each of the three years in the period ended December 31, 2013, in conformity with accounting principles generally accepted in the United States of America.

We have also audited, in accordance with the standards of the Public Company Accounting Oversight Board (United States), the Company’s internal control over financial reporting as of December 31, 2013, based on the criteria established in Internal Control—Integrated Framework (1992) issued by the Committee of Sponsoring Organizations of the Treadway Commission and our report dated March 13, 2014 expressed an unqualified opinion on the Company’s internal control over financial reporting.

/s/ DELOITTE & TOUCHE LLP

San Francisco, California

March 13, 2014

 

74


Table of Contents
Index to Financial Statements

REPORT OF INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM

To the Board of Directors and Stockholders of

Solazyme, Inc.

South San Francisco, California

We have audited the internal control over financial reporting of Solazyme, Inc. and subsidiaries (the “Company”) as of December 31, 2013, based on criteria established in Internal Control—Integrated Framework (1992) issued by the Committee of Sponsoring Organizations of the Treadway Commission. The Company’s management is responsible for maintaining effective internal control over financial reporting and for its assessment of the effectiveness of internal control over financial reporting, included in the accompanying Management’s Report on Internal Control Over Financial Reporting. Our responsibility is to express an opinion on the Company’s internal control over financial reporting based on our audit.

We conducted our audit in accordance with the standards of the Public Company Accounting Oversight Board (United States). Those standards require that we plan and perform the audit to obtain reasonable assurance about whether effective internal control over financial reporting was maintained in all material respects. Our audit included obtaining an understanding of internal control over financial reporting, assessing the risk that a material weakness exists, testing and evaluating the design and operating effectiveness of internal control based on the assessed risk, and performing such other procedures as we considered necessary in the circumstances. We believe that our audit provides a reasonable basis for our opinion.

A company’s internal control over financial reporting is a process designed by, or under the supervision of, the company’s principal executive and principal financial officers, or persons performing similar functions, and effected by the company’s board of directors, management, and other personnel to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles. A company’s internal control over financial reporting includes those policies and procedures that (1) pertain to the maintenance of records that, in reasonable detail, accurately and fairly reflect the transactions and dispositions of the assets of the company; (2) provide reasonable assurance that transactions are recorded as necessary to permit preparation of financial statements in accordance with generally accepted accounting principles, and that receipts and expenditures of the company are being made only in accordance with authorizations of management and directors of the company; and (3) provide reasonable assurance regarding prevention or timely detection of unauthorized acquisition, use, or disposition of the company’s assets that could have a material effect on the financial statements.

Because of the inherent limitations of internal control over financial reporting, including the possibility of collusion or improper management override of controls, material misstatements due to error or fraud may not be prevented or detected on a timely basis. Also, projections of any evaluation of the effectiveness of the internal control over financial reporting to future periods are subject to the risk that the controls may become inadequate because of changes in conditions, or that the degree of compliance with the policies or procedures may deteriorate.

In our opinion, the Company maintained, in all material respects, effective internal control over financial reporting as of December 31, 2013, based on the criteria established in Internal Control—Integrated Framework (1992) issued by the Committee of Sponsoring Organizations of the Treadway Commission.

We have also audited, in accordance with the standards of the Public Company Accounting Oversight Board (United States), the consolidated financial statements as of and for the fiscal year ended December 31, 2013 of the Company and our report dated March 13, 2014 expressed an unqualified opinion on those financial statements.

/s/ Deloitte & Touche LLP

San Francisco, California

March 13, 2014

 

75


Table of Contents
Index to Financial Statements

SOLAZYME, INC.

CONSOLIDATED BALANCE SHEETS

In thousands, except share and per share amounts

 

    December  31,
2013
    December  31,
2012
 
     

ASSETS

   

Current assets:

   

Cash and cash equivalents

  $ 54,977      $ 30,818   

Marketable securities

    112,544        118,187   

Accounts receivable, net—includes related party receivables of $6.9 million and $2.2 million as of December 31, 2013 and 2012, respectively

    10,452        3,280   

Unbilled revenues

    1,101        3,150   

Inventories

    9,836        6,890   

Prepaid expenses and other current assets

    2,907        2,954   
 

 

 

   

 

 

 

Total current assets

    191,817        165,279   

Property, plant and equipment, net

    40,089        32,225   

Investments in unconsolidated joint ventures

    22,532        19,047   

Other assets

    4,267        473   
 

 

 

   

 

 

 

Total assets

  $ 258,705      $ 217,024   
 

 

 

   

 

 

 

LIABILITIES AND STOCKHOLDERS’ EQUITY

   

Current liabilities:

   

Accounts payable

  $ 7,949      $ 7,552   

Accrued liabilities

    15,005        9,320   

Current portion of long-term debt

    65        7,331   

Deferred revenue

    2,275        292   

Other current liabilities

           443   
 

 

 

   

 

 

 

Total current liabilities

    25,294        24,938   

Warrant liability

    688        835   

Long-term debt

    10,374        7,637   

Convertible debt, inclusive of derivative liability of $5,914 and net of unamortized debt discount of $4,610 as of December 31, 2013

    83,083          

Other liabilities

    318        303   
 

 

 

   

 

 

 

Total liabilities

    119,757        33,713   
 

 

 

   

 

 

 

Commitments and contingencies (Note 12)

   

Stockholders’ equity:

   

Preferred stock, par value $0.001—5,000,000 shares authorized at December 31, 2013 and 2012; 0 shares issued and outstanding at December 31, 2013 and 2012

             

Common stock, par value $0.001—150,000,000 shares authorized at December 31, 2013 and 2012; 68,744,534 and 61,000,724 shares issued and outstanding at December 31, 2013 and 2012, respectively

    69        61   

Additional paid-in capital

    448,990        373,577   

Accumulated other comprehensive loss

    (3,794     (399

Accumulated deficit

    (306,317     (189,928
 

 

 

   

 

 

 

Total stockholders’ equity

    138,948        183,311   
 

 

 

   

 

 

 

Total liabilities and stockholders’ equity

  $ 258,705      $ 217,024   
 

 

 

   

 

 

 

See accompanying notes to the consolidated financial statements.

 

76


Table of Contents
Index to Financial Statements

SOLAZYME, INC.

CONSOLIDATED STATEMENTS OF OPERATIONS

In thousands, except share and per share amounts

 

     Year Ended December 31,  
     2013     2012     2011  

Revenues:

      

Research and development programs

   $ 19,788      $ 27,649      $ 26,793   

Product revenues

     19,962        16,459        7,173   

License fees

                   5,000   
  

 

 

   

 

 

   

 

 

 

Total revenues

     39,750        44,108        38,966   
  

 

 

   

 

 

   

 

 

 

Costs and operating expenses:

      

Cost of product revenue

     6,385        5,311        2,420   

Research and development

     66,572        66,384        45,613   

Sales, general and administrative

     62,933        57,516        41,426   
  

 

 

   

 

 

   

 

 

 

Total costs and operating expenses

     135,890        129,211        89,459   
  

 

 

   

 

 

   

 

 

 

Loss from operations

     (96,140     (85,103     (50,493

Other income (expense):

      

Interest and other income, net

     1,369        2,072        871   

Interest expense

     (7,136     (561     (642

Loss from equity method investments

     (8,237     (1,824       

Gain (loss) from change in fair value of warrant liability

     147        2,284        (3,637

Loss from change in fair value of derivative liability

     (6,392              
  

 

 

   

 

 

   

 

 

 

Total other income (expense)

     (20,249     1,971        (3,408
  

 

 

   

 

 

   

 

 

 

Net loss

   $ (116,389   $ (83,132   $ (53,901

Accretion of redeemable convertible preferred stock

                   (60
  

 

 

   

 

 

   

 

 

 

Net loss attributable to Solazyme, Inc. common stockholders

   $ (116,389   $ (83,132   $ (53,961
  

 

 

   

 

 

   

 

 

 

Net loss per share attributable to Solazyme, Inc. common stockholders, basic and diluted

   $ (1.81   $ (1.37   $ (1.35
  

 

 

   

 

 

   

 

 

 

Weighted average number of common shares used in loss per share computation, basic and diluted

     64,211,958        60,509,048        39,934,013   
  

 

 

   

 

 

   

 

 

 

See accompanying notes to the consolidated financial statements.

 

77


Table of Contents
Index to Financial Statements

SOLAZYME, INC.

CONSOLIDATED STATEMENTS OF COMPREHENSIVE LOSS

In thousands

 

     Year Ended December 31,  
     2013     2012     2011  

Net loss

   $ (116,389   $ (83,132   $ (53,901

Other comprehensive income (loss), net:

      

Change in unrealized gain/loss on available-for-sale securities

     (240     642        (276

Foreign currency translation adjustment

     (3,155     (252     (473
  

 

 

   

 

 

   

 

 

 

Other comprehensive income (loss)

     (3,395     390        (749
  

 

 

   

 

 

   

 

 

 

Total comprehensive loss

   $ (119,784   $ (82,742   $ (54,650
  

 

 

   

 

 

   

 

 

 

See accompanying notes to the consolidated financial statements.

 

78


Table of Contents
Index to Financial Statements

SOLAZYME, INC.

CONSOLIDATED STATEMENTS OF REDEEMABLE CONVERTIBLE PREFERRED STOCK AND

STOCKHOLDERS’ EQUITY (DEFICIT)

In thousands, except share and per share amounts

 

    Redeemable
Convertible
Preferred Stock
          Common Stock     Additional
Paid-In
Capital
    Notes
Receivable
From
Stockholders
    Accumulated
Other
Comprehensive
Loss
    Accumulated
Deficit
    Total
Stockholders’
Equity
(Deficit)
 
    Shares     Amount           Shares     Amount            

December 31, 2010

    34,534,125      $ 128,313            12,067,090      $ 12      $ 4,393      $ (1,597   $ (40   $ (52,835   $ (50,067

Issuance of common stock to nonemployee for services rendered

            2,000          16              16   

Issuance of common stock upon exercise of stock options

            844,800        1        865              866   

Restricted stock issued to nonemployees related to services performed

            42,583          547              547   

Common stock issued pursuant to vesting of restricted stock units

            23,332          318              318   

Stock-based compensation expense related to employees

                6,188              6,188   

Stock-based compensation expense related to nonemployees

                3,854              3,854   

Interest earned on stockholder promissory notes

                  (4         (4

Accretion of redeemable convertible preferred stock

      60                      (60     (60

Payments received on notes receivable from stockholders

                  1,601            1,601   

Stock issued for initial public offering, net of offering costs

            12,021,250        12        196,928              196,940   

Conversion of redeemable convertible preferred stock at initial public offering

    (34,534,125     (128,373         34,534,125        35        128,339              128,374   

Conversion of preferred stock warrant to redeemable convertible preferred stock at initial public offering

    303,855                            

Conversion of redeemable convertible preferred stock to common stock at initial public offering

    (303,855           303,855                    

Exercise of preferred stock warrant and conversion to common stock

            64,103          25              25   

Conversion of convertible preferred stock warrant to common stock and common stock warrants

                6,598              6,598   

Exercise of common stock warrants

            5,000          12              12   

Change in unrealized loss on available-for-sale securities

                    (276       (276

Foreign currency translation adjustment

                    (473       (473

Net loss

                      (53,901     (53,901
 

 

 

   

 

 

       

 

 

   

 

 

   

 

 

   

 

 

   

 

 

   

 

 

   

 

 

 

December 31, 2011

                      59,908,138        60        348,083               (789     (106,796     240,558   

 

 

See accompanying notes to the consolidated financial statements.

 

79


Table of Contents
Index to Financial Statements

SOLAZYME, INC.

CONSOLIDATED STATEMENTS OF REDEEMABLE CONVERTIBLE PREFERRED STOCK AND

STOCKHOLDERS’ EQUITY (DEFICIT)—(Continued)

In thousands, except share and per share amounts

 

    Redeemable
Convertible
Preferred Stock
    Common Stock     Additional
Paid-In
Capital
    Notes
Receivable
From
Stockholders
    Accumulated
Other
Comprehensive
Loss
    Accumulated
Deficit
    Total
Stockholders’
Equity
(Deficit)
 
    Shares     Amount     Shares     Amount            

December 31, 2011

                  59,908,138        60        348,083               (789     (106,796     240,558   

Issuance of common stock to nonemployee for services rendered

          20,000          221              221   

Issuance of common stock upon exercise of stock options

          846,608        1        1,736              1,737   

Issuance of common stock pursuant to ESPP

          115,980          1,161              1,161   

Common stock issued pursuant to vesting of restricted stock units

          64,998          1,561              1,561   

Common stock issued pursuant to vesting of performance stock units

          45,000                    

Stock-based compensation expense related to employees

              11,629              11,629   

Stock-based compensation expense related to nonemployees

              1,944              1,944   

Vesting of warrant shares issued for investment in unconsolidated joint venture

              2,656              2,656   

Reclassification of warrant liability to additional paid-in capital upon vesting of warrant shares issued for investment in unconsolidated joint venture

              4,586              4,586   

Change in unrealized loss on available-for-sale securities

                  642          642   

Foreign currency translation adjustment

                  (252       (252

Net loss

                    (83,132     (83,132
 

 

 

   

 

 

   

 

 

   

 

 

   

 

 

   

 

 

   

 

 

   

 

 

   

 

 

 

December 31, 2012

                  61,000,724        61        373,577               (399     (189,928     183,311   

 

 

See accompanying notes to the consolidated financial statements.

 

80


Table of Contents
Index to Financial Statements

SOLAZYME, INC.

CONSOLIDATED STATEMENTS OF REDEEMABLE CONVERTIBLE PREFERRED STOCK AND

STOCKHOLDERS’ EQUITY (DEFICIT)—(Continued)

In thousands, except share and per share amounts

 

    Redeemable
Convertible
Preferred Stock
          Common Stock     Additional
Paid-In
Capital
    Notes
Receivable
From
Stockholders
    Accumulated
Other
Comprehensive
Loss
    Accumulated
Deficit
    Total
Stockholders’
Equity
(Deficit)
 
     Shares       Amount            Shares     Amount            

December 31, 2012

                      61,000,724        61        373,577               (399     (189,928     183,311   

Issuance of common stock to nonemployee for services rendered

            23,167          260              260   

Issuance of common stock to consultant for services rendered

            39,578          452              452   

Issuance of common stock upon exercise of stock options

            1,135,207        1        3,713              3,714   

Issuance of common stock pursuant to ESPP

            134,497          1,039              1,039   

Common stock issued pursuant to vesting of restricted stock and restricted stock units

            68,835          5,209              5,209   

Common stock issued pursuant to vesting of performance stock units

            15,000                    

Common stock issued in lieu of cash bonus

            15,168          121              121   

Stock-based compensation expense related to employees

                12,087              12,087   

Stock-based compensation expense related to nonemployees

                1,097              1,097   

Common stock issued upon early conversion of Senior Convertible Notes

            5,541,597        6        44,212              44,218   

Common stock issued in connection with use and operation of the Clinton Facility (see Note 10)

            770,761        1        7,125              7,126   

Vesting of warrant shares issued in connection with use and operation of the Clinton Facility (see Note 10)

                98              98   

Change in unrealized loss on available-for-sale securities

                    (240       (240

Foreign currency translation adjustment

                    (3,155       (3,155

Net loss

                      (116,389     (116,389
 

 

 

   

 

 

       

 

 

   

 

 

   

 

 

   

 

 

   

 

 

   

 

 

   

 

 

 

December 31, 2013

         $            68,744,534      $ 69      $ 448,990      $      $ (3,794   $ (306,317   $ 138,948   
 

 

 

   

 

 

       

 

 

   

 

 

   

 

 

   

 

 

   

 

 

   

 

 

   

 

 

 

 

See accompanying notes to the consolidated financial statements.

 

81


Table of Contents
Index to Financial Statements

SOLAZYME, INC.

CONSOLIDATED STATEMENTS OF CASH FLOWS

In thousands

 

     Year Ended December 31,  
     2013     2012     2011  

Operating activities:

      

Net loss

   $ (116,389   $ (83,132   $ (53,901

Adjustments to reconcile net loss to net cash used in operating activities:

      

Depreciation and amortization

     5,108        3,519        1,707   

Loss on disposal of property and equipment

                   46   

Net amortization of premiums on marketable securities

     1,685        2,494        1,882   

Amortization of debt discount

     1,179        144        109   

Amortization of loan fees

     350               13   

Noncash interest income, net

                   (4

Issuance of common stock in connection with professional services rendered

     452               16   

Warrant expense related to vesting of ADM Warrant (see Note 10)

     98                 

Stock-based compensation expense

     18,653        15,356        10,907   

Loss from equity method investments

     8,237        1,824          

Revaluation of warrant liability

     (147     (2,284     3,637   

Revaluation of derivative liability

     6,392                 

Changes in operating assets and liabilities:

      

Accounts receivable

     (7,268     749        (3,359

Unbilled revenue

     2,045        739        (422

Inventories

     (2,946     (3,762     (3,129

Prepaid expenses and other current assets

     (764     611        (2,298

Other assets

     3,262        2        69   

Accounts payable

     (2,563     (1,396     3,025   

Accrued liabilities

     5,955        9        5,183   

Deferred revenue

     1,983        (2,722     1,651   

Other current and long-term liabilities

     (112     278        (37
  

 

 

   

 

 

   

 

 

 

Net cash used in operating activities

     (74,790     (67,571     (34,905
  

 

 

   

 

 

   

 

 

 

Investing activities:

      

Purchases of property, plant and equipment

     (10,217     (12,554     (15,502

Proceeds received from the sale of equipment

                   290   

Purchases of marketable securities

     (133,601     (64,908     (240,298

Maturities of marketable securities

     126,073        130,682        58,866   

Proceeds from sales of marketable securities

     10,890        29,014        13,863   

Capital contributions in unconsolidated joint ventures

     (12,431     (10,000       

Capitalized interest related to unconsolidated joint venture

     (1,055              

Restricted cash

                   (50
  

 

 

   

 

 

   

 

 

 

Net cash (used in) provided by investing activities

     (20,341     72,234        (182,831
  

 

 

   

 

 

   

 

 

 

Financing activities:

      

Repayments under loan agreements

     (14,917     (5,408     (333

Proceeds from the issuance of senior subordinated convertible notes, net of discount

     119,750                 

Payment for equity financing costs

                   (3,868

Proceeds from the issuance of common stock, net of repurchases

     3,714